CA2988391C - Substituted aminoalkylazoles as malarial aspartic protease inhibitors - Google Patents
Substituted aminoalkylazoles as malarial aspartic protease inhibitors Download PDFInfo
- Publication number
- CA2988391C CA2988391C CA2988391A CA2988391A CA2988391C CA 2988391 C CA2988391 C CA 2988391C CA 2988391 A CA2988391 A CA 2988391A CA 2988391 A CA2988391 A CA 2988391A CA 2988391 C CA2988391 C CA 2988391C
- Authority
- CA
- Canada
- Prior art keywords
- mmol
- added
- equiv
- synthesis
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/333—Radicals substituted by oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The present invention relates to novel aminoalkylazoles acting as inhibitors of malarial protease plasmepsin II. These can be used as medicines or as constituent of medicines for the treatment of malaria infection.
Description
SUBSTITUTED AMINOALKYLAZOLES AS MALARIAL
ASPARTIC PROTEASE INHIBITORS
.. Field of invention The present invention relates to medicine and in particular to the treatment of malaria, more particularly to inhibitors of malaria aspartic proteases known as plasmepsins.
Even more particularly, the invention relates to novel substituted aminoalkylazoles and pharmaceutical compositions thereof and their use as inhibitors of malarial aspartic protease plasmepsin II or related malarial aspartic proteases.
Background of invention Malaria is a life threatening infectious disease caused by the plasmodium parasite carried by mosquitoes. In 2010, World Health Organization has estimated 219 million cases of malaria infection, resulting in 660,000 deaths (WHO. World Malaria Report 2012; World Health Organization: Geneva, 2012; p 59). Widespread resistance to practically all currently used drugs has activated the search for antimalarials with novel mechanisms of action (Hyde, J. E.
Drug-resistant malaria - an insight. FEBS J. 2007, 274, 4688-4698; Choi, S.
R.; Mukherjee, P.; Avery, M. A. The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr. Med. Chem. 2008, 15, 161-171; Wells, T. N.; Alonso, P. L.;
Gutteridge, W. E. New medicines to improve control and contribute to the eradication of malaria. Nat. Rev. Drug Discov. 2009, 8, 879-891). Resistance to current anti-malaria agents in regions threatened by malaria continues to spread, and it means that current therapeutic agents will be practically ineffective in the near future. A precondition for the development of a new resistance free malaria agent is inhibition of malaria parasite life cycle by a mechanism that differs from the mode of action of currently used therapeutic agents (N. K.
Sahu, S. Sahu and D. V. Kohli, Novel Molecular Targets for Antimalarial Drug.
Chem. Biol.
Drug. Des. 2008, 71, 287-297). Such product would be resistance free for a particular period of time, and it would be effective in all malaria endemic regions. One group of promising biological targets for the development of new anti-malaria agents are plasmepsins (I, II, IV
.. and HAP) - aspartic proteases of the parasite plasmodium, which are used by the parasite in the first stage of hemoglobin digestion, which is the main nutrition source during its erythrocytic cycle (K. Ersmark, B. Samuelsson, A. Hallberg, Plasmepsins as Potential
ASPARTIC PROTEASE INHIBITORS
.. Field of invention The present invention relates to medicine and in particular to the treatment of malaria, more particularly to inhibitors of malaria aspartic proteases known as plasmepsins.
Even more particularly, the invention relates to novel substituted aminoalkylazoles and pharmaceutical compositions thereof and their use as inhibitors of malarial aspartic protease plasmepsin II or related malarial aspartic proteases.
Background of invention Malaria is a life threatening infectious disease caused by the plasmodium parasite carried by mosquitoes. In 2010, World Health Organization has estimated 219 million cases of malaria infection, resulting in 660,000 deaths (WHO. World Malaria Report 2012; World Health Organization: Geneva, 2012; p 59). Widespread resistance to practically all currently used drugs has activated the search for antimalarials with novel mechanisms of action (Hyde, J. E.
Drug-resistant malaria - an insight. FEBS J. 2007, 274, 4688-4698; Choi, S.
R.; Mukherjee, P.; Avery, M. A. The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr. Med. Chem. 2008, 15, 161-171; Wells, T. N.; Alonso, P. L.;
Gutteridge, W. E. New medicines to improve control and contribute to the eradication of malaria. Nat. Rev. Drug Discov. 2009, 8, 879-891). Resistance to current anti-malaria agents in regions threatened by malaria continues to spread, and it means that current therapeutic agents will be practically ineffective in the near future. A precondition for the development of a new resistance free malaria agent is inhibition of malaria parasite life cycle by a mechanism that differs from the mode of action of currently used therapeutic agents (N. K.
Sahu, S. Sahu and D. V. Kohli, Novel Molecular Targets for Antimalarial Drug.
Chem. Biol.
Drug. Des. 2008, 71, 287-297). Such product would be resistance free for a particular period of time, and it would be effective in all malaria endemic regions. One group of promising biological targets for the development of new anti-malaria agents are plasmepsins (I, II, IV
.. and HAP) - aspartic proteases of the parasite plasmodium, which are used by the parasite in the first stage of hemoglobin digestion, which is the main nutrition source during its erythrocytic cycle (K. Ersmark, B. Samuelsson, A. Hallberg, Plasmepsins as Potential
2 Targets for New Antimalarial Therapy. Med. Res. Rev., 2006, 26, 626-666; G. H.
Coombs, D. E. Goldberg, M. Klemba, C. Berry, J. Kay and J. C. Mottram, Aspartic proteases of Plasmodium falciparum and other parasitic protozoa as drug targets. Trends in Parasitology, 2001, 17, 532-537). Therapeutic potential of plasmepsins in the treatment of malaria is still unused as there is no marketed anti-malarial drug acting on this target. Most of known plasmepsin inhibitors are based on N-acylated amino alcohols as transition state analogues that are peptidic or peptide-like which suffer from problems in bioavailability and pharmacokinetic profile (K. Ersmark, B. Samuelsson, A. Hallberg, Plasmepsins as Potential Targets for New Antimalarial Therapy. Med. Res. Rev., 2006, 26, 626-666). In order to find more drug-like compound there is an increased interest for non-peptidic plasmepsin inhibitors and several such inhibitors have been reported (0. Corminboeuf, G.
Dunet, M.
Hafsi, J. Grimont, C. Grisostomi, S. Meyer, C. Binkert, D. Bur, A. Jones, L.
Prade, R. Brun, C. Boss, Inhibitors of Plasmepsin II-potential antimalarial agents. Bioorganic & Medicinal Chemistry Letters 2006, 16, 6194-6199; F. Hof, A. Schutz, C. Fah, S. Meyer, D.Bur, J. Liu, D. E. Goldberg, and F. Diederich, Starving the Malaria Parasite: Inhibitors Active against the Aspartic Proteases Plasmepsins I, II, IV Angew. Chem. Int. Ed. 2006, 45, 2138 -2141;
T. Luksch, A. Blum, N. Klee, W. E. Diederich, C. A. Sotriffer, G. Klebe, Pyrrolidine Derivatives as Plasmepsin Inhibitors: Binding Mode Analysis Assisted by Molecular Dynamics Simulations of a Highly Flexible Protein. ChernMedChem., 2010, 5, 443-454).
Summary of the invention In accordance with an aspect of at least one embodiment there is provided a compound with general formula I
Formula I
wherein:
Date Recue/Date Received 2022-02-22 2a Rl/R2 are attached to a nitrogen atom and wherein R1/R2 are H/unsubstituted benzyl, H/
benzyl substituted with methoxy or phenyl, H/phenyl, H/CH2c-hexyl, H/CH(Me)Ph, H/H, H/C1.6a1ky1, Ci_6alkyl/C1-6a1ky1, or Et/CH2pyridinyl, or R1, R2 together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocyclyl, or R1, R2 together with the nitrogen atom to which they are attached form a 6-membered heterocyclic ring fused with a phenyl ring;
R3 is pyridinyl, unsubstituted phenyl, phenyl substituted with t-butyl, -0Me, -OH, morpholinyl or NH2C(0)-, thiophenyl, or bromo;
R4 is methyl or C5H11(n-pentyl);
A-D-E-G-J constitutes saturated or unsaturated azole ring;
wherein:
A is C= or CH;
D is independently N= or C=;
E is independently CH, C= or N=;
G is independently CH2, CH= or N=;
J is independently CH=, 0 or N=;
and at least one of D-E-G-J is nitrogen;
and wherein:
Q is unsubstituted C1_3alkylene;
or an optical isomer, a pharmaceutically acceptable salt, a hydrate, or a solvate thereof.
In a first aspect, the invention features a method of treating malaria in humans, comprising administering to a human in need thereof a therapeutically effective amount of a compound or prodrug thereof, or pharmaceutically acceptable salt, hydrate, solvate, or polymorph of said compound or prodrug, wherein the compound is an inhibitor of malarial aspartic protease plasmepsin II or related malarial aspartic proteases.
In another aspect, the invention features a pharmaceutical composition for treatment of malaria comprising a therapeutically effective amount of a composition comprising (i) a compound or prodrug thereof, or pharmaceutically acceptable salt, hydrate, solvate, or polymorph of said compound or prodrug; and (ii) a pharmaceutically acceptable carrier, wherein the compound is an inhibitor of malarial aspartic protease plasmepsin II or related malarial aspartic proteas es.
Date Regue/Date Received 2022-08-23 In another aspect, the invention features the use of a compound or prodrug thereof, or pharmaceutically acceptable salt, hydrate, solvate, or polymorph of said compound or prodrug, wherein the compound is an inhibitor of malarial aspartic protease plasmepsin II or related malarial aspartic proteases, in the manufacture of a medicament for treatment or prevention of malaria.
In another aspect, the invention features a compound or prodrug thereof, or pharmaceutically acceptable salt or ester of said compound or prodrug for use in treating or preventing malaria, wherein the compound is an inhibitor of a malarial aspartic protease plasmepsin II or related malarial aspartic proteases.
In one embodiment the inhibitor of a malarial aspartic protease plasmepsin II
or related malarial aspartic proteases is a compound of Formula I, generally referred herein as aminoalkylazole derivative:
G ¨J
./N¨R1 D Q
Formula I
wherein:
R1,R2 are optional amino group substituents;
R3,R4 are optional phenyl group susbtituents;
A-D-E-G-J constitutes saturated or unsaturated azole ring;
Q is a covalent bond or a linker.
Compound with general formula I wherein:
Ri,R2, R3, R4, 5 R4,¨K is independently -H, -F, -Cl, -Br, -I, -CF3, -CH2CF3, -CF2CF2H, -OH, -0R6, -0-L-NHR6, -0-L-NR62, -0-L-NR6R7,
Coombs, D. E. Goldberg, M. Klemba, C. Berry, J. Kay and J. C. Mottram, Aspartic proteases of Plasmodium falciparum and other parasitic protozoa as drug targets. Trends in Parasitology, 2001, 17, 532-537). Therapeutic potential of plasmepsins in the treatment of malaria is still unused as there is no marketed anti-malarial drug acting on this target. Most of known plasmepsin inhibitors are based on N-acylated amino alcohols as transition state analogues that are peptidic or peptide-like which suffer from problems in bioavailability and pharmacokinetic profile (K. Ersmark, B. Samuelsson, A. Hallberg, Plasmepsins as Potential Targets for New Antimalarial Therapy. Med. Res. Rev., 2006, 26, 626-666). In order to find more drug-like compound there is an increased interest for non-peptidic plasmepsin inhibitors and several such inhibitors have been reported (0. Corminboeuf, G.
Dunet, M.
Hafsi, J. Grimont, C. Grisostomi, S. Meyer, C. Binkert, D. Bur, A. Jones, L.
Prade, R. Brun, C. Boss, Inhibitors of Plasmepsin II-potential antimalarial agents. Bioorganic & Medicinal Chemistry Letters 2006, 16, 6194-6199; F. Hof, A. Schutz, C. Fah, S. Meyer, D.Bur, J. Liu, D. E. Goldberg, and F. Diederich, Starving the Malaria Parasite: Inhibitors Active against the Aspartic Proteases Plasmepsins I, II, IV Angew. Chem. Int. Ed. 2006, 45, 2138 -2141;
T. Luksch, A. Blum, N. Klee, W. E. Diederich, C. A. Sotriffer, G. Klebe, Pyrrolidine Derivatives as Plasmepsin Inhibitors: Binding Mode Analysis Assisted by Molecular Dynamics Simulations of a Highly Flexible Protein. ChernMedChem., 2010, 5, 443-454).
Summary of the invention In accordance with an aspect of at least one embodiment there is provided a compound with general formula I
Formula I
wherein:
Date Recue/Date Received 2022-02-22 2a Rl/R2 are attached to a nitrogen atom and wherein R1/R2 are H/unsubstituted benzyl, H/
benzyl substituted with methoxy or phenyl, H/phenyl, H/CH2c-hexyl, H/CH(Me)Ph, H/H, H/C1.6a1ky1, Ci_6alkyl/C1-6a1ky1, or Et/CH2pyridinyl, or R1, R2 together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocyclyl, or R1, R2 together with the nitrogen atom to which they are attached form a 6-membered heterocyclic ring fused with a phenyl ring;
R3 is pyridinyl, unsubstituted phenyl, phenyl substituted with t-butyl, -0Me, -OH, morpholinyl or NH2C(0)-, thiophenyl, or bromo;
R4 is methyl or C5H11(n-pentyl);
A-D-E-G-J constitutes saturated or unsaturated azole ring;
wherein:
A is C= or CH;
D is independently N= or C=;
E is independently CH, C= or N=;
G is independently CH2, CH= or N=;
J is independently CH=, 0 or N=;
and at least one of D-E-G-J is nitrogen;
and wherein:
Q is unsubstituted C1_3alkylene;
or an optical isomer, a pharmaceutically acceptable salt, a hydrate, or a solvate thereof.
In a first aspect, the invention features a method of treating malaria in humans, comprising administering to a human in need thereof a therapeutically effective amount of a compound or prodrug thereof, or pharmaceutically acceptable salt, hydrate, solvate, or polymorph of said compound or prodrug, wherein the compound is an inhibitor of malarial aspartic protease plasmepsin II or related malarial aspartic proteases.
In another aspect, the invention features a pharmaceutical composition for treatment of malaria comprising a therapeutically effective amount of a composition comprising (i) a compound or prodrug thereof, or pharmaceutically acceptable salt, hydrate, solvate, or polymorph of said compound or prodrug; and (ii) a pharmaceutically acceptable carrier, wherein the compound is an inhibitor of malarial aspartic protease plasmepsin II or related malarial aspartic proteas es.
Date Regue/Date Received 2022-08-23 In another aspect, the invention features the use of a compound or prodrug thereof, or pharmaceutically acceptable salt, hydrate, solvate, or polymorph of said compound or prodrug, wherein the compound is an inhibitor of malarial aspartic protease plasmepsin II or related malarial aspartic proteases, in the manufacture of a medicament for treatment or prevention of malaria.
In another aspect, the invention features a compound or prodrug thereof, or pharmaceutically acceptable salt or ester of said compound or prodrug for use in treating or preventing malaria, wherein the compound is an inhibitor of a malarial aspartic protease plasmepsin II or related malarial aspartic proteases.
In one embodiment the inhibitor of a malarial aspartic protease plasmepsin II
or related malarial aspartic proteases is a compound of Formula I, generally referred herein as aminoalkylazole derivative:
G ¨J
./N¨R1 D Q
Formula I
wherein:
R1,R2 are optional amino group substituents;
R3,R4 are optional phenyl group susbtituents;
A-D-E-G-J constitutes saturated or unsaturated azole ring;
Q is a covalent bond or a linker.
Compound with general formula I wherein:
Ri,R2, R3, R4, 5 R4,¨K is independently -H, -F, -Cl, -Br, -I, -CF3, -CH2CF3, -CF2CF2H, -OH, -0R6, -0-L-NHR6, -0-L-NR62, -0-L-NR6R7,
3 -OCH2CF3, -0CF2CF2H, -OCH2CF3, -0CF2CF2H, SR6, SCF3, CN, -NO2, -NO2, -NH2, -NHR6, -NR62, -NR6R7,-L-NH2, -L-NHR6, -L-NR62, -L-NR6R7, -NH-L-NH2, -NH-L-NHR6, -NH-L-NR62, -NH-L-NR6R7,-NR6-L-NH2, -NR6-L-NHR6, -NR6-L-N12.62, -NR6-L-NR6R7,L-NR6R7,-C(.0)0H, -C(=0)0R6, -C(=0)NH2, -C(=0)NHR6, -C(=0)NR62, -C(=0)NR6R7, -NHC(=0)R6, -NR6C(=0)R7, -NHC(=0)0R6, -NR6C(.0)0R7, -0C(=0)NH2, -0C(=0)NHR6, -0C(.0)NR62, -0C(=0)NR6R7,-0C(.0)R6, -C(=0)R6,-NHC(=0)NH2, -NHC(=0)N1-1R6, -NHC(=0)NR62, -NHC(=0)NR6R7, -NR6C(=0)NH2, -NR6C(=0)NHR7, -NR6C(=0)NR72, -NR6C(=0)N, -NHS (=0)2R6, -NR6S(=0)2R7 ,-S(=0)2NE12, -S(=0)2NHR6, -S(=0)2NR62, -S(=0)2NR6R7,-S(=0)R6, -S(=0)2R6,-0S(.0)2R6,-S(.0)20R6, Ci_6alkyl, cycloC3_12a1ky1, cycloC3_12alkyl-Ci_6a1ky1, C2_6a1keny1, C2_6a1kynyl, aryl, biaryl, arylCi_6alky1, ary1C2_6a1keny1, ary1C2.6a1kynyl, heteroaryl, heteroarylC1_6alkyl, heteroary1C2-6alkenyl, heteroarylthio, 2,3-dihydro-1H-indenyl, 2-indanylamino, tetrahydrofuryl, pyrrolidino, piperidino, 4-arylpiperidino, 4-heteroarylpiperidino, morpholino, piperazino, 4-C1_6alky1piperazino, 4-arylpiperazino, hexamethyleneimino, benzazepinyl, 1,3-dihydro-2H-isoindo1-2-yl, wherein:
L represents wherein:
W represents a single bond, oxygen, sulfur, -NR6 or -CR6R7, X represents oxygen, sulfur, -NR6 or -CR6R7, Y represents oxygen, sulfur, -NR6 or -CR6R7 and Z represents oxygen, sulfur, -NR6 or -CR6R7;
wherein:
or RI and R2
L represents wherein:
W represents a single bond, oxygen, sulfur, -NR6 or -CR6R7, X represents oxygen, sulfur, -NR6 or -CR6R7, Y represents oxygen, sulfur, -NR6 or -CR6R7 and Z represents oxygen, sulfur, -NR6 or -CR6R7;
wherein:
or RI and R2
4 together represent -W-X-Y-Z-, wherein:
W represents a single bond, oxygen, sulfur, -NR6 or -CR6R7, X represents oxygen, sulfur, -NR6 or -CR6R7, Y represents oxygen, sulfur, -NR6 or -CR6R7 and Z represents oxygen, sulfur, -NR6 or -CR6R7;
wherein:
R6 and R7 is independently H, Ci_6alky1, cycloC3_12alkyl, cycloC3_12alkyl-Ci.6alkyl, C2_6alkenyl, C2_6alkyny1, aryl, biaryl, arylCi_6a1ky1, ary1C2_6a1keny1, ary1C2_6a1kynyl, heteroaryl, heteroary1C1_6alkyl, heteroary1C2_6alkeny1, heteroarylthio, 2,3-dihydro-1H-indenyl, C 1_6allcoxyC _6allcyl , ary1oxyary1Ci_6alkoxy, C _6alkylthio, C4_6alkenylthio, cyc1oC3_12alkylthio, cyc1oC3_12alky1-Ci_6alkylthio, cycloC3_12a1kyl-C3_6alkeny1thio, C 1_6alkox yCi_6alkylthio, C _ 6alkoxyC3_6alkenylthio, ary1C3_6a1kenylthio, heteroary1C1.6alkylthio, C1_6alkylsulfonyl, cycloC3_ i2alkyl-Ci_6alkylsulfonyl, arylCi_6alkylsulfonyl, Ci_6alkylamino, di-C i_6alkyl amino, cyc1oC3_12a1kylamino, C -C6alkoxy-cycloC3-C ualkylamino, cycloC3_ 2alkyl-C
1_6a1ky1 amino, di-C1_6alkylaminoCi.6alkyl, C1_6a1koxy-C2_6alky1 amino, arylamino, arylCi_6alkylamino, N-cycloC 3-12alkyl-N-Ci_6alkylarnino, N-aryl-N-C i_6alkylamino, N-ary1C 1_6a1ky1-N-C 1_ 6a11ky1amin0, 2-indanylamino, tetrahydrofuryl, pyrrolidino, piperidino, 4-arylpiperidino, 4-heteroarylpiperidino, morpholino, piperazino, 4-C1_6alkylpiperazino, 4-arylpiperazino, hexamethyleneimino, benzazepinyl, 1,3-dihydro-2H-isoindo1-2-yl, heteroarylCi_6alkoxy, heteroarylamino, heteroarylCalkyamino Compound with general formula I
wherein:
.. A is independently nitrogen or carbon;
D is independently nitrogen or carbon;
E is independently nitrogen or carbon;
G is independently oxygen or sulphur or -N= or -NR8- -CR9= or -CR9R 10 J is is independently oxygen or sulphur or -N= or -NR8- -CR9= or -CR9R to;
and at least one of A-D-E-G-J is nitrogen
W represents a single bond, oxygen, sulfur, -NR6 or -CR6R7, X represents oxygen, sulfur, -NR6 or -CR6R7, Y represents oxygen, sulfur, -NR6 or -CR6R7 and Z represents oxygen, sulfur, -NR6 or -CR6R7;
wherein:
R6 and R7 is independently H, Ci_6alky1, cycloC3_12alkyl, cycloC3_12alkyl-Ci.6alkyl, C2_6alkenyl, C2_6alkyny1, aryl, biaryl, arylCi_6a1ky1, ary1C2_6a1keny1, ary1C2_6a1kynyl, heteroaryl, heteroary1C1_6alkyl, heteroary1C2_6alkeny1, heteroarylthio, 2,3-dihydro-1H-indenyl, C 1_6allcoxyC _6allcyl , ary1oxyary1Ci_6alkoxy, C _6alkylthio, C4_6alkenylthio, cyc1oC3_12alkylthio, cyc1oC3_12alky1-Ci_6alkylthio, cycloC3_12a1kyl-C3_6alkeny1thio, C 1_6alkox yCi_6alkylthio, C _ 6alkoxyC3_6alkenylthio, ary1C3_6a1kenylthio, heteroary1C1.6alkylthio, C1_6alkylsulfonyl, cycloC3_ i2alkyl-Ci_6alkylsulfonyl, arylCi_6alkylsulfonyl, Ci_6alkylamino, di-C i_6alkyl amino, cyc1oC3_12a1kylamino, C -C6alkoxy-cycloC3-C ualkylamino, cycloC3_ 2alkyl-C
1_6a1ky1 amino, di-C1_6alkylaminoCi.6alkyl, C1_6a1koxy-C2_6alky1 amino, arylamino, arylCi_6alkylamino, N-cycloC 3-12alkyl-N-Ci_6alkylarnino, N-aryl-N-C i_6alkylamino, N-ary1C 1_6a1ky1-N-C 1_ 6a11ky1amin0, 2-indanylamino, tetrahydrofuryl, pyrrolidino, piperidino, 4-arylpiperidino, 4-heteroarylpiperidino, morpholino, piperazino, 4-C1_6alkylpiperazino, 4-arylpiperazino, hexamethyleneimino, benzazepinyl, 1,3-dihydro-2H-isoindo1-2-yl, heteroarylCi_6alkoxy, heteroarylamino, heteroarylCalkyamino Compound with general formula I
wherein:
.. A is independently nitrogen or carbon;
D is independently nitrogen or carbon;
E is independently nitrogen or carbon;
G is independently oxygen or sulphur or -N= or -NR8- -CR9= or -CR9R 10 J is is independently oxygen or sulphur or -N= or -NR8- -CR9= or -CR9R to;
and at least one of A-D-E-G-J is nitrogen
5 wherein:
-=-,8 10 =
,R9 ,R is independently H, C1_6alkyl, cycloC3_12alkyl, cycloC3_12alkyl-Ci_6alky1, C2-6alkenyl, Cmalkynyl, aryl, biaryl, ary1C1_6a1ky1, ary1C2_6alkeny1, ary1C2_6alkynyl, heteroaryl, heteroarylCi_6alkyl, heteroary1C2.6a1keny1, heteroarylthio, 2,3-dihydro-1H-indenyl, C1_ 6alkoxyC 1_6a1ky1, aryloxyarylCi_6alkoxy, Ci_6alkylthio, C4_6a1kenylthio, cyc1oC342alky1thio, cyc1oC3_12a1ky1-c i_6alkylthio, cycloC3-12a1kyl-C3_6alkenylthio, C .6alkoxyC
1_6a1ky1thio, C 1-6alkox yC3_6a1kenylthio, ary1C3_6alkenylthio, heteroarylCi_6alkylthio, Ci_6alkylsulfonyl, cyc1oC3_ i2alkyl-C _6alkyisulfonyl, arylC1_6a1kylsu1fonyl, C _6a1ky1amin0, di-C1_6a1ky1amin0, cycloC3_12alkyl amino, C1 -C6alkoxy-cycloC3-C12alkylamino, cyc1oC3_12alkyl-C1_6a1ky1am1no, di-C1_6alky1aminoC i6alky1, C _6alkoxy-C2_6alkyl amino, arylamino, arylCi_6alkylamino, N-eyeloC3_12alkyl-N-C1_6a11cy1amino, N-aryl-N-C1_6alkylamino, N-arylCi_6alkyl-N-Ci.
6alkylamino, 2-indanylamino, tetrahydrofuryl, pyrrolidino, piperidino, 4-arylpiperidino, 4-heteroarylpiperidino, morpholino, piperazino, 4-C 1.6a1ky1piperazin0, 4-arylpiperazino, hexamethyleneimino, benzazepinyl, 1,3-dihydro-2H-isoindo1-2-yl, heteroarylCi_6alkoxy, heteroarylamino, heteroarylCI.6alkylamino.
-=-,8 10 =
,R9 ,R is independently H, C1_6alkyl, cycloC3_12alkyl, cycloC3_12alkyl-Ci_6alky1, C2-6alkenyl, Cmalkynyl, aryl, biaryl, ary1C1_6a1ky1, ary1C2_6alkeny1, ary1C2_6alkynyl, heteroaryl, heteroarylCi_6alkyl, heteroary1C2.6a1keny1, heteroarylthio, 2,3-dihydro-1H-indenyl, C1_ 6alkoxyC 1_6a1ky1, aryloxyarylCi_6alkoxy, Ci_6alkylthio, C4_6a1kenylthio, cyc1oC342alky1thio, cyc1oC3_12a1ky1-c i_6alkylthio, cycloC3-12a1kyl-C3_6alkenylthio, C .6alkoxyC
1_6a1ky1thio, C 1-6alkox yC3_6a1kenylthio, ary1C3_6alkenylthio, heteroarylCi_6alkylthio, Ci_6alkylsulfonyl, cyc1oC3_ i2alkyl-C _6alkyisulfonyl, arylC1_6a1kylsu1fonyl, C _6a1ky1amin0, di-C1_6a1ky1amin0, cycloC3_12alkyl amino, C1 -C6alkoxy-cycloC3-C12alkylamino, cyc1oC3_12alkyl-C1_6a1ky1am1no, di-C1_6alky1aminoC i6alky1, C _6alkoxy-C2_6alkyl amino, arylamino, arylCi_6alkylamino, N-eyeloC3_12alkyl-N-C1_6a11cy1amino, N-aryl-N-C1_6alkylamino, N-arylCi_6alkyl-N-Ci.
6alkylamino, 2-indanylamino, tetrahydrofuryl, pyrrolidino, piperidino, 4-arylpiperidino, 4-heteroarylpiperidino, morpholino, piperazino, 4-C 1.6a1ky1piperazin0, 4-arylpiperazino, hexamethyleneimino, benzazepinyl, 1,3-dihydro-2H-isoindo1-2-yl, heteroarylCi_6alkoxy, heteroarylamino, heteroarylCI.6alkylamino.
6 In one preferred embodiment, A-D-E-G-J constitutes 1,2,5-substituted imidazole group of the formula with optional substitiuent R9:
'N
I \
In one preferred embodiment, A-D-E-G-J constitutes 1,4,5-substituted triazole group of the formula:
2..-N3 1N-7? 4 In one preferred embodiment, A-D-E-G-J constitutes 3,4,5-substituted isoxazole group of the formula:
3 Nri, 5 In one preferred embodiment, A-D-E-G-J constitutes 1,2,5-pyroline group of the formula:
RA, `>5 wherein n is an integer from 0 to 3, and each RA is independently a substituent R9 or R11) as defined herein.
In one preferred embodiment, A-D-E-G-J constitutes 1,2,5-pyrolidine group of the formula:
Fi NY
wherein n is an integer from 0 to 4, and each RA is independently a substituent R9 or RI as defined herein.
In one preferred embodiment, A-D-E-G-J constitutes 1,2,5-pyrole group of the formula:
RAõ
2 r\SI5 1\
wherein n is an integer from 0 to 2, and each RA is independently a substituent R9 or R1 as defined herein
'N
I \
In one preferred embodiment, A-D-E-G-J constitutes 1,4,5-substituted triazole group of the formula:
2..-N3 1N-7? 4 In one preferred embodiment, A-D-E-G-J constitutes 3,4,5-substituted isoxazole group of the formula:
3 Nri, 5 In one preferred embodiment, A-D-E-G-J constitutes 1,2,5-pyroline group of the formula:
RA, `>5 wherein n is an integer from 0 to 3, and each RA is independently a substituent R9 or R11) as defined herein.
In one preferred embodiment, A-D-E-G-J constitutes 1,2,5-pyrolidine group of the formula:
Fi NY
wherein n is an integer from 0 to 4, and each RA is independently a substituent R9 or RI as defined herein.
In one preferred embodiment, A-D-E-G-J constitutes 1,2,5-pyrole group of the formula:
RAõ
2 r\SI5 1\
wherein n is an integer from 0 to 2, and each RA is independently a substituent R9 or R1 as defined herein
7 Compound with general formula I wherein, Q represents a linker group:
in some embodiments, Q is a covalent bond; in some embodiments, Q is a linker group.
In one preferred embodiment, Q is a covalent bond.
In one preferred embodiment, Q is a C _4alkylene group and is optionally substituted.
In one preferred embodiment, Q is a methylene group and is optionally substituted.
Optical isomers, pharmaceutically acceptable salts, hydrates, solvates, and polymorphs of compound with general formula I
The use of compounds with general formula I; their optical isomers, pharmaceutically acceptable salts, hydrates, solvates, and polymorphs for the treatement of malaria infection.
In one embodiment, the treatment is treatment of a disease or disorder that is mediated by plasmepsins (malarial aspartic protease) or human aspartic proteases.
In one embodiment, the treatment is treatment of a disease or disorder that is ameliorated by the inhibition of plasmepsins (malarial aspartic protease) or human aspartic proteases.
In one embodiment, the treatment is treatment of a disease or disorder that is treated by a plasmepsins (malarial aspartic protease) or human aspartic proteases inhibitor.
The use of compounds with general formula I their optical isomers, pharmaceutically acceptable salts, hydrates, solvates, and polymorphs for malaria prevention.
In another aspect, the invention features a kit comprising a substituted aminoalkylazole with general foimula I, preferably provided as a pharmaceutical composition and in a suitable container and/or with suitable packaging.
In another aspect, the invention features compounds with general formula I
obtainable by a method of synthesis as described herein, or a method comprising a method of synthesis as described herein.
In another aspect, the invention features compounds with general formula I
obtained by a method of synthesis as described herein, or a method comprising a method of synthesis as described herein.
in some embodiments, Q is a covalent bond; in some embodiments, Q is a linker group.
In one preferred embodiment, Q is a covalent bond.
In one preferred embodiment, Q is a C _4alkylene group and is optionally substituted.
In one preferred embodiment, Q is a methylene group and is optionally substituted.
Optical isomers, pharmaceutically acceptable salts, hydrates, solvates, and polymorphs of compound with general formula I
The use of compounds with general formula I; their optical isomers, pharmaceutically acceptable salts, hydrates, solvates, and polymorphs for the treatement of malaria infection.
In one embodiment, the treatment is treatment of a disease or disorder that is mediated by plasmepsins (malarial aspartic protease) or human aspartic proteases.
In one embodiment, the treatment is treatment of a disease or disorder that is ameliorated by the inhibition of plasmepsins (malarial aspartic protease) or human aspartic proteases.
In one embodiment, the treatment is treatment of a disease or disorder that is treated by a plasmepsins (malarial aspartic protease) or human aspartic proteases inhibitor.
The use of compounds with general formula I their optical isomers, pharmaceutically acceptable salts, hydrates, solvates, and polymorphs for malaria prevention.
In another aspect, the invention features a kit comprising a substituted aminoalkylazole with general foimula I, preferably provided as a pharmaceutical composition and in a suitable container and/or with suitable packaging.
In another aspect, the invention features compounds with general formula I
obtainable by a method of synthesis as described herein, or a method comprising a method of synthesis as described herein.
In another aspect, the invention features compounds with general formula I
obtained by a method of synthesis as described herein, or a method comprising a method of synthesis as described herein.
8
9 In another aspect, the invention features novel intermediates for the compound with general formula I, as described herein, which are suitable for use in the methods of synthesis described herein.
In another aspect, the invention features the use of such novel intermediates, for the compound with general formula I as described herein, in the methods of synthesis described herein.
As will be appreciated by one of skill in the art, features and preferred embodiments of one aspect of the invention will also pertain to other aspects of the invention.
Description of invention Plasmepsins are malarial aspartic proteases have been identified as a group of promising biological targets for the development of new anti-malaria agents. For example, plasmepsin Ills used by the parasite in the first stage of hemoglobin digestion, which is the main nutrition source during its erythrocytic cycle (K. Ersmark, B. Samuelsson, A.
Hallberg, Plasmepsins as Potential Targets for New Antimalarial Therapy. Med. Res. Rev., 2006, 26, 626-666; G. H. Coombs, D. E. Goldberg, M. Klemba, C. Berry, J. Kay and J. C.
Mottram, Aspartic proteases of Plasmodium falciparum and other parasitic protozoa as drug targets.
Trends in Parasitology, 2001, 17, 532-537).
When testing the novel substituted aminoalkylazoles derivatives for their ability to inhibit plasmepsin II we have unexpectedly discovered, that said derivatives exhibit pronounced inhibitor properties toward said plasmepsin and thus are useful in treatment of malaria.
According to this invention, the results from plasmepsin inhibition studies demonstrate that substituted aminoalkylazoles derivatives are novel class of non-peptidic inhibitors of malarial aspartic proteases -plasmepsins. Several example compounds from the present invention display high nanomolar to low micromolecular inhibitory potency that is comparable to known non-peptidic inhibitors (e.g. F. Hof et. al., Starving the malaria parasite: Inhibitors active against the aspartic proteases plasmepsins I, II, and IV. Angew.
Chem. Int. Ed. 2006, 45, 2138-2141; T. Luksch et.al., Computer-Aided Design and Synthesis of Nonpeptidic Plasmepsin II and IV Inhibitors. ChemMedChem., 2008, 3, 1323-1336.; C. Boss et.al., Inhibitors of the Plasmodium falciparum parasite aspartic protease plasmepsin II as potential antimalarial agents. CUlT Med Chem. 2003, 10, 883-907; C. Fah et. al., Enantiomerically Pure and Highly Substituted Alicyclic a,a-Difluoro Ketones:
Date Regue/Date Received 2022-08-23 9a Potential Inhibitors for Malarial Aspartic Proteases, the Plasmepsins.
Eur.J.Chem., 2010, 4617-4629.; T. Luksch et.al.,Pyrrolidine Derivatives as Date Recue/Date Received 2022-02-22 Plasmepsin Inhibitors: Binding Mode Analysis Assisted by Molecular Dynamics Simulations of a Highly Flexible Protein. ChemMedChem., 2010, 5, 443-454) Stereochemistry Many of the chemical structures shown herein indicate one or more specific stereoisomeric configurations. Similarly, many of the chemical structures shown herein are silent in this respect, and do not indicate any stereoisomeric configuration. Similarly, many of the chemical structures shown herein indicate the specific stereoisomeric configurations at one or more positions, but are silent with respect to one or more other positions.
Where a chemical structure herein is silent with respect to the stereoisomeric configuration at a position, that structure is intended to depict all possible stereoisomeric configurations at that position, both individually, as if each possible stereoisomeric configuration was individually recited, and also as a mixture (e.g., a racemic mixture) of stereoisomers.
Combinations Each and every compatible combination of the embodiments described above is explicitly disclosed herein, as if each and every combination was individually and explicitly recited.
Examples of Specific Embodiments The following examples further illustrate the invention, but should not be construed to limit the scope of the invention in any way.
The following aminoalkylazoles were prepared as an examples of the current invention:
ID ComdNo Structure N NEk 1. GL-1547 8.1 õpen so 's17.$31 2. GL-1556 8.2 L
3. GL-1562 8.3 n-Pent 4. GL-1570 8,4 5. GL-1634 8,5 U.
ir,,yr,14 6. GL-1643 8.6 11-Penp:
, #
7. GL-1686 8.7 N
1-11$31 8. GL-1726 8.8 Me 9. GL-1638 8.9 n-Pent "
In another aspect, the invention features the use of such novel intermediates, for the compound with general formula I as described herein, in the methods of synthesis described herein.
As will be appreciated by one of skill in the art, features and preferred embodiments of one aspect of the invention will also pertain to other aspects of the invention.
Description of invention Plasmepsins are malarial aspartic proteases have been identified as a group of promising biological targets for the development of new anti-malaria agents. For example, plasmepsin Ills used by the parasite in the first stage of hemoglobin digestion, which is the main nutrition source during its erythrocytic cycle (K. Ersmark, B. Samuelsson, A.
Hallberg, Plasmepsins as Potential Targets for New Antimalarial Therapy. Med. Res. Rev., 2006, 26, 626-666; G. H. Coombs, D. E. Goldberg, M. Klemba, C. Berry, J. Kay and J. C.
Mottram, Aspartic proteases of Plasmodium falciparum and other parasitic protozoa as drug targets.
Trends in Parasitology, 2001, 17, 532-537).
When testing the novel substituted aminoalkylazoles derivatives for their ability to inhibit plasmepsin II we have unexpectedly discovered, that said derivatives exhibit pronounced inhibitor properties toward said plasmepsin and thus are useful in treatment of malaria.
According to this invention, the results from plasmepsin inhibition studies demonstrate that substituted aminoalkylazoles derivatives are novel class of non-peptidic inhibitors of malarial aspartic proteases -plasmepsins. Several example compounds from the present invention display high nanomolar to low micromolecular inhibitory potency that is comparable to known non-peptidic inhibitors (e.g. F. Hof et. al., Starving the malaria parasite: Inhibitors active against the aspartic proteases plasmepsins I, II, and IV. Angew.
Chem. Int. Ed. 2006, 45, 2138-2141; T. Luksch et.al., Computer-Aided Design and Synthesis of Nonpeptidic Plasmepsin II and IV Inhibitors. ChemMedChem., 2008, 3, 1323-1336.; C. Boss et.al., Inhibitors of the Plasmodium falciparum parasite aspartic protease plasmepsin II as potential antimalarial agents. CUlT Med Chem. 2003, 10, 883-907; C. Fah et. al., Enantiomerically Pure and Highly Substituted Alicyclic a,a-Difluoro Ketones:
Date Regue/Date Received 2022-08-23 9a Potential Inhibitors for Malarial Aspartic Proteases, the Plasmepsins.
Eur.J.Chem., 2010, 4617-4629.; T. Luksch et.al.,Pyrrolidine Derivatives as Date Recue/Date Received 2022-02-22 Plasmepsin Inhibitors: Binding Mode Analysis Assisted by Molecular Dynamics Simulations of a Highly Flexible Protein. ChemMedChem., 2010, 5, 443-454) Stereochemistry Many of the chemical structures shown herein indicate one or more specific stereoisomeric configurations. Similarly, many of the chemical structures shown herein are silent in this respect, and do not indicate any stereoisomeric configuration. Similarly, many of the chemical structures shown herein indicate the specific stereoisomeric configurations at one or more positions, but are silent with respect to one or more other positions.
Where a chemical structure herein is silent with respect to the stereoisomeric configuration at a position, that structure is intended to depict all possible stereoisomeric configurations at that position, both individually, as if each possible stereoisomeric configuration was individually recited, and also as a mixture (e.g., a racemic mixture) of stereoisomers.
Combinations Each and every compatible combination of the embodiments described above is explicitly disclosed herein, as if each and every combination was individually and explicitly recited.
Examples of Specific Embodiments The following examples further illustrate the invention, but should not be construed to limit the scope of the invention in any way.
The following aminoalkylazoles were prepared as an examples of the current invention:
ID ComdNo Structure N NEk 1. GL-1547 8.1 õpen so 's17.$31 2. GL-1556 8.2 L
3. GL-1562 8.3 n-Pent 4. GL-1570 8,4 5. GL-1634 8,5 U.
ir,,yr,14 6. GL-1643 8.6 11-Penp:
, #
7. GL-1686 8.7 N
1-11$31 8. GL-1726 8.8 Me 9. GL-1638 8.9 n-Pent "
10. GL-1566 8.10 n Pent ip 8.11
11. GL-1625 N
npe., mo
npe., mo
12. GL-1639 8.12 m "1.
n Pent *
I
n Pent *
I
13. LV-1136 33.1 C4HU'O'N'N
14. LV-1087 34.1 ci
15. LV-1154 34.2 z I1) \
16. LV-1155 34.3
17. LV-1157 34.4 4A-10 ¨N.= **
18. LV-1170 34.5 IP
19. LV-1077 34.6 c "1"0-NAN
20. LV-1130 35.1 0 r--
21. LV-1124 35.2 amnia ,p4.cip
22. KD-302 36.1
23. VGP-153 36.2
24. KD-294 44 * NN
25. KD-263 47 C'Fla * N-14'N Cl
26. KD-304 48.1ci ,
27. KD-307 48.2 c5H1--0-NA'N
¨
coõ
¨
coõ
28. KD-309 48.3 cAl ON
29. KD-329 48.4 0 ¨
¨0 N,NN
¨0 N,NN
30. 1CD-330 48.5 GA' N'N'N
31. K13-315 48.6 0 N¨\
Nr:
Nr:
32. KD-199 56.1 CI
0_ LN
colt, _0
0_ LN
colt, _0
33. KD-233 56.2 C5Hi, N
34. LV-1341 63 C51-1õ
35. LV - 1402 71 IP
c\
õ
c\
õ
36. LV-1417 72 N ¨\\
Gall" N )
Gall" N )
37. LV-1528 84 G51-1õ
38. LV-1532 85 1.1 c,H,, ¨ N
39. LV-1570 88 0¨
General Synthesis The synthesis of aminoalkylimidazoles 8.1-9 is shown in scheme 1. Commercially available acyl chloride 1 was transformed to amide the intermediate amide was dehydrated to give cyano benzene derivative 2. This was subjected to the reaction with 4-aminomethyl (bromobenzene) hydrochloride (3) in the presence of A1Me3 providing amidine derivative 4.
This was transformed to 5-formylimidazole 6 in the reaction with unsaturated aldehyde 5 [Shilcrat, Susan C.; Mokhallalati, Mohamed K.; Fortunak, Joseph M. D.;
Pridgen, Lendon N.
A New Regioselective Synthesis of 1,2,5-Trisubstituted 1H-Imidazo1es and Its Application to the Development of Eprosartan. J.Org. Chem. 1997, 62, 8449-8454]. Next, the Suzuki-Miyaura reaction of aldehyde 6 with boronic acid provided intermediate 7 which were subjected to reductive amination with range of amines providing series of compounds 8.1-9.
Br1H 5 Br "H NH ' 01-Pr 1. NH4OH, THF AlMe3 3 CI NH 6 M aq 1<2003 n-Pent¨ * C(0)CI ' n-Pent Cfµ.1 ..
2. SOC * I2, Toluene Toluene n-Pent .
Br N
3-PYB(OH)2 11---L,NRIR2 i ---$_,,ro 27 ahq3pr?i4a2c03 111-1),y0 rta313Ac)3 Iti H IPA, toluene n-Pent n_ pent * H AcOH, THF ropent N
Br 6 , 7 N ' N 8.1.9 Scheme 1 The synthesis of aminomethylimidazoles 8.10,11 is shown in scheme 2.
Formylimidazole 7 (scheme 1) was reduced to hydoxymethylimidazole 9. This was subjected to azidation with 5 diphenylphosforyl azide (DPPA) followed by catalytic reduction of intermediate azide to aminomethylimidazole 8.10. Reductive alkylation of amine 8.10 with isovaleraldehyde provided N-substituted aminomethylimidazole 8.11.
r) ......__AN I. DPPA, DBU, IsrL,NH2 sovaleraldehyde NNR1R2 DIBAL-H Toluene NaB(OHAc)3 7 ________________________________________ 40 N 40 N _________ 0 N
2.H2, 10% Pd/C
DCM n-Pent n-Pent AcOH, n-Pent Me0H THF
----, ',..
N N 8.10 I , 8,11 r N
Scheme 2 10 The synthesis of 2-aminoprop-2-ylimidazole 8.12 is shown in scheme 3.
Aldehyde 7 was subjected to the reaction with Grignard reagent providing alcohol 10. This was oxidized and the intermediate ketone was subjected to the Grignard reagent providing alcohol 11. The Ritter reaction of alcohol 11 with trimethylsilylcyanide (TMSCN) gave amine 8.12.
OH r'il---..icõ01.1 1. TMSCN N<NFI2 1. PDC, DCM AcOH, H2SO4 7 MeMgBr _ 0 N I
Me --==- so N Me' me THF n-Pent 2. MeMgBr io IN Me Me 2. conc. eq.
THF n-Pent HC1, Diox "-Pent -,-.
10 _______________________________ .
i N .^ 11 1 _.- 6,12 N N
Scheme 3 Synthesis of intermediate 2 Chloroanhydride 1 (2.1 g, 10 mmol) was dissolved in THF (50 mL) and to this;
concentrated aqueous ammonia (15 mL) was added at room temperature. The mixture was stirred for 2 h, then diluted with saturated aqueous NaC1 and extracted with Et0Ac. The combined organic extract was dried over Na2SO4 and evaporated. The crude amide was suspended in toluene (150 mL) and to this SOC12 (14.6 mL, 200 mmoL) was added. The mixture was refluxed for 48 h and then evaporated. The residue was purified by column chromatography on silica gel (eluent Petroleum ether: Et0Ac = 1: 0 to 20: 1) to give nitrile 2(1.16 g, 67 %) as an oil.
Synthesis of intermediate 4 4-(Bromophenyl)methanamine hydrochloride (3) (445 mg, 2 mmol) was suspended in toluene (5 mL) and the mixture was cooled in an ice bath. To this, 2 M AlMe3 in Hexane (1 mL, 2 mmol) was added dropwise. The mixture was warmed to room temperature and stirred for 30 min. Then, a solution of 4-pentylbenzonitrile (2) in toluene (12 mL) was added and the mixture was heated to 110 C for 4 h in a sealed reactor. After cooling to room temperature, 1 M aqueous NaOH (20 mL) was added and the mixture was extracted with Et0Ac (3 x mL). The combined organic phase was washed with brine and dried over Na2SO4.
Solvent was removed in vacuo and the residue was treated with Et20. The precipitate was collected on a filter and dried to give product 4 (270 mg, 38 %).
Synthesis of intermediate 6 Exemplified by the synthesis of 6: A mixture of amidine 4 (270 mg, 0.75 mmol) and (E)-2-bromo-3-isopropoxyacrylaldehyde (5) (174 mg, 0.9 mmol), 6 M aqueous K2CO3 (0.15 mL) and CHC13 (7 mL) was stirred at room temperature for 48 h. The mixture was diluted with saturated aqueus NaC1 and extracted with Et0Ac. The organic phase was dried over Na2SO4 and evaporated. The residue was treated with dichloromethane to give crystalline product 6 (54 mg, 18%) which was collected by filtration. An additional amount of product 6 (130 mg, 42%) was isolated from the mother liquid by radial chromatography on silica gel (CH2C12 Me0H = 1 : 0 to 1 :1).
Synthesis of intermediate 7 A mixture of intermediate 6 (130 mg, 0.32 mmol), 3-pyridine boronic acid (39 mg, 0.32 mmol), Pd(PPh3)4 (3 mg, 5 mol%), 2 M aqueous NaHCO3 (5 mL), isopropylalcohol (5 mL) and toluene (5 mL) was heated at 90 C for 4 h. The mixture was cooled to room temperature and solvents evaporated. The residue was purified by radial chromatography on silica gel (eluent, petroleum ether : Et0Ac = 1: 1 to 0: 1) to yield 7 (90 mg, 69% yield) as colorless solid.
Synthesis of aminoalkyl imidazoles 8.1-8.9. General method A.
Exemplified by the synthesis of 8.1 (GL-1547): To the solution of aldehyde 7.
(60 mg, 0.15 mmol) and diethylamine (17 uL, 0.165 mmol) in THF (6 mL) 4A molecular sieves were added and the mixture was cooled in an ice bath. To this, NaBH(OAc)4 (48 mg, 0.225 mmol) and AcOH (34 uL, 0.6 mmol) was added and the mixture was stirred at room temperature for 24 h. Saturated aqueous NaHCO3 was added and the mixture was extracted with Et0Ac. The organic phase was separated and dried over Na2SO4. The solvent was then removed in vacuo and the residue was purified by column chromatography (Et0Ac : Me0H = 1: 0 to 1 : 4) to yield 8.1 (21 mg, 30% yield) as colorless solid.
By a method analogous to Method A using compound 7 as a precursor, the following compounds were obtained:
Compound ID
Structure No NB.
8.1 GL-1547 fl Pe I , 8.2 GL1556 n-Perd 11111-15 rN)'H
8.3 GL 1562 fl.pa.tome , 8.4 GL-1570 rk1},,AX) 8.5 GL-1634 n=p.rec *
8.6 GL-1643 n-Pentcyd ,C?P
8.7 GL-1686 84.9nt 8.8 GL-1726 N, -CrQji 8.9 GL-1638 n.Pent Synthesis of intermediate 9 A solution of aldehyde 7 (1.02 g, 2.5 mmol) in DCM (100 mL) was cooled to -78 C and to this a solution of DIBAL-H in toluene (4.2 mL, 5.0 mmol) was added dropwise.
The mixture was stirred at -78 C for 2 h and then quenched by the addition of Me0H (5 mL).
Saturated Segnet's salt solution was added and the product was extracted with DCM. The organic phase was dried over Na2SO4 and evaporated to give alcohol 9 (940 mg, 91%).
Synthesis of aminomethylimidazole 8.10 The suspension of alcohol 9 (940 mg, 2.28 mmol) in toluene (23 mL) was cooled in an ice bath. To this mixture, diphenylphosphorylazide (DPPA) (0.64 mL, 2.96 mmol) and DBU
(0.44 mL, 2.96 mmol) was added. The mixture was stirred at room temperature for 4 h and diluted with a saturated aqueous NaCl. The product was extracted into Et0Ac and the organic phase was dried over Na2SO4. The solvent was removed in vacuo and the crude product was purified by flash chromatography on silica gel eluting with Et0Ac to give inteimediate azide .. (760 mg, 76 %). Azide (140 mg, 0.32 mmol) was dissolved in Me0H (14 mL) and to this solution, 10% Pd on C was added (4 mg). The reaction mixture was stirred in the hydrogen atmosphere (1 atm) for 1 h 30 min and filtered through the short Celite column. The solvent was evaporated to give product 8.10 (130 mg, 100%).
Synthesis of aminoalkylimidazole 8.11 To the solution of amine 8.10 (12 mg, 0.029 mmol) and isovaleraldehyde (5 uM, 0.044 mmol) in Me0H (2 mL) 4 A molecular sieves were added and the mixture was cooled in an ice bath.
To this, NaBH(OAc)4 (4 mg, 0.066 mmol) and AcOH (7 uL, 0.116 rrunol) was added and the mixture was stirred at room temperature for 24 h. Saturated aqueous NaHCO3 was added and the mixture was extracted with Et0Ac. The organic phase was separated and dried over Na2SO4. The solvent was then removed in vacuo and the residue was purified by column chromatography (eluent, Et0Ac : Me0H = 1: 0 to 1: 4) to yield 8.11 (4 mg, 25%
yield) as colorless solid.
Synthesis of intermediate 10 A solution of aldehyde 7 (1.7 g, 4.15 mmol) in THF (100 mL) was cooled to -78 C. To this, 2.4 M MeMgBr solution in Et20 (3.46 =not, 8.30 mmol) was added dropwise. The reaction mixture was warmed to room temperature and stirred overnight. It was cooled in an ice bath and quenched by the addition of water, and then aqueous phase was saturated with NaCI and extracted with Et0Ac. The organic extract was dried over Na2SO4 and the solvent evaporated in vacuo. The residue was treated with Et20 and the precipitate was collected on the filter to give secondary alcohol 10 as crystalline solid 1.36 g (77%).
Synthesis of intermediate 11 The intermediate alcohol 10 (426 mg, 1.0 mmol) was dissolved in DCM (10 mL) and added dropwise to a solution of pyridinium dichromate (752 mg, 2.0 mmol) in DCM (16 mL). The resulting mixture was stilled at room temperature for 4 h and then diluted with Et20. The suspension was filtered through the Celite and the solvent evaporated. The crude residue (170 mg) was dissolved in THF (20 mL) and the solution was cooled to 0 C. Then 2.4 M
MeMgBr solution in Et20 was added dropwise, the solution was warmed to room temperature and stirred for 2 h. The mixture was cooled in an ice bath and quenched by the addition of water. The aqueous phase was saturated with NaC1 and extracted with Et0Ac. The organic extract was dried over Na2SO4 and evaporated. The residue was purified by flash chromatography on silica gel (eluent, petroleum ether: Et0Ac, 1 : 1 - 0 : 1) to give intermediate 10 (40 mg, 9 %) Synthesis of aminomethylimidazole 8.12 Alcohol 10 (10 mg, 0.023 mmol) was dissolved in AcOH (0.2 mL) and TMSCN (6.1 uL;
0.046 mmol) was added to the solution. The solution was cooled to -15 C and to this concentrated sulfuric acid (0.24 mL) was added dropwise. The mixture was warmed to room temperature and stirred for 16 h, then it was diluted with aqueous saturated NaHCO3 and extracted with Et0Ac. The organic phase was concentrated in vacuo and the residue was dissolved in dioxane. To this concentrated aqueous HCl was added and the resulting mixture was heated at 80 C for 2 h. After cooling to room temperature, 1 M aqueous KOH
was added and the product was extracted into Et0Ac. The organic extract was dried over Na2SO4 and evaporated. Chromatography on preparative TLC provided 8.12 (3 mg, 30%).
Synthesis of aminoalkyltriazoles 33, 34.1-6, 35.1-2 is shown in scheme 4 -...
General Synthesis The synthesis of aminoalkylimidazoles 8.1-9 is shown in scheme 1. Commercially available acyl chloride 1 was transformed to amide the intermediate amide was dehydrated to give cyano benzene derivative 2. This was subjected to the reaction with 4-aminomethyl (bromobenzene) hydrochloride (3) in the presence of A1Me3 providing amidine derivative 4.
This was transformed to 5-formylimidazole 6 in the reaction with unsaturated aldehyde 5 [Shilcrat, Susan C.; Mokhallalati, Mohamed K.; Fortunak, Joseph M. D.;
Pridgen, Lendon N.
A New Regioselective Synthesis of 1,2,5-Trisubstituted 1H-Imidazo1es and Its Application to the Development of Eprosartan. J.Org. Chem. 1997, 62, 8449-8454]. Next, the Suzuki-Miyaura reaction of aldehyde 6 with boronic acid provided intermediate 7 which were subjected to reductive amination with range of amines providing series of compounds 8.1-9.
Br1H 5 Br "H NH ' 01-Pr 1. NH4OH, THF AlMe3 3 CI NH 6 M aq 1<2003 n-Pent¨ * C(0)CI ' n-Pent Cfµ.1 ..
2. SOC * I2, Toluene Toluene n-Pent .
Br N
3-PYB(OH)2 11---L,NRIR2 i ---$_,,ro 27 ahq3pr?i4a2c03 111-1),y0 rta313Ac)3 Iti H IPA, toluene n-Pent n_ pent * H AcOH, THF ropent N
Br 6 , 7 N ' N 8.1.9 Scheme 1 The synthesis of aminomethylimidazoles 8.10,11 is shown in scheme 2.
Formylimidazole 7 (scheme 1) was reduced to hydoxymethylimidazole 9. This was subjected to azidation with 5 diphenylphosforyl azide (DPPA) followed by catalytic reduction of intermediate azide to aminomethylimidazole 8.10. Reductive alkylation of amine 8.10 with isovaleraldehyde provided N-substituted aminomethylimidazole 8.11.
r) ......__AN I. DPPA, DBU, IsrL,NH2 sovaleraldehyde NNR1R2 DIBAL-H Toluene NaB(OHAc)3 7 ________________________________________ 40 N 40 N _________ 0 N
2.H2, 10% Pd/C
DCM n-Pent n-Pent AcOH, n-Pent Me0H THF
----, ',..
N N 8.10 I , 8,11 r N
Scheme 2 10 The synthesis of 2-aminoprop-2-ylimidazole 8.12 is shown in scheme 3.
Aldehyde 7 was subjected to the reaction with Grignard reagent providing alcohol 10. This was oxidized and the intermediate ketone was subjected to the Grignard reagent providing alcohol 11. The Ritter reaction of alcohol 11 with trimethylsilylcyanide (TMSCN) gave amine 8.12.
OH r'il---..icõ01.1 1. TMSCN N<NFI2 1. PDC, DCM AcOH, H2SO4 7 MeMgBr _ 0 N I
Me --==- so N Me' me THF n-Pent 2. MeMgBr io IN Me Me 2. conc. eq.
THF n-Pent HC1, Diox "-Pent -,-.
10 _______________________________ .
i N .^ 11 1 _.- 6,12 N N
Scheme 3 Synthesis of intermediate 2 Chloroanhydride 1 (2.1 g, 10 mmol) was dissolved in THF (50 mL) and to this;
concentrated aqueous ammonia (15 mL) was added at room temperature. The mixture was stirred for 2 h, then diluted with saturated aqueous NaC1 and extracted with Et0Ac. The combined organic extract was dried over Na2SO4 and evaporated. The crude amide was suspended in toluene (150 mL) and to this SOC12 (14.6 mL, 200 mmoL) was added. The mixture was refluxed for 48 h and then evaporated. The residue was purified by column chromatography on silica gel (eluent Petroleum ether: Et0Ac = 1: 0 to 20: 1) to give nitrile 2(1.16 g, 67 %) as an oil.
Synthesis of intermediate 4 4-(Bromophenyl)methanamine hydrochloride (3) (445 mg, 2 mmol) was suspended in toluene (5 mL) and the mixture was cooled in an ice bath. To this, 2 M AlMe3 in Hexane (1 mL, 2 mmol) was added dropwise. The mixture was warmed to room temperature and stirred for 30 min. Then, a solution of 4-pentylbenzonitrile (2) in toluene (12 mL) was added and the mixture was heated to 110 C for 4 h in a sealed reactor. After cooling to room temperature, 1 M aqueous NaOH (20 mL) was added and the mixture was extracted with Et0Ac (3 x mL). The combined organic phase was washed with brine and dried over Na2SO4.
Solvent was removed in vacuo and the residue was treated with Et20. The precipitate was collected on a filter and dried to give product 4 (270 mg, 38 %).
Synthesis of intermediate 6 Exemplified by the synthesis of 6: A mixture of amidine 4 (270 mg, 0.75 mmol) and (E)-2-bromo-3-isopropoxyacrylaldehyde (5) (174 mg, 0.9 mmol), 6 M aqueous K2CO3 (0.15 mL) and CHC13 (7 mL) was stirred at room temperature for 48 h. The mixture was diluted with saturated aqueus NaC1 and extracted with Et0Ac. The organic phase was dried over Na2SO4 and evaporated. The residue was treated with dichloromethane to give crystalline product 6 (54 mg, 18%) which was collected by filtration. An additional amount of product 6 (130 mg, 42%) was isolated from the mother liquid by radial chromatography on silica gel (CH2C12 Me0H = 1 : 0 to 1 :1).
Synthesis of intermediate 7 A mixture of intermediate 6 (130 mg, 0.32 mmol), 3-pyridine boronic acid (39 mg, 0.32 mmol), Pd(PPh3)4 (3 mg, 5 mol%), 2 M aqueous NaHCO3 (5 mL), isopropylalcohol (5 mL) and toluene (5 mL) was heated at 90 C for 4 h. The mixture was cooled to room temperature and solvents evaporated. The residue was purified by radial chromatography on silica gel (eluent, petroleum ether : Et0Ac = 1: 1 to 0: 1) to yield 7 (90 mg, 69% yield) as colorless solid.
Synthesis of aminoalkyl imidazoles 8.1-8.9. General method A.
Exemplified by the synthesis of 8.1 (GL-1547): To the solution of aldehyde 7.
(60 mg, 0.15 mmol) and diethylamine (17 uL, 0.165 mmol) in THF (6 mL) 4A molecular sieves were added and the mixture was cooled in an ice bath. To this, NaBH(OAc)4 (48 mg, 0.225 mmol) and AcOH (34 uL, 0.6 mmol) was added and the mixture was stirred at room temperature for 24 h. Saturated aqueous NaHCO3 was added and the mixture was extracted with Et0Ac. The organic phase was separated and dried over Na2SO4. The solvent was then removed in vacuo and the residue was purified by column chromatography (Et0Ac : Me0H = 1: 0 to 1 : 4) to yield 8.1 (21 mg, 30% yield) as colorless solid.
By a method analogous to Method A using compound 7 as a precursor, the following compounds were obtained:
Compound ID
Structure No NB.
8.1 GL-1547 fl Pe I , 8.2 GL1556 n-Perd 11111-15 rN)'H
8.3 GL 1562 fl.pa.tome , 8.4 GL-1570 rk1},,AX) 8.5 GL-1634 n=p.rec *
8.6 GL-1643 n-Pentcyd ,C?P
8.7 GL-1686 84.9nt 8.8 GL-1726 N, -CrQji 8.9 GL-1638 n.Pent Synthesis of intermediate 9 A solution of aldehyde 7 (1.02 g, 2.5 mmol) in DCM (100 mL) was cooled to -78 C and to this a solution of DIBAL-H in toluene (4.2 mL, 5.0 mmol) was added dropwise.
The mixture was stirred at -78 C for 2 h and then quenched by the addition of Me0H (5 mL).
Saturated Segnet's salt solution was added and the product was extracted with DCM. The organic phase was dried over Na2SO4 and evaporated to give alcohol 9 (940 mg, 91%).
Synthesis of aminomethylimidazole 8.10 The suspension of alcohol 9 (940 mg, 2.28 mmol) in toluene (23 mL) was cooled in an ice bath. To this mixture, diphenylphosphorylazide (DPPA) (0.64 mL, 2.96 mmol) and DBU
(0.44 mL, 2.96 mmol) was added. The mixture was stirred at room temperature for 4 h and diluted with a saturated aqueous NaCl. The product was extracted into Et0Ac and the organic phase was dried over Na2SO4. The solvent was removed in vacuo and the crude product was purified by flash chromatography on silica gel eluting with Et0Ac to give inteimediate azide .. (760 mg, 76 %). Azide (140 mg, 0.32 mmol) was dissolved in Me0H (14 mL) and to this solution, 10% Pd on C was added (4 mg). The reaction mixture was stirred in the hydrogen atmosphere (1 atm) for 1 h 30 min and filtered through the short Celite column. The solvent was evaporated to give product 8.10 (130 mg, 100%).
Synthesis of aminoalkylimidazole 8.11 To the solution of amine 8.10 (12 mg, 0.029 mmol) and isovaleraldehyde (5 uM, 0.044 mmol) in Me0H (2 mL) 4 A molecular sieves were added and the mixture was cooled in an ice bath.
To this, NaBH(OAc)4 (4 mg, 0.066 mmol) and AcOH (7 uL, 0.116 rrunol) was added and the mixture was stirred at room temperature for 24 h. Saturated aqueous NaHCO3 was added and the mixture was extracted with Et0Ac. The organic phase was separated and dried over Na2SO4. The solvent was then removed in vacuo and the residue was purified by column chromatography (eluent, Et0Ac : Me0H = 1: 0 to 1: 4) to yield 8.11 (4 mg, 25%
yield) as colorless solid.
Synthesis of intermediate 10 A solution of aldehyde 7 (1.7 g, 4.15 mmol) in THF (100 mL) was cooled to -78 C. To this, 2.4 M MeMgBr solution in Et20 (3.46 =not, 8.30 mmol) was added dropwise. The reaction mixture was warmed to room temperature and stirred overnight. It was cooled in an ice bath and quenched by the addition of water, and then aqueous phase was saturated with NaCI and extracted with Et0Ac. The organic extract was dried over Na2SO4 and the solvent evaporated in vacuo. The residue was treated with Et20 and the precipitate was collected on the filter to give secondary alcohol 10 as crystalline solid 1.36 g (77%).
Synthesis of intermediate 11 The intermediate alcohol 10 (426 mg, 1.0 mmol) was dissolved in DCM (10 mL) and added dropwise to a solution of pyridinium dichromate (752 mg, 2.0 mmol) in DCM (16 mL). The resulting mixture was stilled at room temperature for 4 h and then diluted with Et20. The suspension was filtered through the Celite and the solvent evaporated. The crude residue (170 mg) was dissolved in THF (20 mL) and the solution was cooled to 0 C. Then 2.4 M
MeMgBr solution in Et20 was added dropwise, the solution was warmed to room temperature and stirred for 2 h. The mixture was cooled in an ice bath and quenched by the addition of water. The aqueous phase was saturated with NaC1 and extracted with Et0Ac. The organic extract was dried over Na2SO4 and evaporated. The residue was purified by flash chromatography on silica gel (eluent, petroleum ether: Et0Ac, 1 : 1 - 0 : 1) to give intermediate 10 (40 mg, 9 %) Synthesis of aminomethylimidazole 8.12 Alcohol 10 (10 mg, 0.023 mmol) was dissolved in AcOH (0.2 mL) and TMSCN (6.1 uL;
0.046 mmol) was added to the solution. The solution was cooled to -15 C and to this concentrated sulfuric acid (0.24 mL) was added dropwise. The mixture was warmed to room temperature and stirred for 16 h, then it was diluted with aqueous saturated NaHCO3 and extracted with Et0Ac. The organic phase was concentrated in vacuo and the residue was dissolved in dioxane. To this concentrated aqueous HCl was added and the resulting mixture was heated at 80 C for 2 h. After cooling to room temperature, 1 M aqueous KOH
was added and the product was extracted into Et0Ac. The organic extract was dried over Na2SO4 and evaporated. Chromatography on preparative TLC provided 8.12 (3 mg, 30%).
Synthesis of aminoalkyltriazoles 33, 34.1-6, 35.1-2 is shown in scheme 4 -...
40 N3 O' I. , Si.õ. 0 Br 0"-- Cl"
HOõOH 13 HOB .OH 051-1.1 Pd(PPh3)4 CuBr 110 0 0 OH Br AgNO3 2M Na2C0? LiAIH4 PBr3 .. i-PrMgCI KCN Cp-RuC23I(COD) ___________________ . _________________________________ . __________ .
THF CH2C12 THF 0 H20, Et0FI
Toluene 1,4-dioxane i-PrOH
?
0 0 '"'= I
I Si-12 14 15 16 18 19 20: n=0 21: n=1 22: n=2 C5H.. 0 N C5H.. *
N C5H11 illp C5H.. 111 N.
_____________________________________ BH3.THF HOBt, EDO __ N-R . n __.- n n 0 OH DMF THF r.-R.
(,\ 1,4-dioxane 12 R2 24: n=0 27: n=0 30: n=0 33: n=0 25: n=1 28: n=1 31.1-6: n=1 34.1-6: n=1 26: n=2 29: n=2 32.1-2: n=2 35.1-2: n=2 Scheme 4 Synthesis of intermediate 14 An oven dried pressure tube was charged with 4-methoxycarbonylphenylboronic acid (12) (2.00 g, 11.10 mmol, 1.0 equiv.), 4-bromoanisole (13) (2.08 g, 11.10 mmol, 1.0 eqiuv.) and Pd(PPh3)4 (40 mg, 0.035 mmol, 0.003 eqiuv.). To the starting materials i-PrOH
(20 mL), toluene (20 mL) and 2M Na2CO3 aq. solution (25 mL) were added and the mixture was heated at 90 C for 9h. The mixture was extracted with CH2C12 (4 x 30 mL). Combined organic layers were dried over Na2SO4 and evaporated under reduced pressure. The residue was purified by column chromatography (100% CH2C12) to yield 14 (2.00 g, 74% yield).
Synthesis of intermediate 15 The carboxylic acid methyl ester derivative 14 (2.00 g, 8.25 mmol, 1.0 eqiuv.) was dissolved in THF (dry) (20 mL) and the solution was cooled to 0 C. To the solution 2.4M
LiA1H4/THF
(4.5 mL, 10.70 mmol, 1.3 equiv.) was added dropwise and stirring was continued at r.t. for 2h. The reaction mixture was cooled to 0 C and 1120 (0.4 mL) was added and stirred for 5 mm, then 4N NaOH sol. (0.8 mL) was added and stirred for 10 min, after that H20 (1.2 mL) was added and stirred for 10 mm. Precipitate was filtered off and filtrate was evaporated, giving the desired product 15 (1.76 g, 99%).
Synthesis of intermediate 16 Alcohol 15 (1.76 g, 8.21 mmol, 1.0 equiv.) was dissolved in CH2C12 and PBr3 (4.22 g, 1.5 mL, 15.60 mmol, 1.9 equiv.) was added dropwise. The mixture was stirred at r.t. for 16h. To the reaction mixture H20 (20 mL) was added and stirring was continued for 20 mm. Organic layer was separated and washed with H20 (2 x 40 mL). Organic layer was dried over Na2SO4 and evaporated under reduced pressure to yield product 16 (2.26 g, 99%).
Synthesis of intermediate 18 Solution of trimethylsilylacetylene (17) (1.42 g; 2.0 mL; 14.40 mmol, 4.0 eqiuv.) in THF
(dry) (10 mL) was cooled to 0 C and 2M i-PrMgCl/THF (5.4 mL; 10.80 mmol, 3.0 equiv.) was added dropwise. The mixture was stirred at 0 C for 30 mm, then at r.t. for lh. Then CuBr (0.31 g, 2.16 mmol, 0.6 equiv.) was added to the reaction mixture and stirred at r.t. for 30 mm, after that solution of benzylbromide 16 (1.00 g, 3.60 mmol, 1.0 equiv.) in THF (5 mL) was added. Reaction mixture was heated at reflw( for 3h. The solvent was then removed in vacuo and H20 (10 mL) and Et0Ac (10 mL) were added to the residue. Precipitate was filtered off and filtrate was extracted with Et0Ac (2 x 30 mL). Combined organic layers were dried over Na2SO4 and evaporated under reduced pressure. Residue was purified by column chromatography (PE/Et0Ac=95:5) to give product 18 (0.94 g, 89%).
Synthesis of intermediate 19 To the solution of (3-(4'-methoxy-[1,1'-bipheny1]-4-yl)prop-1-yn-1-yptrimethylsilane (18) (0.90 g, 3.06 mmol, 1.0 eqiuv.) in Et0H (16 mL) AgNO3 (0.78 g, 1.5 eqiuv.) solution in H20/Et0H (4 mL, 1:3) was added dropwise. Mixture was stirred at r.t. for 30 mm, after that KCN (1.97 g, 9.9 equiv.) solution in H20 was added. Stirring was continued for 2h. Reaction mixture was partitioned between Et0Ac and 1120. Organic layer was washed with H20 (2 x 20 mL), brine, dried over Na2SO4 and evaporated under reduced pressure to give product 19 (0.65 g, 96%).
Synthesis of intermediate 20 An oven dried pressure tube was charged with 4-(bromomethyl)-4'-methoxy-1,1'-biphenyl (16) (1.78 g, 6.40 mmol, 1.0 equiv.), Cu! (1.22 g, 6.40 mmol, 1.0 equiv.), K2CO3 (887 mg, 6.40 mmol, 1.0 equiv.) and Bu4N+I- (2.37 g, 6.40 mmol, 1.0 equiv.). MeCN (15 mL) was added followed by dropwise addition of ethyl propiolate (1.26 g, 12.84 mmol, 2.0 equiv.) was added dropwise. The mixture was stirred at 40 C for 16h. To the reaction mixture sat. NH4C1 so!. (30 mL) was added and the resulting suspension was extracted with Et0Ac (3 x 25 mL).
Combined organic layers were dried over Na2SO4 and evaporated under reduced pressure.
The residue was purified by column chromatography (eluent system PE/Et0Ac=99:1 to 85:15). Yield: 1.52 g (80%).
Synthesis of intermediate 21 To the solution of 4-methoxy-4'-(prop-2-yn-1-y1)-1,1'-biphenyl (19) (0.55 g, 2.50 mmol, 1.0 eqiuv.) in MeCN (dry) (10 mL) CuI (24 mg, 0.12 mmol, 0.048 equiv.) and ethyldiazoacetate (0.31 g, 2.75 mmol, 1.1 eqiuv.) was added. The mixture was stirred at r.t. for 16h. Solvent was removed in vacuo and the residue was purified by direct phase ARMEN
chromatograph, eluent system PE/Et0Ac (95:5 to 0:100), 25 g silica gel column, flow rate 18 mLimin.
Obtained product 21 (0.63 g, 82%).
Synthesis of intermediate 22 An oven dried pressure tube was charged with 4-(bromomethyl)-4'-methoxy-1,11-biphenyl (16) (1.22 g, 4.40 mmol, 1.0 equiv.), Cu! (838 mg, 4.40 mmol, 1.0 equiv.), K2CO3 (669 mg, 4.84 mmol, 1.1 equiv.) and Bu4N+r (1.63 g, 4.40 mmol, 1.0 equiv.). MeCN (15 mL) was added followed by dropwise addition of ethyl pent-4-ynoate (610 mg, 4.84 mmol, 1.1 equiv.).
The reaction mixture was stirred at r.t. for 16h. To the reaction mixture sat.
NH4C1 sol. (30 mL) was added and resulting suspension was extracted with Et0Ac (3 x 25 mL) was performed. Combined organic layers were dried over Na2SO4 and evaporated under reduced .. pressure. The residue was purified by column chromatography (eluent system PE/Et0Ac=99:1 to 85:15). Yield: 749 mg (70%).
Synthesis of azide 23 An oven dried flask was charged with 1-bromo-4-pentylbenzene (2.00 g, 8.80 mmol, 1.0 equiv.) and THF (dry) (15 mL) was added. The solution was cooled to -78 C and 2.5M n-BuLi/hexanes (3.9 mL, 9.68 mmol, 1.1 equiv.) was added dropwise. Reaction mixture was stirred at -78 C lh, then 4-methylbenzenesulfonyl azide (2.60 g, 13.20 mmol, 1.5 eqiuv.) solution in THF (8 mL) was added. Reaction mixture was warmed up to -45 C and 20 mL of sat. NH4C1 solution was added and resulting mixture was extracted with Et0Ac (3 x 35 mL).
Combined organic extracts were washed with brine, dried over Na2SO4 and evaporated under reduced pressure. The residue was purified by column chromatography, eluent system (PE/Et0Ac=98:2). Yield: 1.29 g (77 %).
Synthesis of aminoalkyl triazoles 33,34.1-6, 35.1-2. General method B.
Exemplified by the synthesis of 34.1.
Synthesis of intermediate 25 An oven dried flask was charged with azide 23 (799 mg, 4.22 mmol, 1.2 equiv.), alkyne 21 (1.08 g, 3.52 minol, 1.0 equiv.) and Cp=RuCl(COD) (160 mg, 0.42 mmol, 12 mol%). 1,4-Dioxane (dry) (10 mL) was added and reaction mixture was stirred at r.t. for 16h. The solvent was removed in vacuo and the residue was purified by column chromatography (eluent system PE/Et0Ac=9:1 to 1:1). Yield: 485 mg (28%).
Synthesis of intermediate 28 To the triazole 25 (0.47 g, 0.94 mmol, 1.0 equiv.) in 1,4-dioxane (15 mL) 1N
NaOH sol. (8 mL) was added. Reaction mixture was stirred at r.t. for 16 h. H20 was added and resulting suspesion was extracted with Et0Ac (3 x 25 mL). Combined organic layers were washed with brine, dried over Na2SO4 and evaporated under reduced pressure. Product was used in the .. next step without purification. Yield: 0.26 g (97%).
Synthesis of inteimediate 31.1 An oven dried MW vial was charged with acid 28 (100 mg, 0.21 mmol, 1.0 equiv.) and HOBt (37 mg, 0.27 mmol, 1.3 eqiuv.), DMF (1.5 mL) and EDC (52 mg, 0.27 mmol, 1.3 equiv.) was added. The mixture was stirred at 0 C for lh, then N-methylpiperazine (32 mg, 35 uL, 1.5 equiv.) was added. Stirring continued at r.t. for 16h. To the reaction mixture H20 was added and suspension was extracted with Et0Ac (3 x 10 mL). Combined organic layers were washed with brine, dried over Na2SO4 and evaporated under reduced pressure.
Residue was purified by direct phase ARMEN chromatograph (eluent system CH2C12/Me0H=1:0 to 4:1), 12 g silicagel column, flow rate 12 mL/min. Yield: 65 mg (56%).
Synthesis of product 34.1 To the solution of amide 31.1 (56 mg, 0.11 mmol) in THF (dry) (1 mL) was added BH3=TI-1F/THF (0.5 mL). Reaction mixture was stirred at 80 C for 16, the 4N
HC! sol. (1 mL) was added and stirring was continued for lh. Reaction mixture was cooled to r.t. and basified with sat. NaHCO3 so!. to pH=8 and extracted with Et0Ac (3 x 10 mL). Combined organic layers were washed with brine, dried over Na2SO4 and evaporated under reduced pressure.
The residue was purified by column chromatography (eluent system CH2C12/Me0F1=1:0 to 4:1). Yield: 19 mg (36%).
By a method analogous to Method B using compounds 20, 21, 22 as a precursors, the following compounds were obtainded:
Compound ID Structure No c5H1, =
33.1 LV-1136 0 ¨ _ NH.,c1 34.1 LV-1087 c ) c5H" NN
_ 34.2 LV-1154 "C) 0¨
Cs 34.3 LV-1155 0¨
e511 N
34.4 LV-1157 0¨
co,' dit _ 34.5 LV-1170 0_ c5Hil 'N
34.6 LV-1077 r 35.1 LV-1130 35.2 LV-1124 N,N
36.1* KD-302 OH
¨ a-.
36.2* VGP-153 OH
*-obtained from compounds 34.5 and 34.6 Synthesis of product 36.1 An oven dried MW vial was charged with Nall (60% mineral oil) (10 mg, 0.24 mmol, 4.0 equiv.), washed with Et20 (dry) (3 x 1 mL). DMF was added (1 mL), mixture was cooled to 0 C and n-DodSH (49 mg, 58 L, 0.24 mmol, 4.0 equiv.) was added. The mixture was stirred was continued at r.t. for 10 min, then solution of 2-(2-(5-44'-methoxy-[1,1?-biphenyl]-4-ypmethyl)-1-(4-pentylpheny1)-1H-1,2,3-triazol-4-ypethyl)-1,2,3,4-tetrahydroisoquinoline (36.1) (35 mg, 0.06 mmol, 1.0 equiv.) in DMF was added. Reaction mixture was stirred at 130 C for 2h. Solvent was removed in vacuo and 1120 and sat. NH4C1 so!. was added, mixture was extracted with Et0Ac (3 x 10 mL). Combined organic layers were washed with H20, brine, dried over Na2SO4 and evaporated under reduced pressure. The residue was purified by direct phase ARMEN chromatograph, eluent system CH2C12/Me0H=100:0 to 90:10, 12 g silicagel column, flow rate 12 mL/min. HC1 salt was made and precipitate was washed with petroleum ether. Yield: 13 mg (36%).
Product 36.2 was synthesized according to the procedure provided for product 36.1 Synthesis of aminoalkyltriazoles 44, 47, 48.1-5 is shown in scheme 5 Br Br R
B(OH)2 Azide Alk N
Rd(RN13)4 __... CFRuCI(C011) ¨ Mk 411 N
'N 2M Na2CO3, 1,4-clioxane Br 0 0 Br ---\\ Toluene Br n n 0 n 0 37 38: n=0 40: n=0, Alk=Me 42: n=0, Alk=Me BH3=THF
39: n=1 41: n=1, Alk=C5H11 43: n=1, Alk=C5H11 Alk Alk N
N-N'N BH31HF W 'N Mk 411 N
¨ ________________________ = ' THF
" 0 Br N1NJNJ
45: n=0, Alk=Me 47: n=0, Alk=Me 46.1-6: n=1, Alk=C5H11 48.1-6: n=1, Alk=C5H11 44 Scheme 5 Synthesis of intermediate 38 An oven dried pressure tube was charged with 1-bromo-4-(prop-2-yn- 1 -yl)benzene (1.24 g, 6.36 mmol, 1.0 equiv.) and THF (dry) (7 mL) was added. Then 1M MeMgBr/THF (7.6 mL, 7.63 mmol, 1.2 equiv.) was added dropwise. Reaction mixture was stirred at 65 C for 3h, then cooled to r.t. and methylchloroformate (2.40 g, 2.0 mL, 25.40 mmol, 4.0 equiv.) was added quickly. The reaction mixture was stirred at 65 C for 18h. Reaction mixture was cooled to r.t.
and Et0Ac was added. The mixture was washed with 1N HC1 so!., H20 and brine, dried over Na2SO4 and evaporated under reduced pressure. The residue was purified by direct phase ARMEN chromatograph, eluent system PE/Et0Ac=98:2 to 90:10, 25 g silicagel column, flow rate 18 mL/min. Yield: 1.14 g (71 %).
Synthesis of intermediate 39 Intermediate 39 was synthesized according to the procedures provided for compound 21.
Synthesis of intermediates 42, 43 Intermediates 42, 43 were synthesized according to the procedures provided for compounds 30-32.
Synthesis of intermediates 45, 46.1-5. General method C. Exemplified by the synthesis of 46.1.
An oven dried pressure tube was charged with phenylboronic acid (26 mg, 0.21 mmol, 1.05 equiv.), amide 43 (100 mg, 0.20 mmol, 1.0 equiv.) and Pd(PPh3)4 (7 mg, 0.006 mmol, 0.03 equiv.). To the starting materials i-PrOH (1 mL), toluene (1 mL) and 2M Na2CO3 aq. solution (300 pL) were added and the mixture was heated at 90 C for 16h. Reaction mixture was extracted with Et0Ac (3 x 10 mL). Combined organic layers were dried over Na2SO4 and evaporated under reduced pressure. The residue was purified by column chromatography (PE/Et0Ac=4:1 to Et0Ac/Me0H=95:5) to yield 46.1 (86 mg, 87% yield).
By a method analogous to Method C using compound 42 and 43 as a precursors, the following compounds were obtainded:
Compound ID Structure No N 0 N.¨
_ GBH, 46.1 KD-303 -05Hõ N
46.2 KD-305 MAY
C5Fl1 hi,N,N
46.3 KD-306 \
o C'H\" WI%
46.4 KD-308 - N--Q51111,41-11 46.5 KD-328 Synthesis of products 47, 48.1-5. General method D. Exemplified by the synthesis of 48.1.
To the solution of amide 46.1 (70 mg, 0.11 mmol, 1.0 equiv.) in THF (dry) (1 mL) was added 1M BH3=THF/THF (0.5 mL). Reaction mixture was stirred at 80 C for 16, the 4N
HC1 sol. (1 mL) was added and stirring was continued for lh. Reaction mixture was cooled to r.t. and basified with sat. NaHCO3 sol. to p11=8. Extraction with Et0Ac (3 x 10 mL) was performed.
Combined organic layers were washed with brine, dried over Na2SO4 and evaporated under reduced pressure. The residue was purified by column chromatography (eluent system C112C12/Me0H=1:0 to 4:1). Yield: 49 mg (68%).
By a method analogous to Method D using amides 45, 46.1-5 as a precursors, the following compounds were obtainded:
Compound ID Structure No c,Hõ
44 KD-294 W N 'N
- N-\
Br 47 1CD-263 r\ ¨ r--\--N-001,1 *
48.1 KD-304 48.2 ICD-307 c5Hõ 4 N-N- ( 48.3 1CD-309 , c,Hõ di ,N, /
48.4 1CD-329 -0/-' Ca/10 411 NL
0 48.5 1CD-330 Tair - ---\
\--/
CcH0 ar N i 48.6* KD-315 *Obtained from 44 according to general method C.
Synthesis of aminoalkylisoxazoles 56.1-2 is shown in scheme 6 OH OH
Br H 0 4, H N,.ci 1,1..., ci Alkyne 38 TEA
io 52 n-BuLLOMF io NaH 0 CO3 .. 0 io CirRuCI(COD).
THE 1120/E120 DMF ' DCE
C5H11 C5H11 C51-11 i C5H11 N C51-111 40 o5H1, op ...- so _ ,,_ NI, --. 0 -0. _ u r - , 0 ) \--- .---Br = *
Br R
Scheme 6 Synthesis of intermediate 50 Solution of 1-bromo-4-pentylbenzene (49) (2.00 g, 8.8 mmol, 1.0 equiv.) in THF
(10 mL) was cooled to -78 C and 2.5M n-BuLi/hexanes (3.9 mL, 9.7 mmol, 1.1 equiv.) was added dropwise. The mixture was stirred at -78 C for lh. Then DMF (dry) (1.0 mL, 13.2 mmol, 1.5 equiv.) was added dropwise and the reaction mixture was warmed up to r.t. To the reaction mixture sat. NH4C1 sol. was added and mixture was extracted with Et0Ac (3 x 30 mL).
Combined organic layers were washed with brine, dried over Na2SO4 and evaporated under reduced pressure. The residue was purified by column chromatography (eluent system PE/Et0Ac=95:5). Yield: 1.55 g (99%).
Synthesis of intermediate 51 To the solution of 4-pentylbenzaldehyde (50) (1.56 g, 8.85 mmol) in 1120 (14 mL) and Et20 (14 mL) NH2011. HC1 (1.53 g, 22.1 mmol, 2.5 equiv.) and NaHCO3 (2.23 g, 26.6 mmol, 3.0 equiv.) were added. Stirred at r.t. for 16h. The reaction mixture was transferred to separating funnel and organic layer was separated off. Water layer was extracted with CH2C12 (2 x 30 mL). Combined extracts were dried over Na2SO4 and evaporated under reduced pressure (bath temperature 26 C). The residue was purified by column chromatography (eluent system PE/Et0Ac=98:2 to 90:10). Yield: 1.43 g (85%).
Synthesis of intermediate 53 To the solution of 4-pentylbenzaldehyde oxime (51) (1.30 g, 6.8 mmol, 1.0 equiv.) in DMF
(13 mL) solution of NCS 52 (908 mg, 6.8 mmol, 1.0 equiv.) in DMF (3 mL) was added dropwise. Stirred at r.t. for 40 min. To reaction mixture H20 was added and extracted with Et20 (3 x 20 mL). Combined extracts were washed with H20 and brine, dried over Na2SO4 and evaporated under reduced pressure. Yield: 1.53 g (99%).
Synthesis of intermediate 54 An oven dried pressure tube was charged with N-hydroxy-4-pentylbenzimidoyl chloride (53) (530 mg, 2.35 mmol, 1.1 equiv.), alkyne 38 (628 mg, 2.13 mmol, 1.0 equiv.), Cp=RuCl(COD) (80 mg, 0.21 mmol, 10 mol%) and DCE (dry) (4 mL) was added. To the reaction mixture TEA (431 mg, 592 pit, 4.26 mmol, 2.0 equiv.) solution in DCE (1 mL) was slowly dropwise (during 1h) added. Stirred at r.t. for 16h. Solvent was removed in vacuo and the residue was purified by direct phase ARMEN chromatograph, eluent system PE/Et0Ac=90:10 to 75:25, 25 g silicagel column, flow rate 18 mL/min. Yield: 427 mg (37%).
Synthesis of intermediate 55 Intermediate 55 was synthesized according to the procedures provided for compounds 30-32.
By a method analogous to Method C andD using compound 55 as a precursor, the following compounds were obtainded:
Compound ID Structure No c5Hõ
tudj ¨
56.1 KD-199 cr N.
0 r-56.2 ICD-233 /
Synthesis of aminoalkylpyrole 63 is shown in scheme 7 o.B-0 Br 58 Br / ph13(OH)2 KOAc \ 0 37 Pd(PF113)4 Pd(dpp0C17=CH,Clp NaH C5Hii 2M
Na2C93 Br N 1,4-dioxene CsHii H DMF Toluene f_y< Br 57 69 so MsCI
C5Hii LiA1114, C5Hii OH TEA C5Hii /N--1 THF CH2a2 \ I
Scheme 7 Synthesis of intermediate 58 An oven dried pressure tube was charged with 1-bromo-4-pentylbenzene (500 mg, 2.20 mmol, 1.0 equiv.), bis(pinacolato)diborane (670 mg, 2.64 mrnol, 1.2 equiv.), KOAc (1.08 g, 11.00 mmol, 5.0 equiv.), Pd(dppf)C12=CH2C12 (18 mg, 0.022 rrunol, 0.01 equiv.) and 1,4-.. dioxane (dry) (5 mL) was added. Reaction mixture was heated at 100 C for 18h. To the reaction mixture 1420 was added and suspension was extracted with Et0Ac (3 x 20 mL).
Combined organic layers were washed with brine, dried over Na2SO4 and evaporated under reduced pressure. The residue was purified by direct phase ARMEN
chromatograph, eluent system PE/Et0Ac=98:2 to 4:1, 25 g silicagel column, flow rate 25 mL/min.
Yield: 480 mg (80%).
Synthesis of intermediate 59 Product 59 was synthesized according to general method C.
Synthesis of intermediate 60 An oven dried flask was charged with NaH (60% mineral oil) (33 mg, 0.81 mmol, 1.5 equiv.), washed with Et20 (dry) (3 x 2 mL). DMF was added and the suspension was cooled to 0 C.
Then solution of ethyl 5-(4-pentylpheny1)-1H-pyrrole-2-carboxylate (59) (155 mg, 0.54 mmol, 1.0 equiv.) in DMF was added dropwise. Stirred at 0 C for 0.5h, then solution of 1-bromo-4-(bromomethyl)benzene (37) (135 mg, 0.54 rrunol, 1.0 equiv.) in DMF was added.
Stirred at r.t. for 16h. H20 was added and resulting suspension was extracted with Et0Ac (3 x 20 mL). Combined extracts were washed with brine, dried over Na2SO4 and evaporated under reduced pressure. Purified by column chromatography (eluent system PE/Et0Ac=9:1 to 1:1).
Yield: 165 mg (67%).
Synthesis of intermediate 61 Intermediate 61 was synthesized according to general method C.
Synthesis of product 63. General method E.
The carboxylic acid ethyl ester 61 (48 mg, 0.10 mmol, 1.0 equiv.) was dissolved in THE (dry) (2 mL) and the solution was cooled to 0 C. 1M LiA1H4/THF (100 L, 0.10 mmol, 1.0 equiv.) was added dropwise and the mixture was stirred at r.t. for lh. The reaction mixture was cooled to 0 C, H20 (8 pt) was added and stirred for 5 mm, then 4N NaOH sol.
(16 L) was added and stirred for 10 min, after that H20 (24 L) was added and stirred for 10 min. The filtrate was evaporated, giving the desired product 62 (40 mg, 91%).
Synthesis of product 63 Solution of alcohol 62 (34 mg, 0.08 mmol, 1.0 equiv.) in CH2C12 was cooled to 0 C and TEA
(15 mg, 20 ilLõ 0.15 mmol, 1.9 equiv.) and MsC1 (14 mg, 9 ttL, 0.12 mmol, 1.5 equiv.) were added. Stirred at 0 C for lh, then diethylamine (29 mg, 41 IAL, 0.40 mmol, 5.0 equiv.) was added and strirring was continued for 16h at r.t. H20 was added and suspension was extracted with Et0Ac (3 x 7 mL). Combined organic layers were washed with brine, dried over Na2SO4 and evaporated. The residue was purified by column chromatography (eluent sytem PE/Et0Ac=85:15 to 0:100). Yield: 20 mg (50%).
Synthesis of aminoallcyltriazoles 71-73 is shown in scheme 8 HO CsHil 051-111 CsHit Br x 40 1)MsCI, TEA *
N3 65 Ilk CH2C12 CuSO4'5H20 Pd(OAc)2 N,NN 2)Diethylamine N'%
Na ascorbale NNW (Bu)4N+MO 1,4-di0x8ne Witt 67: X=0 OH OH N--\\
68: X=C=0 X X
69: X=0 71: )(=0 70: X=C=0 72: X=C=0 73: X=CH-OH*-obtained from ketone 72 Scheme 8 Synthesis of intermediate 66 Solution of 1-(azidomethyl)-4-pentylbenzene (64) (1.3 g, 6.39 mmol) and but-3-yn-1-ol (65) (583 mg, 629 ttL, 8.31 mmol, 1.3 equiv.) in CH2C12 (20 mL) was stirred at r.t.
for 15 mm, then 1-120 (5 mL), CuSO4=5H20 (209 mg) and sodium ascorbate (587 mg) were added.
Stirring was continued for 16h. To the reaction mixture additional H20 was added and suspension was extracted with Et0Ac (3 x 20 mL). Combined organic layers were washed with H20, brine, dried over Na2SO4 and evaporated under reduced pressure.
Yield: 1.38 g (79%).
Synthesis of intermediate 67 An oven dried pressure tube was charged with 4-methoxyphenol (500 mg, 4.03 mmol, 1.1 equiv.), 1-bromo-4-iodobenzene (1.04 g, 3.66 mmol, 1.0 equiv.), N,N-dimethylglycine (28 mg, 0.27 mmol, 0.075 equiv.), Cs2CO3 (2.34 g, 7.32 mmol, 2.0 equiv.), CuI
(13.9 mg, 0.073 mmol, 0.02 equiv.) and 1,4-dioxane (dry) (8 mL) was added. Reaction mixture was stirred at 90 C for 18h. To the reaction mixture sat. NH4C1 sol. was added and suspension was extracted with Et0Ac (3x 50 mL). Combined organic layers were washed with brine, dried over Na2SO4 and evaporated. The residue was purified by column chromatography (eluent system PE/Et0Ac=95:5 to 1:1). Yield: 584 mg (57%).
Synthesis of intermediate 68 The solution of 1,4-dibromobenzene (1.0 g, 4.24 mmol, 1.0 equiv.) in THF (15 mL) was cooled to -78 C and 2.5M n-BuLi/hexanes (1.7 mL, 4.24 mmol, 1.0 equiv.) was added dropwise. Stirred at -78 C for 30 mm, then solution of 4-methoxybenzaldehyde (520 mg, 3.82 mmol, 0.9 equiv.) in THF (10 mL) was added. Stirred for 16h. To the reaction mixture sat.
NH4C1 sol. was added and suspension was extracted with Et0Ac (3 x 35 mL).
Combined organic layers were washed with brine, dried over Na2SO4 and evaporated.
Product was purified by column chromatography (eluent system PE/Et0Ac=9:1 to 1:1). Yield:
960 mg (77%).
Synthesis of intermediate 69, general method F.
An oven dried MW vial was charged with triazol 66 (300 mg, 1.1 mmol), Pd(OAc)2 (12 mg, 0.055 mmol, 0.05 equiv.), tetrabutylammonium acetate (663 mg, 2.2 mmol, 2.0 equiv.) and 1-bromo-4-(4-methoxyphenoxy)benzene (67) (460 mg, 1.65 mmol, 1.5 equiv.) and NMP
was added (4 mL). Reaction mixture was stirred at 100 C for 18h. Then H20 and brine was added and resulting suspension was extracted with Et0Ac (4 x 20 mL). Combined extracts were washed with H20 (2 x 60 mL), brine, dried over Na2SO4 and evaporated under reduced pressure. The residue was purified by column chromatography (eluent system PE/Et0Ac=9:1 to 0:100). Yield: 254 mg (49%).
By a method analogous to Methods F, C and D using compound 66 as a precursor, the following compounds were obtainded:
Compound BD
Structure No N.
N N
7.4\
Synthesis of product 73 Solution of (4-(4-(2-(diethylamino)ethyl)-1-(4-pentylbenzy1)-1 H-1,2,3-triazol-5-yl)phenyl)(4-methoxyphenyl)methanone (72) (50 mg, 0.093 mmol, 1.0 equiv.) in Me0H (1.8 mL) was cooled to 0 C and NaBH4 (7 mg, 0.19 mmol, 2.0 equiv.) was added portionwise.
Stirred at r.t.
for 2h. Reaction mixture was diluted with Et20, sat. NaHCO3 so!. was added and the mixture was extracted with Et0Ac (3 x 15 mL). Combined organic layers were washed with sat.
NaHCO3 so!., brine, dried over Na2SO4 and evaporated under reduced pressure.
The residue was purified by column chromatography (eluent system CH2C12/Me0H=100:0 to 4:1). Yield:
.. 35 mg (70%).
Synthesis of intermediate 76 An oven dried flask was charged with AlC13 (3.46 g, 26.0 mmol, 1.2 equiv.) and CS2 (7 mL) was added. Then solution of pentylbenzene (74) (3.21 g, 21.6 mmol, 1.0 equiv.) in CS2 (7 mL) and 3-chloropropionylchloride (75) (3.02 g, 2.3 mL, 23.8 mmol, 1.1 equiv.) solution in CS2 (5 mL) was added dropwise. Stirred at r.t. for 15 mm. To the reaction mixture H20 (25 mL) was added carefully, extracted with Et0Ac (3 x 40 mL). Combined organic layers were washed with brine, dried over Na2SO4 and evaporated under reduced pressure.
Yield: 4.65 g (90%).
Synthesis of intermediate 78 An oven dried pressure tube was charged with diethylacetamidomalonate (77) (4.23 g, 19.5 mmol, 1.0 equiv.) and Na0Et (1.33 g, 19.48 mmol, 1.0 equiv.), and Et0H (dry) was added (25 mL). Then solution of chloride 76 (4.65 g, 19.48 mmol) in Et0H (15 mL) was added dropwise. Reaction mixture was heated at 85 C for 18h. Solvent was removed in vacuo. The residue was suspended in H20 and extracted with Et0Ac (3 x 40 mL). Combined organic layers were washed with brine, dried over Na2SO4 and evaporated under reduced pressure.
Product 78 was purified by column chromatography (eluent system PE/Et0Ac=9:1 to 1:1).
Yield: 3.12 g (38%).
Synthesis of intermediate 79 To the diethyl 2-acetamido-2-(3-oxo-3-(4-pentylphenyl)propyl)malonate (78) (3.12 g, 7.44 mmol) HC1 (conc.) (30 mL) and CH3C00II (10 mL) was added. Reaction mixture was heated at 80 C for 16h. Solvent was removed in vacuo. To the residue toluene was added (2 x 40 mL) and the mixture was evaporated under reduced pressure. Precipitate was washed with mixture of CH2C12 and Et20 (1:1). Yield: 1.77 g (80%).
.. Synthesis of intermediate 80 To the solution of 5-(4-pentylpheny1)-2,3-dihydro-1H-pyrrole-2-carboxylic acid hydrochloride (79) (600 mg, 2.31 mmol) in Et0H (dry) (15 mL) S0C12 (824 mg, 503 pL, 6.93 mmol, 3.0 equiv.) was added. Reaction mixture stirred at 50 C for 24h. Solvent was removed in vacuo and toluene (2 x 20 mL) was added and evaporated under reduced pressure. Yield:
664 mg (100%).
Synthesis of intermediate 81 Solution of 2,3-dihydro-1H-pyrrole 80 (664 mg, 2.05 mmol, 1.0 equiv.) in THF
(dry) (10 mL) was cooled to -78 C and 1M KHMDS/THF (4.7 mL, 4.71 mmol, 2.3 equiv.) was added dropwise. Reaction mixture was stirred at -78 C for 45 min, then 4-brombenzylbromide (693 mg, 2.77 mmol, 1.35 mmol) solution in TI-IF (10 mL) was added dropwise.
Stirred at -78 C
for lh, then warmed up to r.t. To the reaction mixture H20 was added and suspension was extracted with Et0Ac (3 x 25 mL). Combined extracts were washed with brine, dried over Na2SO4 and evaporated under reduced pressure. Product was purified by column chromatography (eluent system PE/Et0Ac=7:1). Yield: 363 mg (39%).
Synthesis of intermediate 82 Intermediate 82 was synthesized according to general method B.
Synthesis of intermediate 83 LTMP solution was prepared as follows: a solution of 2.5M n-BuLi/hexanes (544 L, 1.36 mmol, 2.0 equiv.) was added to a stirred, cold (0 C) solution of TMP (211 mg, 252 Idõ 1.50 .. mmol, 2.2 equiv.) in THF. In a separate flask solution of ethyl 14(4'-methoxy-[1,11-bipheny1]-4-yl)methyl)-5-(4-pentylpheny1)-2,3-dihydro-lH-pyrrole-2-carboxylate (82) (330 mg, 0.68 mmol, 1.0 equiv.) and CH2Br2 (237 mg, 96 L, 1.36 mmol, 2.0 equiv.) in TI-IF
was cooled to -78 C and TMP solution was added via cannula. Stirring was continued for 20 min at -78 C.
Reaction was quenched with 1.2 M HC1 aq. sol. and extracted with Et0Ac (3 x 15 mL).
Combined organic layers were dried over Na2SO4 and evaporated under reduced pressure.
Obtained intermediate was dissolved in TI-IF and the solution was cooled to -78 C, then 1M
LiHMDS/THF (700 ILL, 1.09 equiv.) was added dropwise. Stirred at -78 C for 20 mm, then 2.5M n-BuLi/hexanes (563 ttL, 202 equiv.) was added dropwise. Stirring was continued at -78 C for lh. Reaction mixture was warmed up to r.t., and solution of CH3C0C1 in Me0H
(1:5) was added. H20 was added and resulting suspension was extracted with Et0Ac (3 x 15 mL). Combined extracts were washed with brine, dried over Na2SO4 and evaporated under reduced pressure. Product was purified by column chromatography (eluent system PE/Et0Ac=9:1 to 5:1). Yield: 100 mg (32%).
Synthesis of product 84 Product 84 was synthesized according to general method E.
Synthesis of product 85 To the solution of N,N-diethy1-2-(14(4'-methoxy41,11-biphenyl]-4-yOmethyl)-5-(4-pentylphenyl)-2,3-dihydro-1H-pyrrol-2-y1)ethan-1-amine (84) (17 mg, 0.033 mmol) in Me0H
(dry) (1 mL) NaBH3CN (2.5 mg, 0.04 mmol, 1.2 equiv.) and HC1 (1 drop) was added. Stirred at r.t. for 16h. To the reaction mixture H20 was added and extraction with Et0Ac (3 x 5 mL) was performed. Combined organic layers were washed with brine, dried over Na2SO4 and evaporated under reduced pressure. Product was isolated as HC1 salt. Yield: 10 mg (56%).
Synthesis of aminoalkyltriazole 88 is shown in scheme 9 c5H,1 111 NN
c5H11 =
N, C5H11 N.
'N
- \O
FIN-bCN:1[23 H3CN
_ Me0H
Scheme 9 Synthesis of intermediate 87 Intermediate 87 was synthesized according to general method E.
Synthesis of product 88 To the solution of triazole 87 (40 mg, 0.073 mmol) in Me0H (1 mL) acetaldehyde (10 L) and NaBH3CN (6.3 mg, 0.1 mmol, 1.5 equiv.) were added. Reaction mixture was stirred at r.t.
for lh. The solvent was removed in vacua and residue was purified by column chromatography (CH2C12/Me0H=100:0 to 4:1). Yield: 15 mg (36%).
All compounds were characterized by 111-NMR and occasionally by 13C-NMR
spectroscopy performed on Varian Mercury spectrometer (400 MHz) with chemical shifts values (8) in ppm relative to TMS using the residual chloroform signal as internal standard and by tandem LC/MS spectrometer on Water Acquity UPLC with SQ mass selective detector.
Physicochemical characterization of compounds 8.1-8.12, 33.1, 34.1-4, 35.1-2, 36.1-2, 48.1-6, 44, 47, 56.1-2, 63, 71-73, 84, 85, 88.
Compound NMR and UPLC/MS data ID
No 1H-NMR (TMS, CDC13, 400 MHz) a 0.87 (t, 7.0 Hz, 311); 0.91 (t, 7.0 Hz, 6H); 1.2-1.4 (m, 4H); 1.5-1.7 (m, 2H); 2.47 (q, 7.0 Hz, 4 H);
2.59 (t, 7.4 Hz, 2H); 3.37 (s, 2H); 5.56 (s, 2H); 7.07 (d, 8.2 Hz, 2H);
GL-1547 8.1 7.07 (s, 111); 7.17 (d, 8.2 Hz, 2H); 7.35 (dd, 3.1 and 7.8 Hz, 1H);
7.45 (d, 8.2 Hz, 2H); 7.54 (d, 8.2 Hz, 2H); 7.86 (dt, 2.0 and 7.8 Hz, 1H); 8.59 (dd, 1.6 and 4.7 Hz, 111); and 8.84 ppm (d, 2.3 Hz, 1H).
UPLC/MS: [M-1-1] = 467.6 1H-NMR (TMS, CDC13, 400 MHz) D: 0.80 (t, 7.0 Hz, 3H); 1.1-1.3 (m, 4H); 1.53 (m, 2H); 2.12 (s, 1H); 2.53 (t, 7.8 Hz, 2H); 3.56 (s, 2H); 3.68 (s, 211); 5.40 (s, 2H); 6.96 (d, 8.2 Hz, 2H); 7.04 (t, 3.9 Hz, 1H); 7.11 (d, 8.2 Hz, 2H); 7.16 (d, 7.0 Hz, 2H); 7.20 (d, 7.0 Hz, 2H);
GL-1556 8.2 7.29 (dd, 4.7 and 7.8 Hz, 111); 7.38 (d, 8.2 Hz, 2H); 7.42 (d, 8.2 Hz, 2H); 7.76 (dt, 2.0 and 7.8 Hz, 1H); 8.52 (dd, 1.6 and 4.7 Hz, 1H); and 8.74 ppm (d, 2.0 Hz, 1H).
UPLC/MS: [M+1] = 501.5 1H-NMR (TMS, CDC13, 400 MHz) El 0.87 (t, 7.0 Hz, 3H); 1.2-1.4 (m, 4H); 1.60 (m, 2H); 2.60 (t, 7.8 Hz, 2H); 3.51 (s, 1H); 3.59 (s, 211); 3.71 (s, 2H); 3.78 (s, 611); 5.66 (s, 2H); 6.39 (dd, 2.4 and 8.2 GL-1562 Hz, 1H); 6.43 (d, 2.4 Hz, 1H); 7.04 (dd, 5.1 and 8.2 Hz, 2H); 7.13 (s, 8.3 1H); 7.18 (d, 8.2 Hz, 211); 7.37 (dd, 5.1 and 7.8 Hz, 2H); 7.43 (d, 8.2 Hz, 2H); 7.51 (d, 8.2 Hz, 211); 7.85 (dt, 2.0 and 8.2 Hz, 1H); 8.59 (dd, 1.6 and 5.5 Hz, 1H); and 8.82 ppm (d, 2.0 Hz, 111).
UPLC/MS: [M+11 = 561.7 1H-NMR (TMS, CDC13, 400 MHz) EL: 0.81 (t, 7.4 Hz, 311); 1.2-1.3 (m, 4H); 1.5-1.6 (m, 211); 2.12 (s, 1H); 2.54 (t, 7.4 Hz, 211); 3.38 (s, 2H); 4.07 (d, 4.3 Hz, 2H); 5.33 (s, 2H); 6.47 (d, 7.8 Hz, 2H); 6.67 (t, 7.4 Hz, 114); 7.02 (d, 8.2 Hz, 2H); 7.07 (d, 7.4 Hz, 211); 7.09 (d, 7.4 GL-1570 8.4 Hz, 2H); 7.13 (d, 7.4 Hz, 2H); 7.14 (s, 1H); 7.31 (ddd, 0.8 and 4.7 and 7.8 Hz, 111); 7.40 (d, 8.2 Hz, 2H); 7.48 (d, 8.2 Hz, 2H); 7.79 (dt, 2.0 and 8.2 Hz, 1H); 8.54 (dd, 1.6 and 5.1 Hz, 111); and 8.77 ppm (d, 2.0 Hz, 1H).
UPLC/MS: [M+1] = 487.5 1H-NMR (TMS, DMSO-d6, 400 MHz) EL: 0.5-1.0 (m, 2H); 0.83 (t, 7.0 Hz, 3H); 1.0-1.4 (m, 8H); 1.4-1.7 (m, 711); 2.26 (d, 6.7 Hz, 4H);
GL-1634 85 2.5-2.7 (m, 2H); 3.53 (s, 211); 5.48 (s, 211); 6.97 (s, 1H);
7.04 (d, 8.2 Hz, 2H); 7.22 (d, 8.2 Hz, 2H); 7.42 (d, 8.2 Hz, 2H); 7.45 (dd, 4.7 and 7.8 Hz, 1H); 7.69 (d, 8.2 Hz, 211); 8.03 (dt, 1.8 and 8.2 Hz, 111);
8.55 (dd, 1.6 and 4.7 Hz, 1H); and 8.85 ppm (d, 2.3 Hz, 111).
UPLC/MS: [M+1] = 507.5 111-NMR (TMS, CDC13, 400 MHz) n11: 0.87 (t, 7.0 Hz, 3H); 1.37 -1.21 (m, 4H); 1.5-1.7 (m, 2H); 2.60 (t, 7.8 Hz, 211); 3.63 (s, 2H); 3.73 (s, 2H); 3.76 (s, 3H); 5.46 (s, 2H); 6.7 - 6.9 (m, 3H); 7.04 (d, 8.4 Hz, 211); 7.11 (s, 111); 7.18 (d, 8.3 Hz, 311); 7.36 (ddd, 0.8 and 4.8 and GL-1643 8.6 7.9 Hz, 1H); 7.45 (d, 8.2 Hz, 2H); 7.50 (d, 8.3 Hz, 2H); 7.83 (ddd, 1.7 and 2.3 and 7.9 Hz, 1H); 8.59 (dd, 4.8 and 1.6 Hz, 1H) and 8.81 ppm (dd, 0.8 and 2.4 Hz, 111).
UPLC/MS: [M+1] = 531.6 11-1-NMR (TMS, CDC13, 400 MHz) El 0: 0.88 (t, 7.0 Hz, 3H); 1.2-1.4 (m, 7H); 1.5-1.7 (m, 2H); 2.61 (t, 7.8 Hz, 2H); 3.48 (dd, 14.1 and 42.3, 2H); 3.73 (q, 6.7 Hz, 1H); 5.42 (dd, 3.5 and 16.8, 2H); 6.98 (d, GL-1686 8.7 8.2 Hz, 2H); 7.09 (s, 1H); 7.19 (d, 8.2 Hz, 2H); 7.2-7.3 (m, 4H); 7.37 (dd, 4.7 and 7.8 Hz, 1H); 7.47 (t, 8.2 Hz, 411); 7.83 (dt, 1.6 and 7.8 Hz, 1H); 8.60 (s, 1H) and 8.82 ppm (s, 1H).
UPLC/MS: [M+1] = 515.6 11-1-NMR (TMS, CDC13, 400 MHz) 0 0: 0.87 (t, 7.0 Hz, 31-1); 1.2-1.4 (m, 4H); 1.5-1.7 (m, 2H); 2.60 (t, 7.8 Hz, 2H); 3.66 (s, 211); 3.83 (s, GL-1726 8 2H); 5.45 (s, 2H); 6.99 (d, 8.2 Hz, 211); 7.13 (s, 1H); 7.17 (d, 8.2 Hz, .8 2H); 7.2-7.6 (m, 1411); 7.76 (dt, 2.3 and 7.8 Hz, 111); 8.77 (dd, 1.6 and 4.7 Hz, 1H) and 8.77 (dd, 0.8 and 2.3 Hz, 1H).
UPLC/MS: [M+1] = 577.6 111-NMR (TMS, DMSO-d6, 400 MHz) LL: 0.78 (d, 6.7 Hz, 6H);
0.83 (t, 7.0 Hz, 3H); 1.1-1.3 (m, 611); 1.4-1.6 (m, 3H); 2.43 (t, 7.4 Hz, 2H); 2.56 (t, 7.4 Hz, 2H); 3.54 (s, 2H); 5.47 (s, 2H); 6.97 (s, 1H);
GL1638 8.9 7.04 (d, 8.2 Hz, 2H); 7.21 (d, 8.2 Hz, 2H); 7.42 (d, 8.2 Hz, 2H); 7.46 (dd, 4.7 and 7.8 Hz, 1H); 7.69 (d, 8.2 Hz, 211); 8.04 (dt, 1.6 and 8.2 Hz, 1H); 8.55 (dd, 1.6 and 4.7 Hz, 1H); and 8.85 ppm (d, 2.3 Hz, 1H) UPLC/MS: [M+1] = 481.3 GL-1566 8.10 1H-NMR (TMS, CDC13, 400 MHz) 0 0: 0.87 (t, 7.4 Hz, 3H);
1.2-1.4 (m, 4H); 1.5-1.7 (m, 2H); 2.60 (t, 7.8 Hz, 2H); 3.73 (s, 2H); 5.42 (s, 2H); 7.01 (s, 1H); 7.12 (d, 8.2 Hz, 2H); 7.18 (d, 8.2 Hz, 21-1); 7.3-7.4 (m, 1H); 7.44 (d, 8.2 Hz, 2H); 7.55 (d, 8.2 Hz, 2H); 7.85 (dt, 2.0 and 8.2 Hz, 1H); 8.59 (dd, 1.6 and 4.7 Hz, 1H); and 8.83 ppm (dd, 0.8 and 2.4 Hz, 1H).
UPLC/MS: [M+l] = 411.6 11-1-NMR (TMS, CDC13, 400 MHz) U [1: 0.79 (d, 6.3 Hz, 12H); 0.87 (t, 7.0 Hz, 3H); 1.1-1.3 (m, 4H); 1.3-1.4 (m, 4H); 1.4-1.5 (m, 2H);
1.5-1.7 (m, 2H); 2.37 (t, 7.8 Hz, 4H); 2.59 (t, 7.8 Hz, 2H); 3.33 (s, 2H); 5.55 (s, 2H); 7.05 (d, 8.2 Hz, 2H); 7.07 (s, 1H); 7.17 (d, 8.2 Hz, GL-1625 8.11 2H); 7.37 (dd, 4.7 and 7.8 Hz, 1H); 7.43 (d, 8.2 Hz, 211); 7.54 (d, 8.2 Hz, 2H); 7.85 (dt, 2.0 and 8.2 Hz, 1H); 8.59 (dd, 1.2 and 4.7 Hz, 1H);
and 8.83 ppm (d, 2.0 Hz, 1H).
UPLC/MS: [M+1] = 551.6 1H-NMR (TMS, DMSO-d6, 400 MHz) n: 0.6-0.9 (m, 3H); 1.0-1.3 (m, 6H); 1.38 (s, 6H); 1.7-2.1 (m, 2H); 5.96 (s, 2H); 6.90 (d, 8.3 Hz, 2H); 6.93 (s, 1H); 7.11 (d, 8.2 Hz, 2H); 7.36 (d, 8.2 Hz, 2H); 7.44 8.12 (dd, 8.0 and 4.8 Hz, 111); 7.60 (d, 8.3 Hz, 211); 8.03-7.98 (m, 1H);
8.53 (dd, 4.7 and 1.5 Hz, 1H) and 8.83 ppm (d, 2.4 Hz, 1H).
UPLC/MS: [M+1] = 439.6 1H-NMR (DMSO-d6) 5: 8.53-8.41 (3H, m) 7.55-7,49 (2H, m) 7.45-7.40 (211, m) 7.38-7.33 (211, m) 7.32-7.27 (2H, m) 7.02-6.97 (2H, m) 6.97-6.93 (211, m) 4.24 (211, s) 4.13 (211, q, J=5.6 Hz) 3.78 (3H, s) 2.65 (2H, t, J=7.5 Hz) 1.59 (2H, quintet, J=7.3 Hz) 1.36-1.21 (4H, m) 0.85 (311, t, J=7.0 Hz) LV-1136 33.1 õ
'3C-NMR (100 MHz, CDC13) 5: 159.0, 144.7, 138.9, 136.3, 134.7, 133.6, 133.0, 129.0, 128.6, 127.9, 126.7, 125.6, 114.1, 55.3, 35.5, 31.4, 30.9, 22.4, 14.0 1-1RMS: Calculated for C28H33N40: 441.2654 Found: 441.2659 [M+1-1]
111-NMR (CDC13) 13: 7.51-7.44 (2H, m) 7.43-7.38 (2H, m) 7.25-7.18 LV-1087 34.1 (411, m) 7.00-6.93 (4H, m) 4.04 (2H, s) 3.84 (3H, s) 2.91-2.83 (2H,
HOõOH 13 HOB .OH 051-1.1 Pd(PPh3)4 CuBr 110 0 0 OH Br AgNO3 2M Na2C0? LiAIH4 PBr3 .. i-PrMgCI KCN Cp-RuC23I(COD) ___________________ . _________________________________ . __________ .
THF CH2C12 THF 0 H20, Et0FI
Toluene 1,4-dioxane i-PrOH
?
0 0 '"'= I
I Si-12 14 15 16 18 19 20: n=0 21: n=1 22: n=2 C5H.. 0 N C5H.. *
N C5H11 illp C5H.. 111 N.
_____________________________________ BH3.THF HOBt, EDO __ N-R . n __.- n n 0 OH DMF THF r.-R.
(,\ 1,4-dioxane 12 R2 24: n=0 27: n=0 30: n=0 33: n=0 25: n=1 28: n=1 31.1-6: n=1 34.1-6: n=1 26: n=2 29: n=2 32.1-2: n=2 35.1-2: n=2 Scheme 4 Synthesis of intermediate 14 An oven dried pressure tube was charged with 4-methoxycarbonylphenylboronic acid (12) (2.00 g, 11.10 mmol, 1.0 equiv.), 4-bromoanisole (13) (2.08 g, 11.10 mmol, 1.0 eqiuv.) and Pd(PPh3)4 (40 mg, 0.035 mmol, 0.003 eqiuv.). To the starting materials i-PrOH
(20 mL), toluene (20 mL) and 2M Na2CO3 aq. solution (25 mL) were added and the mixture was heated at 90 C for 9h. The mixture was extracted with CH2C12 (4 x 30 mL). Combined organic layers were dried over Na2SO4 and evaporated under reduced pressure. The residue was purified by column chromatography (100% CH2C12) to yield 14 (2.00 g, 74% yield).
Synthesis of intermediate 15 The carboxylic acid methyl ester derivative 14 (2.00 g, 8.25 mmol, 1.0 eqiuv.) was dissolved in THF (dry) (20 mL) and the solution was cooled to 0 C. To the solution 2.4M
LiA1H4/THF
(4.5 mL, 10.70 mmol, 1.3 equiv.) was added dropwise and stirring was continued at r.t. for 2h. The reaction mixture was cooled to 0 C and 1120 (0.4 mL) was added and stirred for 5 mm, then 4N NaOH sol. (0.8 mL) was added and stirred for 10 min, after that H20 (1.2 mL) was added and stirred for 10 mm. Precipitate was filtered off and filtrate was evaporated, giving the desired product 15 (1.76 g, 99%).
Synthesis of intermediate 16 Alcohol 15 (1.76 g, 8.21 mmol, 1.0 equiv.) was dissolved in CH2C12 and PBr3 (4.22 g, 1.5 mL, 15.60 mmol, 1.9 equiv.) was added dropwise. The mixture was stirred at r.t. for 16h. To the reaction mixture H20 (20 mL) was added and stirring was continued for 20 mm. Organic layer was separated and washed with H20 (2 x 40 mL). Organic layer was dried over Na2SO4 and evaporated under reduced pressure to yield product 16 (2.26 g, 99%).
Synthesis of intermediate 18 Solution of trimethylsilylacetylene (17) (1.42 g; 2.0 mL; 14.40 mmol, 4.0 eqiuv.) in THF
(dry) (10 mL) was cooled to 0 C and 2M i-PrMgCl/THF (5.4 mL; 10.80 mmol, 3.0 equiv.) was added dropwise. The mixture was stirred at 0 C for 30 mm, then at r.t. for lh. Then CuBr (0.31 g, 2.16 mmol, 0.6 equiv.) was added to the reaction mixture and stirred at r.t. for 30 mm, after that solution of benzylbromide 16 (1.00 g, 3.60 mmol, 1.0 equiv.) in THF (5 mL) was added. Reaction mixture was heated at reflw( for 3h. The solvent was then removed in vacuo and H20 (10 mL) and Et0Ac (10 mL) were added to the residue. Precipitate was filtered off and filtrate was extracted with Et0Ac (2 x 30 mL). Combined organic layers were dried over Na2SO4 and evaporated under reduced pressure. Residue was purified by column chromatography (PE/Et0Ac=95:5) to give product 18 (0.94 g, 89%).
Synthesis of intermediate 19 To the solution of (3-(4'-methoxy-[1,1'-bipheny1]-4-yl)prop-1-yn-1-yptrimethylsilane (18) (0.90 g, 3.06 mmol, 1.0 eqiuv.) in Et0H (16 mL) AgNO3 (0.78 g, 1.5 eqiuv.) solution in H20/Et0H (4 mL, 1:3) was added dropwise. Mixture was stirred at r.t. for 30 mm, after that KCN (1.97 g, 9.9 equiv.) solution in H20 was added. Stirring was continued for 2h. Reaction mixture was partitioned between Et0Ac and 1120. Organic layer was washed with H20 (2 x 20 mL), brine, dried over Na2SO4 and evaporated under reduced pressure to give product 19 (0.65 g, 96%).
Synthesis of intermediate 20 An oven dried pressure tube was charged with 4-(bromomethyl)-4'-methoxy-1,1'-biphenyl (16) (1.78 g, 6.40 mmol, 1.0 equiv.), Cu! (1.22 g, 6.40 mmol, 1.0 equiv.), K2CO3 (887 mg, 6.40 mmol, 1.0 equiv.) and Bu4N+I- (2.37 g, 6.40 mmol, 1.0 equiv.). MeCN (15 mL) was added followed by dropwise addition of ethyl propiolate (1.26 g, 12.84 mmol, 2.0 equiv.) was added dropwise. The mixture was stirred at 40 C for 16h. To the reaction mixture sat. NH4C1 so!. (30 mL) was added and the resulting suspension was extracted with Et0Ac (3 x 25 mL).
Combined organic layers were dried over Na2SO4 and evaporated under reduced pressure.
The residue was purified by column chromatography (eluent system PE/Et0Ac=99:1 to 85:15). Yield: 1.52 g (80%).
Synthesis of intermediate 21 To the solution of 4-methoxy-4'-(prop-2-yn-1-y1)-1,1'-biphenyl (19) (0.55 g, 2.50 mmol, 1.0 eqiuv.) in MeCN (dry) (10 mL) CuI (24 mg, 0.12 mmol, 0.048 equiv.) and ethyldiazoacetate (0.31 g, 2.75 mmol, 1.1 eqiuv.) was added. The mixture was stirred at r.t. for 16h. Solvent was removed in vacuo and the residue was purified by direct phase ARMEN
chromatograph, eluent system PE/Et0Ac (95:5 to 0:100), 25 g silica gel column, flow rate 18 mLimin.
Obtained product 21 (0.63 g, 82%).
Synthesis of intermediate 22 An oven dried pressure tube was charged with 4-(bromomethyl)-4'-methoxy-1,11-biphenyl (16) (1.22 g, 4.40 mmol, 1.0 equiv.), Cu! (838 mg, 4.40 mmol, 1.0 equiv.), K2CO3 (669 mg, 4.84 mmol, 1.1 equiv.) and Bu4N+r (1.63 g, 4.40 mmol, 1.0 equiv.). MeCN (15 mL) was added followed by dropwise addition of ethyl pent-4-ynoate (610 mg, 4.84 mmol, 1.1 equiv.).
The reaction mixture was stirred at r.t. for 16h. To the reaction mixture sat.
NH4C1 sol. (30 mL) was added and resulting suspension was extracted with Et0Ac (3 x 25 mL) was performed. Combined organic layers were dried over Na2SO4 and evaporated under reduced .. pressure. The residue was purified by column chromatography (eluent system PE/Et0Ac=99:1 to 85:15). Yield: 749 mg (70%).
Synthesis of azide 23 An oven dried flask was charged with 1-bromo-4-pentylbenzene (2.00 g, 8.80 mmol, 1.0 equiv.) and THF (dry) (15 mL) was added. The solution was cooled to -78 C and 2.5M n-BuLi/hexanes (3.9 mL, 9.68 mmol, 1.1 equiv.) was added dropwise. Reaction mixture was stirred at -78 C lh, then 4-methylbenzenesulfonyl azide (2.60 g, 13.20 mmol, 1.5 eqiuv.) solution in THF (8 mL) was added. Reaction mixture was warmed up to -45 C and 20 mL of sat. NH4C1 solution was added and resulting mixture was extracted with Et0Ac (3 x 35 mL).
Combined organic extracts were washed with brine, dried over Na2SO4 and evaporated under reduced pressure. The residue was purified by column chromatography, eluent system (PE/Et0Ac=98:2). Yield: 1.29 g (77 %).
Synthesis of aminoalkyl triazoles 33,34.1-6, 35.1-2. General method B.
Exemplified by the synthesis of 34.1.
Synthesis of intermediate 25 An oven dried flask was charged with azide 23 (799 mg, 4.22 mmol, 1.2 equiv.), alkyne 21 (1.08 g, 3.52 minol, 1.0 equiv.) and Cp=RuCl(COD) (160 mg, 0.42 mmol, 12 mol%). 1,4-Dioxane (dry) (10 mL) was added and reaction mixture was stirred at r.t. for 16h. The solvent was removed in vacuo and the residue was purified by column chromatography (eluent system PE/Et0Ac=9:1 to 1:1). Yield: 485 mg (28%).
Synthesis of intermediate 28 To the triazole 25 (0.47 g, 0.94 mmol, 1.0 equiv.) in 1,4-dioxane (15 mL) 1N
NaOH sol. (8 mL) was added. Reaction mixture was stirred at r.t. for 16 h. H20 was added and resulting suspesion was extracted with Et0Ac (3 x 25 mL). Combined organic layers were washed with brine, dried over Na2SO4 and evaporated under reduced pressure. Product was used in the .. next step without purification. Yield: 0.26 g (97%).
Synthesis of inteimediate 31.1 An oven dried MW vial was charged with acid 28 (100 mg, 0.21 mmol, 1.0 equiv.) and HOBt (37 mg, 0.27 mmol, 1.3 eqiuv.), DMF (1.5 mL) and EDC (52 mg, 0.27 mmol, 1.3 equiv.) was added. The mixture was stirred at 0 C for lh, then N-methylpiperazine (32 mg, 35 uL, 1.5 equiv.) was added. Stirring continued at r.t. for 16h. To the reaction mixture H20 was added and suspension was extracted with Et0Ac (3 x 10 mL). Combined organic layers were washed with brine, dried over Na2SO4 and evaporated under reduced pressure.
Residue was purified by direct phase ARMEN chromatograph (eluent system CH2C12/Me0H=1:0 to 4:1), 12 g silicagel column, flow rate 12 mL/min. Yield: 65 mg (56%).
Synthesis of product 34.1 To the solution of amide 31.1 (56 mg, 0.11 mmol) in THF (dry) (1 mL) was added BH3=TI-1F/THF (0.5 mL). Reaction mixture was stirred at 80 C for 16, the 4N
HC! sol. (1 mL) was added and stirring was continued for lh. Reaction mixture was cooled to r.t. and basified with sat. NaHCO3 so!. to pH=8 and extracted with Et0Ac (3 x 10 mL). Combined organic layers were washed with brine, dried over Na2SO4 and evaporated under reduced pressure.
The residue was purified by column chromatography (eluent system CH2C12/Me0F1=1:0 to 4:1). Yield: 19 mg (36%).
By a method analogous to Method B using compounds 20, 21, 22 as a precursors, the following compounds were obtainded:
Compound ID Structure No c5H1, =
33.1 LV-1136 0 ¨ _ NH.,c1 34.1 LV-1087 c ) c5H" NN
_ 34.2 LV-1154 "C) 0¨
Cs 34.3 LV-1155 0¨
e511 N
34.4 LV-1157 0¨
co,' dit _ 34.5 LV-1170 0_ c5Hil 'N
34.6 LV-1077 r 35.1 LV-1130 35.2 LV-1124 N,N
36.1* KD-302 OH
¨ a-.
36.2* VGP-153 OH
*-obtained from compounds 34.5 and 34.6 Synthesis of product 36.1 An oven dried MW vial was charged with Nall (60% mineral oil) (10 mg, 0.24 mmol, 4.0 equiv.), washed with Et20 (dry) (3 x 1 mL). DMF was added (1 mL), mixture was cooled to 0 C and n-DodSH (49 mg, 58 L, 0.24 mmol, 4.0 equiv.) was added. The mixture was stirred was continued at r.t. for 10 min, then solution of 2-(2-(5-44'-methoxy-[1,1?-biphenyl]-4-ypmethyl)-1-(4-pentylpheny1)-1H-1,2,3-triazol-4-ypethyl)-1,2,3,4-tetrahydroisoquinoline (36.1) (35 mg, 0.06 mmol, 1.0 equiv.) in DMF was added. Reaction mixture was stirred at 130 C for 2h. Solvent was removed in vacuo and 1120 and sat. NH4C1 so!. was added, mixture was extracted with Et0Ac (3 x 10 mL). Combined organic layers were washed with H20, brine, dried over Na2SO4 and evaporated under reduced pressure. The residue was purified by direct phase ARMEN chromatograph, eluent system CH2C12/Me0H=100:0 to 90:10, 12 g silicagel column, flow rate 12 mL/min. HC1 salt was made and precipitate was washed with petroleum ether. Yield: 13 mg (36%).
Product 36.2 was synthesized according to the procedure provided for product 36.1 Synthesis of aminoalkyltriazoles 44, 47, 48.1-5 is shown in scheme 5 Br Br R
B(OH)2 Azide Alk N
Rd(RN13)4 __... CFRuCI(C011) ¨ Mk 411 N
'N 2M Na2CO3, 1,4-clioxane Br 0 0 Br ---\\ Toluene Br n n 0 n 0 37 38: n=0 40: n=0, Alk=Me 42: n=0, Alk=Me BH3=THF
39: n=1 41: n=1, Alk=C5H11 43: n=1, Alk=C5H11 Alk Alk N
N-N'N BH31HF W 'N Mk 411 N
¨ ________________________ = ' THF
" 0 Br N1NJNJ
45: n=0, Alk=Me 47: n=0, Alk=Me 46.1-6: n=1, Alk=C5H11 48.1-6: n=1, Alk=C5H11 44 Scheme 5 Synthesis of intermediate 38 An oven dried pressure tube was charged with 1-bromo-4-(prop-2-yn- 1 -yl)benzene (1.24 g, 6.36 mmol, 1.0 equiv.) and THF (dry) (7 mL) was added. Then 1M MeMgBr/THF (7.6 mL, 7.63 mmol, 1.2 equiv.) was added dropwise. Reaction mixture was stirred at 65 C for 3h, then cooled to r.t. and methylchloroformate (2.40 g, 2.0 mL, 25.40 mmol, 4.0 equiv.) was added quickly. The reaction mixture was stirred at 65 C for 18h. Reaction mixture was cooled to r.t.
and Et0Ac was added. The mixture was washed with 1N HC1 so!., H20 and brine, dried over Na2SO4 and evaporated under reduced pressure. The residue was purified by direct phase ARMEN chromatograph, eluent system PE/Et0Ac=98:2 to 90:10, 25 g silicagel column, flow rate 18 mL/min. Yield: 1.14 g (71 %).
Synthesis of intermediate 39 Intermediate 39 was synthesized according to the procedures provided for compound 21.
Synthesis of intermediates 42, 43 Intermediates 42, 43 were synthesized according to the procedures provided for compounds 30-32.
Synthesis of intermediates 45, 46.1-5. General method C. Exemplified by the synthesis of 46.1.
An oven dried pressure tube was charged with phenylboronic acid (26 mg, 0.21 mmol, 1.05 equiv.), amide 43 (100 mg, 0.20 mmol, 1.0 equiv.) and Pd(PPh3)4 (7 mg, 0.006 mmol, 0.03 equiv.). To the starting materials i-PrOH (1 mL), toluene (1 mL) and 2M Na2CO3 aq. solution (300 pL) were added and the mixture was heated at 90 C for 16h. Reaction mixture was extracted with Et0Ac (3 x 10 mL). Combined organic layers were dried over Na2SO4 and evaporated under reduced pressure. The residue was purified by column chromatography (PE/Et0Ac=4:1 to Et0Ac/Me0H=95:5) to yield 46.1 (86 mg, 87% yield).
By a method analogous to Method C using compound 42 and 43 as a precursors, the following compounds were obtainded:
Compound ID Structure No N 0 N.¨
_ GBH, 46.1 KD-303 -05Hõ N
46.2 KD-305 MAY
C5Fl1 hi,N,N
46.3 KD-306 \
o C'H\" WI%
46.4 KD-308 - N--Q51111,41-11 46.5 KD-328 Synthesis of products 47, 48.1-5. General method D. Exemplified by the synthesis of 48.1.
To the solution of amide 46.1 (70 mg, 0.11 mmol, 1.0 equiv.) in THF (dry) (1 mL) was added 1M BH3=THF/THF (0.5 mL). Reaction mixture was stirred at 80 C for 16, the 4N
HC1 sol. (1 mL) was added and stirring was continued for lh. Reaction mixture was cooled to r.t. and basified with sat. NaHCO3 sol. to p11=8. Extraction with Et0Ac (3 x 10 mL) was performed.
Combined organic layers were washed with brine, dried over Na2SO4 and evaporated under reduced pressure. The residue was purified by column chromatography (eluent system C112C12/Me0H=1:0 to 4:1). Yield: 49 mg (68%).
By a method analogous to Method D using amides 45, 46.1-5 as a precursors, the following compounds were obtainded:
Compound ID Structure No c,Hõ
44 KD-294 W N 'N
- N-\
Br 47 1CD-263 r\ ¨ r--\--N-001,1 *
48.1 KD-304 48.2 ICD-307 c5Hõ 4 N-N- ( 48.3 1CD-309 , c,Hõ di ,N, /
48.4 1CD-329 -0/-' Ca/10 411 NL
0 48.5 1CD-330 Tair - ---\
\--/
CcH0 ar N i 48.6* KD-315 *Obtained from 44 according to general method C.
Synthesis of aminoalkylisoxazoles 56.1-2 is shown in scheme 6 OH OH
Br H 0 4, H N,.ci 1,1..., ci Alkyne 38 TEA
io 52 n-BuLLOMF io NaH 0 CO3 .. 0 io CirRuCI(COD).
THE 1120/E120 DMF ' DCE
C5H11 C5H11 C51-11 i C5H11 N C51-111 40 o5H1, op ...- so _ ,,_ NI, --. 0 -0. _ u r - , 0 ) \--- .---Br = *
Br R
Scheme 6 Synthesis of intermediate 50 Solution of 1-bromo-4-pentylbenzene (49) (2.00 g, 8.8 mmol, 1.0 equiv.) in THF
(10 mL) was cooled to -78 C and 2.5M n-BuLi/hexanes (3.9 mL, 9.7 mmol, 1.1 equiv.) was added dropwise. The mixture was stirred at -78 C for lh. Then DMF (dry) (1.0 mL, 13.2 mmol, 1.5 equiv.) was added dropwise and the reaction mixture was warmed up to r.t. To the reaction mixture sat. NH4C1 sol. was added and mixture was extracted with Et0Ac (3 x 30 mL).
Combined organic layers were washed with brine, dried over Na2SO4 and evaporated under reduced pressure. The residue was purified by column chromatography (eluent system PE/Et0Ac=95:5). Yield: 1.55 g (99%).
Synthesis of intermediate 51 To the solution of 4-pentylbenzaldehyde (50) (1.56 g, 8.85 mmol) in 1120 (14 mL) and Et20 (14 mL) NH2011. HC1 (1.53 g, 22.1 mmol, 2.5 equiv.) and NaHCO3 (2.23 g, 26.6 mmol, 3.0 equiv.) were added. Stirred at r.t. for 16h. The reaction mixture was transferred to separating funnel and organic layer was separated off. Water layer was extracted with CH2C12 (2 x 30 mL). Combined extracts were dried over Na2SO4 and evaporated under reduced pressure (bath temperature 26 C). The residue was purified by column chromatography (eluent system PE/Et0Ac=98:2 to 90:10). Yield: 1.43 g (85%).
Synthesis of intermediate 53 To the solution of 4-pentylbenzaldehyde oxime (51) (1.30 g, 6.8 mmol, 1.0 equiv.) in DMF
(13 mL) solution of NCS 52 (908 mg, 6.8 mmol, 1.0 equiv.) in DMF (3 mL) was added dropwise. Stirred at r.t. for 40 min. To reaction mixture H20 was added and extracted with Et20 (3 x 20 mL). Combined extracts were washed with H20 and brine, dried over Na2SO4 and evaporated under reduced pressure. Yield: 1.53 g (99%).
Synthesis of intermediate 54 An oven dried pressure tube was charged with N-hydroxy-4-pentylbenzimidoyl chloride (53) (530 mg, 2.35 mmol, 1.1 equiv.), alkyne 38 (628 mg, 2.13 mmol, 1.0 equiv.), Cp=RuCl(COD) (80 mg, 0.21 mmol, 10 mol%) and DCE (dry) (4 mL) was added. To the reaction mixture TEA (431 mg, 592 pit, 4.26 mmol, 2.0 equiv.) solution in DCE (1 mL) was slowly dropwise (during 1h) added. Stirred at r.t. for 16h. Solvent was removed in vacuo and the residue was purified by direct phase ARMEN chromatograph, eluent system PE/Et0Ac=90:10 to 75:25, 25 g silicagel column, flow rate 18 mL/min. Yield: 427 mg (37%).
Synthesis of intermediate 55 Intermediate 55 was synthesized according to the procedures provided for compounds 30-32.
By a method analogous to Method C andD using compound 55 as a precursor, the following compounds were obtainded:
Compound ID Structure No c5Hõ
tudj ¨
56.1 KD-199 cr N.
0 r-56.2 ICD-233 /
Synthesis of aminoalkylpyrole 63 is shown in scheme 7 o.B-0 Br 58 Br / ph13(OH)2 KOAc \ 0 37 Pd(PF113)4 Pd(dpp0C17=CH,Clp NaH C5Hii 2M
Na2C93 Br N 1,4-dioxene CsHii H DMF Toluene f_y< Br 57 69 so MsCI
C5Hii LiA1114, C5Hii OH TEA C5Hii /N--1 THF CH2a2 \ I
Scheme 7 Synthesis of intermediate 58 An oven dried pressure tube was charged with 1-bromo-4-pentylbenzene (500 mg, 2.20 mmol, 1.0 equiv.), bis(pinacolato)diborane (670 mg, 2.64 mrnol, 1.2 equiv.), KOAc (1.08 g, 11.00 mmol, 5.0 equiv.), Pd(dppf)C12=CH2C12 (18 mg, 0.022 rrunol, 0.01 equiv.) and 1,4-.. dioxane (dry) (5 mL) was added. Reaction mixture was heated at 100 C for 18h. To the reaction mixture 1420 was added and suspension was extracted with Et0Ac (3 x 20 mL).
Combined organic layers were washed with brine, dried over Na2SO4 and evaporated under reduced pressure. The residue was purified by direct phase ARMEN
chromatograph, eluent system PE/Et0Ac=98:2 to 4:1, 25 g silicagel column, flow rate 25 mL/min.
Yield: 480 mg (80%).
Synthesis of intermediate 59 Product 59 was synthesized according to general method C.
Synthesis of intermediate 60 An oven dried flask was charged with NaH (60% mineral oil) (33 mg, 0.81 mmol, 1.5 equiv.), washed with Et20 (dry) (3 x 2 mL). DMF was added and the suspension was cooled to 0 C.
Then solution of ethyl 5-(4-pentylpheny1)-1H-pyrrole-2-carboxylate (59) (155 mg, 0.54 mmol, 1.0 equiv.) in DMF was added dropwise. Stirred at 0 C for 0.5h, then solution of 1-bromo-4-(bromomethyl)benzene (37) (135 mg, 0.54 rrunol, 1.0 equiv.) in DMF was added.
Stirred at r.t. for 16h. H20 was added and resulting suspension was extracted with Et0Ac (3 x 20 mL). Combined extracts were washed with brine, dried over Na2SO4 and evaporated under reduced pressure. Purified by column chromatography (eluent system PE/Et0Ac=9:1 to 1:1).
Yield: 165 mg (67%).
Synthesis of intermediate 61 Intermediate 61 was synthesized according to general method C.
Synthesis of product 63. General method E.
The carboxylic acid ethyl ester 61 (48 mg, 0.10 mmol, 1.0 equiv.) was dissolved in THE (dry) (2 mL) and the solution was cooled to 0 C. 1M LiA1H4/THF (100 L, 0.10 mmol, 1.0 equiv.) was added dropwise and the mixture was stirred at r.t. for lh. The reaction mixture was cooled to 0 C, H20 (8 pt) was added and stirred for 5 mm, then 4N NaOH sol.
(16 L) was added and stirred for 10 min, after that H20 (24 L) was added and stirred for 10 min. The filtrate was evaporated, giving the desired product 62 (40 mg, 91%).
Synthesis of product 63 Solution of alcohol 62 (34 mg, 0.08 mmol, 1.0 equiv.) in CH2C12 was cooled to 0 C and TEA
(15 mg, 20 ilLõ 0.15 mmol, 1.9 equiv.) and MsC1 (14 mg, 9 ttL, 0.12 mmol, 1.5 equiv.) were added. Stirred at 0 C for lh, then diethylamine (29 mg, 41 IAL, 0.40 mmol, 5.0 equiv.) was added and strirring was continued for 16h at r.t. H20 was added and suspension was extracted with Et0Ac (3 x 7 mL). Combined organic layers were washed with brine, dried over Na2SO4 and evaporated. The residue was purified by column chromatography (eluent sytem PE/Et0Ac=85:15 to 0:100). Yield: 20 mg (50%).
Synthesis of aminoallcyltriazoles 71-73 is shown in scheme 8 HO CsHil 051-111 CsHit Br x 40 1)MsCI, TEA *
N3 65 Ilk CH2C12 CuSO4'5H20 Pd(OAc)2 N,NN 2)Diethylamine N'%
Na ascorbale NNW (Bu)4N+MO 1,4-di0x8ne Witt 67: X=0 OH OH N--\\
68: X=C=0 X X
69: X=0 71: )(=0 70: X=C=0 72: X=C=0 73: X=CH-OH*-obtained from ketone 72 Scheme 8 Synthesis of intermediate 66 Solution of 1-(azidomethyl)-4-pentylbenzene (64) (1.3 g, 6.39 mmol) and but-3-yn-1-ol (65) (583 mg, 629 ttL, 8.31 mmol, 1.3 equiv.) in CH2C12 (20 mL) was stirred at r.t.
for 15 mm, then 1-120 (5 mL), CuSO4=5H20 (209 mg) and sodium ascorbate (587 mg) were added.
Stirring was continued for 16h. To the reaction mixture additional H20 was added and suspension was extracted with Et0Ac (3 x 20 mL). Combined organic layers were washed with H20, brine, dried over Na2SO4 and evaporated under reduced pressure.
Yield: 1.38 g (79%).
Synthesis of intermediate 67 An oven dried pressure tube was charged with 4-methoxyphenol (500 mg, 4.03 mmol, 1.1 equiv.), 1-bromo-4-iodobenzene (1.04 g, 3.66 mmol, 1.0 equiv.), N,N-dimethylglycine (28 mg, 0.27 mmol, 0.075 equiv.), Cs2CO3 (2.34 g, 7.32 mmol, 2.0 equiv.), CuI
(13.9 mg, 0.073 mmol, 0.02 equiv.) and 1,4-dioxane (dry) (8 mL) was added. Reaction mixture was stirred at 90 C for 18h. To the reaction mixture sat. NH4C1 sol. was added and suspension was extracted with Et0Ac (3x 50 mL). Combined organic layers were washed with brine, dried over Na2SO4 and evaporated. The residue was purified by column chromatography (eluent system PE/Et0Ac=95:5 to 1:1). Yield: 584 mg (57%).
Synthesis of intermediate 68 The solution of 1,4-dibromobenzene (1.0 g, 4.24 mmol, 1.0 equiv.) in THF (15 mL) was cooled to -78 C and 2.5M n-BuLi/hexanes (1.7 mL, 4.24 mmol, 1.0 equiv.) was added dropwise. Stirred at -78 C for 30 mm, then solution of 4-methoxybenzaldehyde (520 mg, 3.82 mmol, 0.9 equiv.) in THF (10 mL) was added. Stirred for 16h. To the reaction mixture sat.
NH4C1 sol. was added and suspension was extracted with Et0Ac (3 x 35 mL).
Combined organic layers were washed with brine, dried over Na2SO4 and evaporated.
Product was purified by column chromatography (eluent system PE/Et0Ac=9:1 to 1:1). Yield:
960 mg (77%).
Synthesis of intermediate 69, general method F.
An oven dried MW vial was charged with triazol 66 (300 mg, 1.1 mmol), Pd(OAc)2 (12 mg, 0.055 mmol, 0.05 equiv.), tetrabutylammonium acetate (663 mg, 2.2 mmol, 2.0 equiv.) and 1-bromo-4-(4-methoxyphenoxy)benzene (67) (460 mg, 1.65 mmol, 1.5 equiv.) and NMP
was added (4 mL). Reaction mixture was stirred at 100 C for 18h. Then H20 and brine was added and resulting suspension was extracted with Et0Ac (4 x 20 mL). Combined extracts were washed with H20 (2 x 60 mL), brine, dried over Na2SO4 and evaporated under reduced pressure. The residue was purified by column chromatography (eluent system PE/Et0Ac=9:1 to 0:100). Yield: 254 mg (49%).
By a method analogous to Methods F, C and D using compound 66 as a precursor, the following compounds were obtainded:
Compound BD
Structure No N.
N N
7.4\
Synthesis of product 73 Solution of (4-(4-(2-(diethylamino)ethyl)-1-(4-pentylbenzy1)-1 H-1,2,3-triazol-5-yl)phenyl)(4-methoxyphenyl)methanone (72) (50 mg, 0.093 mmol, 1.0 equiv.) in Me0H (1.8 mL) was cooled to 0 C and NaBH4 (7 mg, 0.19 mmol, 2.0 equiv.) was added portionwise.
Stirred at r.t.
for 2h. Reaction mixture was diluted with Et20, sat. NaHCO3 so!. was added and the mixture was extracted with Et0Ac (3 x 15 mL). Combined organic layers were washed with sat.
NaHCO3 so!., brine, dried over Na2SO4 and evaporated under reduced pressure.
The residue was purified by column chromatography (eluent system CH2C12/Me0H=100:0 to 4:1). Yield:
.. 35 mg (70%).
Synthesis of intermediate 76 An oven dried flask was charged with AlC13 (3.46 g, 26.0 mmol, 1.2 equiv.) and CS2 (7 mL) was added. Then solution of pentylbenzene (74) (3.21 g, 21.6 mmol, 1.0 equiv.) in CS2 (7 mL) and 3-chloropropionylchloride (75) (3.02 g, 2.3 mL, 23.8 mmol, 1.1 equiv.) solution in CS2 (5 mL) was added dropwise. Stirred at r.t. for 15 mm. To the reaction mixture H20 (25 mL) was added carefully, extracted with Et0Ac (3 x 40 mL). Combined organic layers were washed with brine, dried over Na2SO4 and evaporated under reduced pressure.
Yield: 4.65 g (90%).
Synthesis of intermediate 78 An oven dried pressure tube was charged with diethylacetamidomalonate (77) (4.23 g, 19.5 mmol, 1.0 equiv.) and Na0Et (1.33 g, 19.48 mmol, 1.0 equiv.), and Et0H (dry) was added (25 mL). Then solution of chloride 76 (4.65 g, 19.48 mmol) in Et0H (15 mL) was added dropwise. Reaction mixture was heated at 85 C for 18h. Solvent was removed in vacuo. The residue was suspended in H20 and extracted with Et0Ac (3 x 40 mL). Combined organic layers were washed with brine, dried over Na2SO4 and evaporated under reduced pressure.
Product 78 was purified by column chromatography (eluent system PE/Et0Ac=9:1 to 1:1).
Yield: 3.12 g (38%).
Synthesis of intermediate 79 To the diethyl 2-acetamido-2-(3-oxo-3-(4-pentylphenyl)propyl)malonate (78) (3.12 g, 7.44 mmol) HC1 (conc.) (30 mL) and CH3C00II (10 mL) was added. Reaction mixture was heated at 80 C for 16h. Solvent was removed in vacuo. To the residue toluene was added (2 x 40 mL) and the mixture was evaporated under reduced pressure. Precipitate was washed with mixture of CH2C12 and Et20 (1:1). Yield: 1.77 g (80%).
.. Synthesis of intermediate 80 To the solution of 5-(4-pentylpheny1)-2,3-dihydro-1H-pyrrole-2-carboxylic acid hydrochloride (79) (600 mg, 2.31 mmol) in Et0H (dry) (15 mL) S0C12 (824 mg, 503 pL, 6.93 mmol, 3.0 equiv.) was added. Reaction mixture stirred at 50 C for 24h. Solvent was removed in vacuo and toluene (2 x 20 mL) was added and evaporated under reduced pressure. Yield:
664 mg (100%).
Synthesis of intermediate 81 Solution of 2,3-dihydro-1H-pyrrole 80 (664 mg, 2.05 mmol, 1.0 equiv.) in THF
(dry) (10 mL) was cooled to -78 C and 1M KHMDS/THF (4.7 mL, 4.71 mmol, 2.3 equiv.) was added dropwise. Reaction mixture was stirred at -78 C for 45 min, then 4-brombenzylbromide (693 mg, 2.77 mmol, 1.35 mmol) solution in TI-IF (10 mL) was added dropwise.
Stirred at -78 C
for lh, then warmed up to r.t. To the reaction mixture H20 was added and suspension was extracted with Et0Ac (3 x 25 mL). Combined extracts were washed with brine, dried over Na2SO4 and evaporated under reduced pressure. Product was purified by column chromatography (eluent system PE/Et0Ac=7:1). Yield: 363 mg (39%).
Synthesis of intermediate 82 Intermediate 82 was synthesized according to general method B.
Synthesis of intermediate 83 LTMP solution was prepared as follows: a solution of 2.5M n-BuLi/hexanes (544 L, 1.36 mmol, 2.0 equiv.) was added to a stirred, cold (0 C) solution of TMP (211 mg, 252 Idõ 1.50 .. mmol, 2.2 equiv.) in THF. In a separate flask solution of ethyl 14(4'-methoxy-[1,11-bipheny1]-4-yl)methyl)-5-(4-pentylpheny1)-2,3-dihydro-lH-pyrrole-2-carboxylate (82) (330 mg, 0.68 mmol, 1.0 equiv.) and CH2Br2 (237 mg, 96 L, 1.36 mmol, 2.0 equiv.) in TI-IF
was cooled to -78 C and TMP solution was added via cannula. Stirring was continued for 20 min at -78 C.
Reaction was quenched with 1.2 M HC1 aq. sol. and extracted with Et0Ac (3 x 15 mL).
Combined organic layers were dried over Na2SO4 and evaporated under reduced pressure.
Obtained intermediate was dissolved in TI-IF and the solution was cooled to -78 C, then 1M
LiHMDS/THF (700 ILL, 1.09 equiv.) was added dropwise. Stirred at -78 C for 20 mm, then 2.5M n-BuLi/hexanes (563 ttL, 202 equiv.) was added dropwise. Stirring was continued at -78 C for lh. Reaction mixture was warmed up to r.t., and solution of CH3C0C1 in Me0H
(1:5) was added. H20 was added and resulting suspension was extracted with Et0Ac (3 x 15 mL). Combined extracts were washed with brine, dried over Na2SO4 and evaporated under reduced pressure. Product was purified by column chromatography (eluent system PE/Et0Ac=9:1 to 5:1). Yield: 100 mg (32%).
Synthesis of product 84 Product 84 was synthesized according to general method E.
Synthesis of product 85 To the solution of N,N-diethy1-2-(14(4'-methoxy41,11-biphenyl]-4-yOmethyl)-5-(4-pentylphenyl)-2,3-dihydro-1H-pyrrol-2-y1)ethan-1-amine (84) (17 mg, 0.033 mmol) in Me0H
(dry) (1 mL) NaBH3CN (2.5 mg, 0.04 mmol, 1.2 equiv.) and HC1 (1 drop) was added. Stirred at r.t. for 16h. To the reaction mixture H20 was added and extraction with Et0Ac (3 x 5 mL) was performed. Combined organic layers were washed with brine, dried over Na2SO4 and evaporated under reduced pressure. Product was isolated as HC1 salt. Yield: 10 mg (56%).
Synthesis of aminoalkyltriazole 88 is shown in scheme 9 c5H,1 111 NN
c5H11 =
N, C5H11 N.
'N
- \O
FIN-bCN:1[23 H3CN
_ Me0H
Scheme 9 Synthesis of intermediate 87 Intermediate 87 was synthesized according to general method E.
Synthesis of product 88 To the solution of triazole 87 (40 mg, 0.073 mmol) in Me0H (1 mL) acetaldehyde (10 L) and NaBH3CN (6.3 mg, 0.1 mmol, 1.5 equiv.) were added. Reaction mixture was stirred at r.t.
for lh. The solvent was removed in vacua and residue was purified by column chromatography (CH2C12/Me0H=100:0 to 4:1). Yield: 15 mg (36%).
All compounds were characterized by 111-NMR and occasionally by 13C-NMR
spectroscopy performed on Varian Mercury spectrometer (400 MHz) with chemical shifts values (8) in ppm relative to TMS using the residual chloroform signal as internal standard and by tandem LC/MS spectrometer on Water Acquity UPLC with SQ mass selective detector.
Physicochemical characterization of compounds 8.1-8.12, 33.1, 34.1-4, 35.1-2, 36.1-2, 48.1-6, 44, 47, 56.1-2, 63, 71-73, 84, 85, 88.
Compound NMR and UPLC/MS data ID
No 1H-NMR (TMS, CDC13, 400 MHz) a 0.87 (t, 7.0 Hz, 311); 0.91 (t, 7.0 Hz, 6H); 1.2-1.4 (m, 4H); 1.5-1.7 (m, 2H); 2.47 (q, 7.0 Hz, 4 H);
2.59 (t, 7.4 Hz, 2H); 3.37 (s, 2H); 5.56 (s, 2H); 7.07 (d, 8.2 Hz, 2H);
GL-1547 8.1 7.07 (s, 111); 7.17 (d, 8.2 Hz, 2H); 7.35 (dd, 3.1 and 7.8 Hz, 1H);
7.45 (d, 8.2 Hz, 2H); 7.54 (d, 8.2 Hz, 2H); 7.86 (dt, 2.0 and 7.8 Hz, 1H); 8.59 (dd, 1.6 and 4.7 Hz, 111); and 8.84 ppm (d, 2.3 Hz, 1H).
UPLC/MS: [M-1-1] = 467.6 1H-NMR (TMS, CDC13, 400 MHz) D: 0.80 (t, 7.0 Hz, 3H); 1.1-1.3 (m, 4H); 1.53 (m, 2H); 2.12 (s, 1H); 2.53 (t, 7.8 Hz, 2H); 3.56 (s, 2H); 3.68 (s, 211); 5.40 (s, 2H); 6.96 (d, 8.2 Hz, 2H); 7.04 (t, 3.9 Hz, 1H); 7.11 (d, 8.2 Hz, 2H); 7.16 (d, 7.0 Hz, 2H); 7.20 (d, 7.0 Hz, 2H);
GL-1556 8.2 7.29 (dd, 4.7 and 7.8 Hz, 111); 7.38 (d, 8.2 Hz, 2H); 7.42 (d, 8.2 Hz, 2H); 7.76 (dt, 2.0 and 7.8 Hz, 1H); 8.52 (dd, 1.6 and 4.7 Hz, 1H); and 8.74 ppm (d, 2.0 Hz, 1H).
UPLC/MS: [M+1] = 501.5 1H-NMR (TMS, CDC13, 400 MHz) El 0.87 (t, 7.0 Hz, 3H); 1.2-1.4 (m, 4H); 1.60 (m, 2H); 2.60 (t, 7.8 Hz, 2H); 3.51 (s, 1H); 3.59 (s, 211); 3.71 (s, 2H); 3.78 (s, 611); 5.66 (s, 2H); 6.39 (dd, 2.4 and 8.2 GL-1562 Hz, 1H); 6.43 (d, 2.4 Hz, 1H); 7.04 (dd, 5.1 and 8.2 Hz, 2H); 7.13 (s, 8.3 1H); 7.18 (d, 8.2 Hz, 211); 7.37 (dd, 5.1 and 7.8 Hz, 2H); 7.43 (d, 8.2 Hz, 2H); 7.51 (d, 8.2 Hz, 211); 7.85 (dt, 2.0 and 8.2 Hz, 1H); 8.59 (dd, 1.6 and 5.5 Hz, 1H); and 8.82 ppm (d, 2.0 Hz, 111).
UPLC/MS: [M+11 = 561.7 1H-NMR (TMS, CDC13, 400 MHz) EL: 0.81 (t, 7.4 Hz, 311); 1.2-1.3 (m, 4H); 1.5-1.6 (m, 211); 2.12 (s, 1H); 2.54 (t, 7.4 Hz, 211); 3.38 (s, 2H); 4.07 (d, 4.3 Hz, 2H); 5.33 (s, 2H); 6.47 (d, 7.8 Hz, 2H); 6.67 (t, 7.4 Hz, 114); 7.02 (d, 8.2 Hz, 2H); 7.07 (d, 7.4 Hz, 211); 7.09 (d, 7.4 GL-1570 8.4 Hz, 2H); 7.13 (d, 7.4 Hz, 2H); 7.14 (s, 1H); 7.31 (ddd, 0.8 and 4.7 and 7.8 Hz, 111); 7.40 (d, 8.2 Hz, 2H); 7.48 (d, 8.2 Hz, 2H); 7.79 (dt, 2.0 and 8.2 Hz, 1H); 8.54 (dd, 1.6 and 5.1 Hz, 111); and 8.77 ppm (d, 2.0 Hz, 1H).
UPLC/MS: [M+1] = 487.5 1H-NMR (TMS, DMSO-d6, 400 MHz) EL: 0.5-1.0 (m, 2H); 0.83 (t, 7.0 Hz, 3H); 1.0-1.4 (m, 8H); 1.4-1.7 (m, 711); 2.26 (d, 6.7 Hz, 4H);
GL-1634 85 2.5-2.7 (m, 2H); 3.53 (s, 211); 5.48 (s, 211); 6.97 (s, 1H);
7.04 (d, 8.2 Hz, 2H); 7.22 (d, 8.2 Hz, 2H); 7.42 (d, 8.2 Hz, 2H); 7.45 (dd, 4.7 and 7.8 Hz, 1H); 7.69 (d, 8.2 Hz, 211); 8.03 (dt, 1.8 and 8.2 Hz, 111);
8.55 (dd, 1.6 and 4.7 Hz, 1H); and 8.85 ppm (d, 2.3 Hz, 111).
UPLC/MS: [M+1] = 507.5 111-NMR (TMS, CDC13, 400 MHz) n11: 0.87 (t, 7.0 Hz, 3H); 1.37 -1.21 (m, 4H); 1.5-1.7 (m, 2H); 2.60 (t, 7.8 Hz, 211); 3.63 (s, 2H); 3.73 (s, 2H); 3.76 (s, 3H); 5.46 (s, 2H); 6.7 - 6.9 (m, 3H); 7.04 (d, 8.4 Hz, 211); 7.11 (s, 111); 7.18 (d, 8.3 Hz, 311); 7.36 (ddd, 0.8 and 4.8 and GL-1643 8.6 7.9 Hz, 1H); 7.45 (d, 8.2 Hz, 2H); 7.50 (d, 8.3 Hz, 2H); 7.83 (ddd, 1.7 and 2.3 and 7.9 Hz, 1H); 8.59 (dd, 4.8 and 1.6 Hz, 1H) and 8.81 ppm (dd, 0.8 and 2.4 Hz, 111).
UPLC/MS: [M+1] = 531.6 11-1-NMR (TMS, CDC13, 400 MHz) El 0: 0.88 (t, 7.0 Hz, 3H); 1.2-1.4 (m, 7H); 1.5-1.7 (m, 2H); 2.61 (t, 7.8 Hz, 2H); 3.48 (dd, 14.1 and 42.3, 2H); 3.73 (q, 6.7 Hz, 1H); 5.42 (dd, 3.5 and 16.8, 2H); 6.98 (d, GL-1686 8.7 8.2 Hz, 2H); 7.09 (s, 1H); 7.19 (d, 8.2 Hz, 2H); 7.2-7.3 (m, 4H); 7.37 (dd, 4.7 and 7.8 Hz, 1H); 7.47 (t, 8.2 Hz, 411); 7.83 (dt, 1.6 and 7.8 Hz, 1H); 8.60 (s, 1H) and 8.82 ppm (s, 1H).
UPLC/MS: [M+1] = 515.6 11-1-NMR (TMS, CDC13, 400 MHz) 0 0: 0.87 (t, 7.0 Hz, 31-1); 1.2-1.4 (m, 4H); 1.5-1.7 (m, 2H); 2.60 (t, 7.8 Hz, 2H); 3.66 (s, 211); 3.83 (s, GL-1726 8 2H); 5.45 (s, 2H); 6.99 (d, 8.2 Hz, 211); 7.13 (s, 1H); 7.17 (d, 8.2 Hz, .8 2H); 7.2-7.6 (m, 1411); 7.76 (dt, 2.3 and 7.8 Hz, 111); 8.77 (dd, 1.6 and 4.7 Hz, 1H) and 8.77 (dd, 0.8 and 2.3 Hz, 1H).
UPLC/MS: [M+1] = 577.6 111-NMR (TMS, DMSO-d6, 400 MHz) LL: 0.78 (d, 6.7 Hz, 6H);
0.83 (t, 7.0 Hz, 3H); 1.1-1.3 (m, 611); 1.4-1.6 (m, 3H); 2.43 (t, 7.4 Hz, 2H); 2.56 (t, 7.4 Hz, 2H); 3.54 (s, 2H); 5.47 (s, 2H); 6.97 (s, 1H);
GL1638 8.9 7.04 (d, 8.2 Hz, 2H); 7.21 (d, 8.2 Hz, 2H); 7.42 (d, 8.2 Hz, 2H); 7.46 (dd, 4.7 and 7.8 Hz, 1H); 7.69 (d, 8.2 Hz, 211); 8.04 (dt, 1.6 and 8.2 Hz, 1H); 8.55 (dd, 1.6 and 4.7 Hz, 1H); and 8.85 ppm (d, 2.3 Hz, 1H) UPLC/MS: [M+1] = 481.3 GL-1566 8.10 1H-NMR (TMS, CDC13, 400 MHz) 0 0: 0.87 (t, 7.4 Hz, 3H);
1.2-1.4 (m, 4H); 1.5-1.7 (m, 2H); 2.60 (t, 7.8 Hz, 2H); 3.73 (s, 2H); 5.42 (s, 2H); 7.01 (s, 1H); 7.12 (d, 8.2 Hz, 2H); 7.18 (d, 8.2 Hz, 21-1); 7.3-7.4 (m, 1H); 7.44 (d, 8.2 Hz, 2H); 7.55 (d, 8.2 Hz, 2H); 7.85 (dt, 2.0 and 8.2 Hz, 1H); 8.59 (dd, 1.6 and 4.7 Hz, 1H); and 8.83 ppm (dd, 0.8 and 2.4 Hz, 1H).
UPLC/MS: [M+l] = 411.6 11-1-NMR (TMS, CDC13, 400 MHz) U [1: 0.79 (d, 6.3 Hz, 12H); 0.87 (t, 7.0 Hz, 3H); 1.1-1.3 (m, 4H); 1.3-1.4 (m, 4H); 1.4-1.5 (m, 2H);
1.5-1.7 (m, 2H); 2.37 (t, 7.8 Hz, 4H); 2.59 (t, 7.8 Hz, 2H); 3.33 (s, 2H); 5.55 (s, 2H); 7.05 (d, 8.2 Hz, 2H); 7.07 (s, 1H); 7.17 (d, 8.2 Hz, GL-1625 8.11 2H); 7.37 (dd, 4.7 and 7.8 Hz, 1H); 7.43 (d, 8.2 Hz, 211); 7.54 (d, 8.2 Hz, 2H); 7.85 (dt, 2.0 and 8.2 Hz, 1H); 8.59 (dd, 1.2 and 4.7 Hz, 1H);
and 8.83 ppm (d, 2.0 Hz, 1H).
UPLC/MS: [M+1] = 551.6 1H-NMR (TMS, DMSO-d6, 400 MHz) n: 0.6-0.9 (m, 3H); 1.0-1.3 (m, 6H); 1.38 (s, 6H); 1.7-2.1 (m, 2H); 5.96 (s, 2H); 6.90 (d, 8.3 Hz, 2H); 6.93 (s, 1H); 7.11 (d, 8.2 Hz, 2H); 7.36 (d, 8.2 Hz, 2H); 7.44 8.12 (dd, 8.0 and 4.8 Hz, 111); 7.60 (d, 8.3 Hz, 211); 8.03-7.98 (m, 1H);
8.53 (dd, 4.7 and 1.5 Hz, 1H) and 8.83 ppm (d, 2.4 Hz, 1H).
UPLC/MS: [M+1] = 439.6 1H-NMR (DMSO-d6) 5: 8.53-8.41 (3H, m) 7.55-7,49 (2H, m) 7.45-7.40 (211, m) 7.38-7.33 (211, m) 7.32-7.27 (2H, m) 7.02-6.97 (2H, m) 6.97-6.93 (211, m) 4.24 (211, s) 4.13 (211, q, J=5.6 Hz) 3.78 (3H, s) 2.65 (2H, t, J=7.5 Hz) 1.59 (2H, quintet, J=7.3 Hz) 1.36-1.21 (4H, m) 0.85 (311, t, J=7.0 Hz) LV-1136 33.1 õ
'3C-NMR (100 MHz, CDC13) 5: 159.0, 144.7, 138.9, 136.3, 134.7, 133.6, 133.0, 129.0, 128.6, 127.9, 126.7, 125.6, 114.1, 55.3, 35.5, 31.4, 30.9, 22.4, 14.0 1-1RMS: Calculated for C28H33N40: 441.2654 Found: 441.2659 [M+1-1]
111-NMR (CDC13) 13: 7.51-7.44 (2H, m) 7.43-7.38 (2H, m) 7.25-7.18 LV-1087 34.1 (411, m) 7.00-6.93 (4H, m) 4.04 (2H, s) 3.84 (3H, s) 2.91-2.83 (2H,
41 m) 2.79-2.71 (2H, m) 2.64 (2H, t, J=7.8 Hz) 2.59-2.33 (6H, m) 2.28 (3H, s) 2.10-1.72 (2H, m) 1.62 (2H, quintet, J=7.4 Hz) 1.39-1.23 (4H, m) 0.89 (3H, t, J=7.0 Hz) ES1/MS: [M+1] = 538 1H-NMR (DMSO-d6) 6: 11.24-11.07 (1H, m) 7.55-7.49 (2H, m) 7.47-7.41 (2H, m) 7.39-7.30 (4H, m) 7.01-6.97 (2H, m) 6.97-6.92 (2H, m) 4.16 (211, s) 3.97 (2H, dd, J=12.1, 2.2 Hz) 3.84-3.78 (2H, m) LV-1154 34.2 3.78 (3H, s) 3.54-3.47 (2H, m) 3.47-3.38 (2H, m) 3.24-3.16 (2H, m) 3.16-3.04 (211, m) 2.65 (211, t, J=7.7 Hz) 1.59 (2H, quintet, J=7.4 Hz) 1.36-1.20 (4H, m) 0.85 (3H, t, J=7.0 Hz) ESI-MS (m/z): 525 [M+Hr.
111-NMR (CDC13) 6: 7.49-7.44 (211, m) 7.42-7.38 (211, m) 7.24-7.22 (4H, m) 6.98-6.91 (4H, m) 4.03 (2H, s) 3.84 (3H, s) 3.34 (2H, t, J=6.4 Hz) 2.99 (2H, t, J=6.4 Hz) 2.64 (211, t, J=7.7 Hz) 1.62 (2H, quintet, J=7.3 Hz) 0.89 (3H, t, J=7.0 Hz) LV-1155 34.3 13C- NMR (100 MHz, CDC13) 6: 159.2, 144.8, 134.9, 133.2, 132.8, 129.3, 128.3, 127.9, 126.9, 125.3, 114.2, 55.3, 47.3, 43.3, 35.5, 31.3, 30.9, 22.5, 14.0 HRMS: Calculated for C31H39N40: 483.3124 Found: 483.3119 [M+H]+
-1H-NMR (CDC13) 8: 7.49-7.44 (2H, m) 7.42-7.38 (2H, m) 7.24-7.22 (411, m) 6.98-6.91 (411, m) 4.03 (2H, s) 3.84 (3H, s) 3.34 (211, t, J=6.4 Hz) 2.99 (2H, t, J=6.4 Hz) 2.64 (2H, t, J=7.7 Hz) 1.62 (2H, quintet, J=7.3 Hz) 0.89 (3H, t, J=7.0 Hz) LV-1157 34.4 13C-NMR (CDC13) 6: 159.1, 144.8, 139.2, 134.7, 134.2, 133.7, 132.8, 129.2, 128.4, 127.9, 126.8, 125.4, 114.2, 55.3, 35.5, 31.4, 30.9, 22.4, 14.0 HRMS: Calculated for C29H35N40: 455.2811 Found: 455.2806 [M+H]
1H-NMR (CDC13) 8: 7.51-7.46 (211, m) 7.46-7.41 (2H, m) 7.30-7.26 (4H, m) 7.01-6.92 (4H, m) 4.06 (2H, m) 3.84 (3H, s) 3.06-2.93 (611, LV4130 35.1 m) 2.71 (2H, t, J=7.0 Hz) 2.66 (2H, t, J=7.8 Hz) 2.28-2.17 (2H, m) 1.64 (2H, quintet, J=7.4 Hz) 1.36-1.26 (9H, m) 0.89 (311, t, J=7.0 Hz)
111-NMR (CDC13) 6: 7.49-7.44 (211, m) 7.42-7.38 (211, m) 7.24-7.22 (4H, m) 6.98-6.91 (4H, m) 4.03 (2H, s) 3.84 (3H, s) 3.34 (2H, t, J=6.4 Hz) 2.99 (2H, t, J=6.4 Hz) 2.64 (211, t, J=7.7 Hz) 1.62 (2H, quintet, J=7.3 Hz) 0.89 (3H, t, J=7.0 Hz) LV-1155 34.3 13C- NMR (100 MHz, CDC13) 6: 159.2, 144.8, 134.9, 133.2, 132.8, 129.3, 128.3, 127.9, 126.9, 125.3, 114.2, 55.3, 47.3, 43.3, 35.5, 31.3, 30.9, 22.5, 14.0 HRMS: Calculated for C31H39N40: 483.3124 Found: 483.3119 [M+H]+
-1H-NMR (CDC13) 8: 7.49-7.44 (2H, m) 7.42-7.38 (2H, m) 7.24-7.22 (411, m) 6.98-6.91 (411, m) 4.03 (2H, s) 3.84 (3H, s) 3.34 (211, t, J=6.4 Hz) 2.99 (2H, t, J=6.4 Hz) 2.64 (2H, t, J=7.7 Hz) 1.62 (2H, quintet, J=7.3 Hz) 0.89 (3H, t, J=7.0 Hz) LV-1157 34.4 13C-NMR (CDC13) 6: 159.1, 144.8, 139.2, 134.7, 134.2, 133.7, 132.8, 129.2, 128.4, 127.9, 126.8, 125.4, 114.2, 55.3, 35.5, 31.4, 30.9, 22.4, 14.0 HRMS: Calculated for C29H35N40: 455.2811 Found: 455.2806 [M+H]
1H-NMR (CDC13) 8: 7.51-7.46 (211, m) 7.46-7.41 (2H, m) 7.30-7.26 (4H, m) 7.01-6.92 (4H, m) 4.06 (2H, m) 3.84 (3H, s) 3.06-2.93 (611, LV4130 35.1 m) 2.71 (2H, t, J=7.0 Hz) 2.66 (2H, t, J=7.8 Hz) 2.28-2.17 (2H, m) 1.64 (2H, quintet, J=7.4 Hz) 1.36-1.26 (9H, m) 0.89 (311, t, J=7.0 Hz)
42 BSI/MS (m/z): 525 [M+H].
11-1-NMR (CDC13) 8: 7.50-7.46 (21-1, m) 7.45-7.40 (2H, m) 7.30-7.25 (4H, m, overlapped with CDC13) 7.01-6.93 (4H, m) 4.06 (2H, s) 3.84 LV-1124 35.2 (3H, s) 3.06 (2H, t, J=8.0 Hz) 2.74 (2H, t, J=7.0 Hz) 2.66 (2H, t, J=7.8 Hz) 2.30-2.19 (2H, m) 2.13-1.97 (4H, m) 1.64 (2H, quintet, J=7.6 Hz) 1.40-1.27(411, m) 0.89 (3H, t, J=7.0 Hz) ESI/MS (m/z): 523 [M+Hr.
111-NMR (CD30D-d4) 8: 7.45-7.40 (2H, m) 7.40-7.33 (314, m) 7.32-7.17 (4H, m) 7.13-7.07 (1H, m) 7.04-6.97 (2H, m) 6.84-6.77 (2H, m) 4.57 (111, d, J=15.2 Hz) 4.31 (111, d, J=15.2 Hz) 4.15 (2H, s) 3.87-ICD-302 36.1 3.72 (11I, m) 3.62-3.46 (2H, m) 3.46-3.34 (1H, m) 3.25-3.15 (2H, m) 3.14-3.01 (2H, m) 2.68 (2H, t, J=7.6 Hz) 1.64 (2H, quintet, J=7.2 Hz) 1.39-1.29 (4H, m) 0.88 (3H, t, J=7.0 Hz) ESI/MS (m/z): 557 [M+H]t 11-1-NMR (CDC13) 8: 7.31-7.26 (4H, m) 7.25-7.19 (4H, m) 4.04 (2H, s) 3.10-2.94 (4H, m) 2.86-2.72 (4H, m) 2.65 (2H, t, J=7.7 Hz) 1.62 (2H, quintet, J=7.5 Hz) 1.40-1.27 (411, m) 1.13 (6H, t, J=7.1 Hz) VGP-153 36.2 0.89 (3H, t, J=7.0 Hz) 13C-NMR (CDC13) 8: 156.5, 144.8, 139.5, 134.8, 133.9, 131.8, 129.3, 128.2, 127.9, 126.7, 125.3, 116.0, 51.7, 46.3, 35.5, 31.3, 30.9, 28.2, 22.5, 14.0 ESI/MS (m/z): 497 [M+Hr.
1H-NMR (CDC13) 8: 7.56-7.51 (2H, m) 7.48-7.43 (2H, m) 7.43-7.39 (2H, m) 7.37-7.31 (1H, m) 7.25-7.21 (4H, m) 7.03-6.98 (2H, m) 4.08 (2H, s) 2.91 (2H, s) 2.71-2.59 (611, m) 1.63 (211, quintet, J=7.5 Hz) KD-304 48.1 1.40-1.26 (4H, m) 1.06 (6H, t, J=7.2 Hz) 0.89 (3H, t, 1=7.0 Hz) 13C-NMR (100 MHz, CDC13) .5: 144.7, 140.4, 139.8, 136.0, 134.1, 132.8, 129.3, 128.8, 128.4, 127.4, 127.3, 126.9, 125.3, 52.0, 46.8, 35.5, 31.3, 30.9, 28.3, 22.4, 14.0, 11.2 LC/MS: 481 [M+H]+
1H-NMR (CDC13) 8: 12.38-12.22 (1H, m) 7.49-7.42 (611, m) 7.34-1(13-307 48.2 726 (4H, m) 7.05-7.00 (211, m) 4.22 (2H, s) 3.48-3.32 (4H, m) 3.22-3.03 (411, m) 2.68 (2H, t, J=7.7 Hz) 1.71-1.59 (2H, m) 1.41-1.30 (10H, m) 0.90 (3H, t, J=7.0 Hz)
11-1-NMR (CDC13) 8: 7.50-7.46 (21-1, m) 7.45-7.40 (2H, m) 7.30-7.25 (4H, m, overlapped with CDC13) 7.01-6.93 (4H, m) 4.06 (2H, s) 3.84 LV-1124 35.2 (3H, s) 3.06 (2H, t, J=8.0 Hz) 2.74 (2H, t, J=7.0 Hz) 2.66 (2H, t, J=7.8 Hz) 2.30-2.19 (2H, m) 2.13-1.97 (4H, m) 1.64 (2H, quintet, J=7.6 Hz) 1.40-1.27(411, m) 0.89 (3H, t, J=7.0 Hz) ESI/MS (m/z): 523 [M+Hr.
111-NMR (CD30D-d4) 8: 7.45-7.40 (2H, m) 7.40-7.33 (314, m) 7.32-7.17 (4H, m) 7.13-7.07 (1H, m) 7.04-6.97 (2H, m) 6.84-6.77 (2H, m) 4.57 (111, d, J=15.2 Hz) 4.31 (111, d, J=15.2 Hz) 4.15 (2H, s) 3.87-ICD-302 36.1 3.72 (11I, m) 3.62-3.46 (2H, m) 3.46-3.34 (1H, m) 3.25-3.15 (2H, m) 3.14-3.01 (2H, m) 2.68 (2H, t, J=7.6 Hz) 1.64 (2H, quintet, J=7.2 Hz) 1.39-1.29 (4H, m) 0.88 (3H, t, J=7.0 Hz) ESI/MS (m/z): 557 [M+H]t 11-1-NMR (CDC13) 8: 7.31-7.26 (4H, m) 7.25-7.19 (4H, m) 4.04 (2H, s) 3.10-2.94 (4H, m) 2.86-2.72 (4H, m) 2.65 (2H, t, J=7.7 Hz) 1.62 (2H, quintet, J=7.5 Hz) 1.40-1.27 (411, m) 1.13 (6H, t, J=7.1 Hz) VGP-153 36.2 0.89 (3H, t, J=7.0 Hz) 13C-NMR (CDC13) 8: 156.5, 144.8, 139.5, 134.8, 133.9, 131.8, 129.3, 128.2, 127.9, 126.7, 125.3, 116.0, 51.7, 46.3, 35.5, 31.3, 30.9, 28.2, 22.5, 14.0 ESI/MS (m/z): 497 [M+Hr.
1H-NMR (CDC13) 8: 7.56-7.51 (2H, m) 7.48-7.43 (2H, m) 7.43-7.39 (2H, m) 7.37-7.31 (1H, m) 7.25-7.21 (4H, m) 7.03-6.98 (2H, m) 4.08 (2H, s) 2.91 (2H, s) 2.71-2.59 (611, m) 1.63 (211, quintet, J=7.5 Hz) KD-304 48.1 1.40-1.26 (4H, m) 1.06 (6H, t, J=7.2 Hz) 0.89 (3H, t, 1=7.0 Hz) 13C-NMR (100 MHz, CDC13) .5: 144.7, 140.4, 139.8, 136.0, 134.1, 132.8, 129.3, 128.8, 128.4, 127.4, 127.3, 126.9, 125.3, 52.0, 46.8, 35.5, 31.3, 30.9, 28.3, 22.4, 14.0, 11.2 LC/MS: 481 [M+H]+
1H-NMR (CDC13) 8: 12.38-12.22 (1H, m) 7.49-7.42 (611, m) 7.34-1(13-307 48.2 726 (4H, m) 7.05-7.00 (211, m) 4.22 (2H, s) 3.48-3.32 (4H, m) 3.22-3.03 (411, m) 2.68 (2H, t, J=7.7 Hz) 1.71-1.59 (2H, m) 1.41-1.30 (10H, m) 0.90 (3H, t, J=7.0 Hz)
43 13C-NMR (100 MHz, CDC13) 8: 150.4, 144.8, 139.6, 137.5, 135.6, 134.0, 129.3, 128.4, 127.2, 126.5, 125.7, 125.3, 62.8, 51.7, 46.8, 35.5, 34.5, 31.3, 30.9, 29.8, 28.3, 22.4, 14.0 ESI/MS: 537 [M+Hr.
1H-NMR (CDC13) 8: 7.45-7.40 (2H, m) 7.29-7.22 (4H, m, overlapped with CDC13) 7.09 (1H, d, J=8.3, 2.1 Hz) 7.05 (1H, d, J=2.1 Hz) 7.02-6.98 (2H, m) 6.92 (1H, d, J=8.3 Hz) 4.09 (2H, s) 3.93 (3H, s) 3.91 (3H, s) 3.07-2.95 (4H, m) 2.87-2.70 (4H, m) 2.66 (2H, t, J=7.7 Hz) KD-329 48.4 1'63 (211, quintet, J=7.5 Hz) 1.39-1.26 (411, m) 1.14 (6H, t, J=7.0 Hz) 0.89 (3H, t, J=7.0 Hz) 13C-NMR (100 MHz, CDC13) 8: 149.2, 148.7, 144.8, 139.6, 135.5, 134.0, 133.4, 129.4, 128.4, 127.1, 125.3, 119.2, 111.5, 110.2, 56.0, 55.9, 46.7, 35.5, 31.3, 30.9, 28.3, 22.5, 14.0 ESI/MS: 541 [M+H].
1H-NMR (CDC13) Es: 7.50-7.45 (2H, m) 7.44-7.40 (2H, m) 7.29-7.24 (4H, m, overlapped with CDC13) 7.01-6.93 (4H, m) 4.08 (2H, s) 3.90-3.85 (4H, m) 3.24-3.16 (411, m) 3.10-2.97 (4H, m) 2.87-2.74 (4H, m) 2.66 (2H, t, J=7.7 Hz) 1.63 (2H, quintet, J=7.4 Hz) 1.40-KD-330 48.5 1.28 (4H, m) 1.15 (6H, t, J=7.0 Hz) 0.89 (311, t, J=7.0 Hz) 13C-NMR (100 MHz, CDC13) 8: 150.6, 144.8, 139.4, 135.0, 134.0, 131.7, 129.3, 128.4, 127.5, 126.7, 125.3, 115.7, 66.8, 49.1, 46.7, 35.5, 31.3, 30.9, 28.3, 22.5, 14.2, 14.0 ESI/MS: 566 [M+Hr.
1H-NMR (CDC13) 8: 7.36-7.32 (2H, m) 7.27-7.23 (2H, m, overlapped with CDC13) 7.20-7.15 (2H, m) 6.84-6.78 (211, m) 4.02 (211, s) 3.17-KD-294 44 2'90 (4H, m) 2.89-2.70 (4H, m) 2.66 (2H, t, J=7.7 Hz) 1.63 (211, quintet, J=7.6 Hz) 1.40-1.27 (4H, m) 1.24-1.07 (6H, m) 0.90 (3H, t, J=7.0 Hz) ESI/MS: 484 [M+Hr.
1H-NMR (CD30D-d4) 8: 7.85-7.80 (2H, m) 7.59-7.53 (2H, m) 7.48-7.42 (2H, m) 7.27-7.22 (2H, m) 7.22-7.18 (2H, m) 6.99-6.93 (2H, m) KD-315 48.6 4.06 (2H, s) 2.78-2.66 (411, m) 2.59 (2H, t, J=7.7 Hz) 2.51 (4H, q, J=7.2 Hz) 1.55 (211, t, J=7.2 Hz) 1.31-1.17 (4H, m) 0.93 (6H, t, J=7.2 Hz) 0.80 (3H, t, J=7.0 Hz)
1H-NMR (CDC13) 8: 7.45-7.40 (2H, m) 7.29-7.22 (4H, m, overlapped with CDC13) 7.09 (1H, d, J=8.3, 2.1 Hz) 7.05 (1H, d, J=2.1 Hz) 7.02-6.98 (2H, m) 6.92 (1H, d, J=8.3 Hz) 4.09 (2H, s) 3.93 (3H, s) 3.91 (3H, s) 3.07-2.95 (4H, m) 2.87-2.70 (4H, m) 2.66 (2H, t, J=7.7 Hz) KD-329 48.4 1'63 (211, quintet, J=7.5 Hz) 1.39-1.26 (411, m) 1.14 (6H, t, J=7.0 Hz) 0.89 (3H, t, J=7.0 Hz) 13C-NMR (100 MHz, CDC13) 8: 149.2, 148.7, 144.8, 139.6, 135.5, 134.0, 133.4, 129.4, 128.4, 127.1, 125.3, 119.2, 111.5, 110.2, 56.0, 55.9, 46.7, 35.5, 31.3, 30.9, 28.3, 22.5, 14.0 ESI/MS: 541 [M+H].
1H-NMR (CDC13) Es: 7.50-7.45 (2H, m) 7.44-7.40 (2H, m) 7.29-7.24 (4H, m, overlapped with CDC13) 7.01-6.93 (4H, m) 4.08 (2H, s) 3.90-3.85 (4H, m) 3.24-3.16 (411, m) 3.10-2.97 (4H, m) 2.87-2.74 (4H, m) 2.66 (2H, t, J=7.7 Hz) 1.63 (2H, quintet, J=7.4 Hz) 1.40-KD-330 48.5 1.28 (4H, m) 1.15 (6H, t, J=7.0 Hz) 0.89 (311, t, J=7.0 Hz) 13C-NMR (100 MHz, CDC13) 8: 150.6, 144.8, 139.4, 135.0, 134.0, 131.7, 129.3, 128.4, 127.5, 126.7, 125.3, 115.7, 66.8, 49.1, 46.7, 35.5, 31.3, 30.9, 28.3, 22.5, 14.2, 14.0 ESI/MS: 566 [M+Hr.
1H-NMR (CDC13) 8: 7.36-7.32 (2H, m) 7.27-7.23 (2H, m, overlapped with CDC13) 7.20-7.15 (2H, m) 6.84-6.78 (211, m) 4.02 (211, s) 3.17-KD-294 44 2'90 (4H, m) 2.89-2.70 (4H, m) 2.66 (2H, t, J=7.7 Hz) 1.63 (211, quintet, J=7.6 Hz) 1.40-1.27 (4H, m) 1.24-1.07 (6H, m) 0.90 (3H, t, J=7.0 Hz) ESI/MS: 484 [M+Hr.
1H-NMR (CD30D-d4) 8: 7.85-7.80 (2H, m) 7.59-7.53 (2H, m) 7.48-7.42 (2H, m) 7.27-7.22 (2H, m) 7.22-7.18 (2H, m) 6.99-6.93 (2H, m) KD-315 48.6 4.06 (2H, s) 2.78-2.66 (411, m) 2.59 (2H, t, J=7.7 Hz) 2.51 (4H, q, J=7.2 Hz) 1.55 (211, t, J=7.2 Hz) 1.31-1.17 (4H, m) 0.93 (6H, t, J=7.2 Hz) 0.80 (3H, t, J=7.0 Hz)
44 13C-NMR (100 MHz, CD30D-d4) 6: 170.5, 145.2, 143.7, 143.2, 138.5, 136.8, 133.8, 133.8, 132.3, 129.2, 128.5, 127.9, 127.0, 126.4, 125.2, 51.4, 46.3, 35.0, 31.0, 30.8, 27.6, 22.1, 21.2, 12.9, 9.9 ESI/MS: 524 [M+H].
11-1-NMR (400 MHz, CDC13) 8: 8.83-8.76 (1H, m) 8.57 (1H, d, J=3.5 Hz) 7.86-7.79 (1H, m) 7.43 (211, d, J=8.2 Hz) 7.35 (1H, d, J=5.5, 7.7 Hz) 7.26-7.16 (4H, m) 7.07 (2H, d, J=8.2 Hz) 4.20 (2H, s) 3.75 (2H, KD-263 47 s) 2.63 (4H, q, J=7.0 Hz) 2.40 (3H, s) 1.06 (6H, t, J=7,0 Hz) 13C-NMR (100 Hz, CDC13) 8: 148.4, 148.1, 139.7, 137.2, 136.1, 134.1, 133.9, 129.9, 128.9, 127.2, 125.3, 123.5, 62.7, 48.0, 46.6, 29.9, 28.3, 21.2, 11.4 ESI/MS: 412 [M+H].
-1H-NMR (400 MHz, CD03) 8: 13.05 (s, 1H), 7.51-7.41 (m, 6H), 7.23-7.21 (m, 1H), 7.15-7.09 (m, 2H), 6.98-6.92 (m, 211), 4.16 (s, 4H), 3.83 (s, 311), 3.15-3.05 (m, 4H), 2.62 (t, 2H, J=7.7 Hz), 1.65-1.55 (m, 3H), 1.46 (t, 6H, J=7.2 Hz), 1.34-1.27 (m, 4H), 0.87 (t, 3H, KD-199 56.1 J= 6.8 Hz).
13C-NMR (100 Hz, CDC13) 8: 163.9, 159.2, 158.0, 145.4, 139.5, 136.0, 132.8, 129.0, 128.5, 128.2, 127.9, 127.1, 125.1, 119.8, 114.2, 55.3, 47.9, 43.7, 35.7, 31.4, 30.8, 27.5, 22.5, 14.0, 9.3.
ESI/MS (m/z): 497 [M+H].
11-1-NMR (400 MHz, CDC13) 8: 7.44-7.40 (m, 111), 7.38-7.34 (m, 1H), 7.18-7.16 (m, 1H), 7.14-7.08 (m, 1H), 7.04-6.98 (m, 1H), 3.89 KD-233 56.2 (s, 2H), 3.64 (s, 2H), 2.57-2.44 (m, 6H), 1.54 (quintet, 2H, J=7.7 Hz), 1.29- 1.21 (m, 4H), 1.18 (m, 2H), 0.99-0.91 (m, 6H), 0.81 (t, 3H, .1=
6.8 Hz).
ESI/MS (m/z): 473 [M+Hr.
1H-NMR (400 MHz, CDC13) 8: 7.52-7.48 (2[1, m) 7.47-7.43 (2H, m) 7.26-7.22 (2H, m) 7.13-7.08 (2H, m) 6.98-6.94 (2H, m) 6.94-6.90 (2H, m) 6.20 (111, d, J=3.5 Hz) 6.14 (111, d, J=3.5 Hz) 5.44 (2H, s) LV-1341 63 3.85 (3H, s) 3.35 (2H, s) 2.57 (2H, t, J=7.8 Hz) 2.48 (2H, q, J=7.1 Hz) 1.60 (2H, quintet, J=7.6 Hz) 1.38-1.25 (4H, m) 0.92 (3H, t, J=7.1 Hz, 0.88 (3H, t, J=7.0 Hz) ESI/MS: 495 [M+11]+.
11-I-NMR (400 MHz, CDC13) 6: 7.10-6.98 (6H, m) 6.97-6.88 (6H, m) 5.36 (2H, s) 3.83 (3H, s) 2.88-2.72 (4H, m) 2.65-2.45 (6H, m) 1.56 LV-1402 71 (2H, quintet, J=7.4 Hz) 1.39-1.17 (4H, m) 1.07-0.91 (6H, m) 0.87 (3H, t, J=6.9 Hz) ES1/MS: 527 [M+Hr.
11-1-NMR (400 MHz, CDC13) 8: 7.86-7.80 (2H, m) 7.80-7.75 (211, m) 7.31-7.24 (2H, m, overlapped with CDC13) 7.09-7.02 (2H, m) 7.02-LV-1417 72 6'95 (2H, m) 6.95-6.89 (2H, m) 5.41 (2H, s) 3.90 (3H, s) 2.89-2.78 (4H, m) 2.63-2.47 (6H, m) 1.55 (2H, quintet, J=7.4 Hz) 1.38-1.18 (4H, m) 0.98 (6H, t, J=7.1 Hz), 0.86 (3H, t, J=6.9 Hz) ESI/MS: 539 [M+Hr.
1H-NMR (400 MHz, CDC13) 6: 7.45-7.39 (21-1, m) 7.31-7.24 (2H, m, overlapped with CDC13) 7.14-7.08 (2H, m) 7.05-6.98 (211, m) 6.92-LV-1424 73 6'85 (411, m) 5.84 (111, s) 5.35 (2H, s) 3.81 (3H, s) 2.84-2.72 (411, m) 2.59-2.45 (6H, m) 1.55 (2H, quintet, J=7.5 Hz) 1.39-1.18 (4H, m) 0.95 (6H, t, J=7.1 Hz) 0.87 (3H, t, J=7.0 Hz) ESI/MS: 541 [M+H].
1H-NMR (400 MHz, CDC13) 8: 7.69-7.64 (2H, m) 7.50-7.45 (2H, m) 7.40-7.34 (2H, m) 7.24-7.17 (4H, m) 6.97-6.91 (2H, m) 3.83 (3H, s) 3.07 (1H, d, J=13.4 Hz) 2.88 (1H, d, J=13.4 Hz) 2.80-2.70 (1H, m) LV-1528 84 2.69-2.44 (7H, m) 2.32-2.21 (1H, m) 2.08-1.76 (4H, m) 1.63 (211, quintet, J=7.4 Hz) 1.40-1.27 (4H, m) 1.10-0.98 (611, m) 0.90 (311, t, J=6.9 Hz) ESI/MS: 511 [M+Hr.
111-NIVIR (400 MHz, CDC13) 6: 7.62-7.46 (4H, m) 7.45-7.37 (2H, m) 7.30-7.22 (2H, m, overlapped with CDC13) 7.17-7.09 (2H, m) 7.03-6.94 (2H, m) 5.18-5.01 (1H, m) 4.24-4.04 (1H, in) 3.86 (3H, s) 3.52-LV-1532 85 3.14 (4H, m) 3.13-2.92 (1H, m) 2.84-2.65 (111, m) 2.60-2.38 (411, m) 2.38-2.16 (1H, m) 2.11-1.87 (1H, m) 1.63-1.47 (2H, m) 1.47-1.19 (10H, m) 0.90-0.83 (3H, m).
ESI/MS: 513 [M+H]t 1H-NMR (400 MHz, CDC13) 8: 8.50 (1H, d, J=1.4 Hz) 8.45 (1H, dd, LV- 1570 88 ./=4.8, 1.4 Hz) 7.64-7.58 (1H, m) 7.49-7.44 (211, m) 7.42-7.37 (211, m) 7.25-7.21 (411, m) 7.21-7.15 (1H, m) 6.99-6.94 (2H, m) 6.94-6.89 (211, m) 3.97 (211, s) 3.84 (3H, s) 3.60 (211, s) 2.87-2.80 (4H, m) 2.64 (2H, t, J=7.7 Hz) 2.56 (2H, q, J=7.1 Hz) 1.62 (2H, quintet, J=7.3 Hz) 1.40-1.23 (4H, m) 1.02 (311, t, J=7.1 Hz) 0.89 (3H, t, J=6.9 Hz) ESITMS: 574 [M+H].
In vitro Assay Fluorescence resonance energy transfer (FRET) assay was performed to evaluate ability of compounds to inhibit plasmepsin II Solution of compounds for testing (concentration 0.01-100uM) on 96 well plate were added to the enzyme (Plasmepsin II) in buffer (0.1 M Na0Ac, pH = 4.5, 10% glycerin). The mixture was incubated for 30 min at 37 C.
Substrate (DABCYL-Glu-Arg-Nle-Phe-Leu-Ser-Phe-Pro-EDANS, AnaSpec Inc) was added to reach final concentration 5 uM. Hydrolysis of substrate was detected as an increase in fluorescence (Em 490 nm, Ex 336 nm) at 37 C. Compounds were tested in three repeated triplicate experiments.
IC50 values for selected inhibitors on plasmepsins II:
ID ComdNo Plm II
1. GL-1547 8.1 9.0 2. GL-1556 8.2 0,9 3. GL-1562 8.3 0,7 4. GL-1570 8.4 12,4 5. GL-1634 8.5 1.0 6. GL-1643 8.6 1,4 7. GL-1686 8.7 0,49 8. GL-1726 8.8 1,1 9. GL-1638 8.9 0,53 10. GL-1566 8.10 0.9 11. 'GL-1625 8.11 1,3 12. GL-1639 8.12 4,1 13. LV-1136 33.1 2,8 14. LV-1087 34.1 1,8 15. LV-1154 34.2 2,9 16. LV-1155 34.3 3 17. LV-1157 34.4 6,5 18. LV-1170 34.5 2,2 19. LV-1077 34.6 0,6 20. LV-1130 35.1 2,7 21. LV-1124 35.2 2,9 22. KD-302 36.1 0.38 23. VGP-153 36.2 1,2 24. KD-294 44 3,5 25. KD-263 47 i.a 26. KD-304 48.1 1,8 27. KD-307 48.2 2,8 28. 1CD-309 48.3 1,6 29. 1CD-329 48.4 1,9 30. KD-330 48.5 1,2 31. 1CD-315 48.6 0,78 32. KD-199 56.1 10 33. KD-233 56.2 13,2 34. LV-1341 63 10.0 35. LV-1402 71 8.0 36. LV-1417 72 15 37. LV-1528 84 4.5 38. LV-1532 85 5.7 39. LV-1570 88 2.2 i.a. ¨ inactive at the concentration below 200 uM; n.d. ¨ not determined
11-1-NMR (400 MHz, CDC13) 8: 8.83-8.76 (1H, m) 8.57 (1H, d, J=3.5 Hz) 7.86-7.79 (1H, m) 7.43 (211, d, J=8.2 Hz) 7.35 (1H, d, J=5.5, 7.7 Hz) 7.26-7.16 (4H, m) 7.07 (2H, d, J=8.2 Hz) 4.20 (2H, s) 3.75 (2H, KD-263 47 s) 2.63 (4H, q, J=7.0 Hz) 2.40 (3H, s) 1.06 (6H, t, J=7,0 Hz) 13C-NMR (100 Hz, CDC13) 8: 148.4, 148.1, 139.7, 137.2, 136.1, 134.1, 133.9, 129.9, 128.9, 127.2, 125.3, 123.5, 62.7, 48.0, 46.6, 29.9, 28.3, 21.2, 11.4 ESI/MS: 412 [M+H].
-1H-NMR (400 MHz, CD03) 8: 13.05 (s, 1H), 7.51-7.41 (m, 6H), 7.23-7.21 (m, 1H), 7.15-7.09 (m, 2H), 6.98-6.92 (m, 211), 4.16 (s, 4H), 3.83 (s, 311), 3.15-3.05 (m, 4H), 2.62 (t, 2H, J=7.7 Hz), 1.65-1.55 (m, 3H), 1.46 (t, 6H, J=7.2 Hz), 1.34-1.27 (m, 4H), 0.87 (t, 3H, KD-199 56.1 J= 6.8 Hz).
13C-NMR (100 Hz, CDC13) 8: 163.9, 159.2, 158.0, 145.4, 139.5, 136.0, 132.8, 129.0, 128.5, 128.2, 127.9, 127.1, 125.1, 119.8, 114.2, 55.3, 47.9, 43.7, 35.7, 31.4, 30.8, 27.5, 22.5, 14.0, 9.3.
ESI/MS (m/z): 497 [M+H].
11-1-NMR (400 MHz, CDC13) 8: 7.44-7.40 (m, 111), 7.38-7.34 (m, 1H), 7.18-7.16 (m, 1H), 7.14-7.08 (m, 1H), 7.04-6.98 (m, 1H), 3.89 KD-233 56.2 (s, 2H), 3.64 (s, 2H), 2.57-2.44 (m, 6H), 1.54 (quintet, 2H, J=7.7 Hz), 1.29- 1.21 (m, 4H), 1.18 (m, 2H), 0.99-0.91 (m, 6H), 0.81 (t, 3H, .1=
6.8 Hz).
ESI/MS (m/z): 473 [M+Hr.
1H-NMR (400 MHz, CDC13) 8: 7.52-7.48 (2[1, m) 7.47-7.43 (2H, m) 7.26-7.22 (2H, m) 7.13-7.08 (2H, m) 6.98-6.94 (2H, m) 6.94-6.90 (2H, m) 6.20 (111, d, J=3.5 Hz) 6.14 (111, d, J=3.5 Hz) 5.44 (2H, s) LV-1341 63 3.85 (3H, s) 3.35 (2H, s) 2.57 (2H, t, J=7.8 Hz) 2.48 (2H, q, J=7.1 Hz) 1.60 (2H, quintet, J=7.6 Hz) 1.38-1.25 (4H, m) 0.92 (3H, t, J=7.1 Hz, 0.88 (3H, t, J=7.0 Hz) ESI/MS: 495 [M+11]+.
11-I-NMR (400 MHz, CDC13) 6: 7.10-6.98 (6H, m) 6.97-6.88 (6H, m) 5.36 (2H, s) 3.83 (3H, s) 2.88-2.72 (4H, m) 2.65-2.45 (6H, m) 1.56 LV-1402 71 (2H, quintet, J=7.4 Hz) 1.39-1.17 (4H, m) 1.07-0.91 (6H, m) 0.87 (3H, t, J=6.9 Hz) ES1/MS: 527 [M+Hr.
11-1-NMR (400 MHz, CDC13) 8: 7.86-7.80 (2H, m) 7.80-7.75 (211, m) 7.31-7.24 (2H, m, overlapped with CDC13) 7.09-7.02 (2H, m) 7.02-LV-1417 72 6'95 (2H, m) 6.95-6.89 (2H, m) 5.41 (2H, s) 3.90 (3H, s) 2.89-2.78 (4H, m) 2.63-2.47 (6H, m) 1.55 (2H, quintet, J=7.4 Hz) 1.38-1.18 (4H, m) 0.98 (6H, t, J=7.1 Hz), 0.86 (3H, t, J=6.9 Hz) ESI/MS: 539 [M+Hr.
1H-NMR (400 MHz, CDC13) 6: 7.45-7.39 (21-1, m) 7.31-7.24 (2H, m, overlapped with CDC13) 7.14-7.08 (2H, m) 7.05-6.98 (211, m) 6.92-LV-1424 73 6'85 (411, m) 5.84 (111, s) 5.35 (2H, s) 3.81 (3H, s) 2.84-2.72 (411, m) 2.59-2.45 (6H, m) 1.55 (2H, quintet, J=7.5 Hz) 1.39-1.18 (4H, m) 0.95 (6H, t, J=7.1 Hz) 0.87 (3H, t, J=7.0 Hz) ESI/MS: 541 [M+H].
1H-NMR (400 MHz, CDC13) 8: 7.69-7.64 (2H, m) 7.50-7.45 (2H, m) 7.40-7.34 (2H, m) 7.24-7.17 (4H, m) 6.97-6.91 (2H, m) 3.83 (3H, s) 3.07 (1H, d, J=13.4 Hz) 2.88 (1H, d, J=13.4 Hz) 2.80-2.70 (1H, m) LV-1528 84 2.69-2.44 (7H, m) 2.32-2.21 (1H, m) 2.08-1.76 (4H, m) 1.63 (211, quintet, J=7.4 Hz) 1.40-1.27 (4H, m) 1.10-0.98 (611, m) 0.90 (311, t, J=6.9 Hz) ESI/MS: 511 [M+Hr.
111-NIVIR (400 MHz, CDC13) 6: 7.62-7.46 (4H, m) 7.45-7.37 (2H, m) 7.30-7.22 (2H, m, overlapped with CDC13) 7.17-7.09 (2H, m) 7.03-6.94 (2H, m) 5.18-5.01 (1H, m) 4.24-4.04 (1H, in) 3.86 (3H, s) 3.52-LV-1532 85 3.14 (4H, m) 3.13-2.92 (1H, m) 2.84-2.65 (111, m) 2.60-2.38 (411, m) 2.38-2.16 (1H, m) 2.11-1.87 (1H, m) 1.63-1.47 (2H, m) 1.47-1.19 (10H, m) 0.90-0.83 (3H, m).
ESI/MS: 513 [M+H]t 1H-NMR (400 MHz, CDC13) 8: 8.50 (1H, d, J=1.4 Hz) 8.45 (1H, dd, LV- 1570 88 ./=4.8, 1.4 Hz) 7.64-7.58 (1H, m) 7.49-7.44 (211, m) 7.42-7.37 (211, m) 7.25-7.21 (411, m) 7.21-7.15 (1H, m) 6.99-6.94 (2H, m) 6.94-6.89 (211, m) 3.97 (211, s) 3.84 (3H, s) 3.60 (211, s) 2.87-2.80 (4H, m) 2.64 (2H, t, J=7.7 Hz) 2.56 (2H, q, J=7.1 Hz) 1.62 (2H, quintet, J=7.3 Hz) 1.40-1.23 (4H, m) 1.02 (311, t, J=7.1 Hz) 0.89 (3H, t, J=6.9 Hz) ESITMS: 574 [M+H].
In vitro Assay Fluorescence resonance energy transfer (FRET) assay was performed to evaluate ability of compounds to inhibit plasmepsin II Solution of compounds for testing (concentration 0.01-100uM) on 96 well plate were added to the enzyme (Plasmepsin II) in buffer (0.1 M Na0Ac, pH = 4.5, 10% glycerin). The mixture was incubated for 30 min at 37 C.
Substrate (DABCYL-Glu-Arg-Nle-Phe-Leu-Ser-Phe-Pro-EDANS, AnaSpec Inc) was added to reach final concentration 5 uM. Hydrolysis of substrate was detected as an increase in fluorescence (Em 490 nm, Ex 336 nm) at 37 C. Compounds were tested in three repeated triplicate experiments.
IC50 values for selected inhibitors on plasmepsins II:
ID ComdNo Plm II
1. GL-1547 8.1 9.0 2. GL-1556 8.2 0,9 3. GL-1562 8.3 0,7 4. GL-1570 8.4 12,4 5. GL-1634 8.5 1.0 6. GL-1643 8.6 1,4 7. GL-1686 8.7 0,49 8. GL-1726 8.8 1,1 9. GL-1638 8.9 0,53 10. GL-1566 8.10 0.9 11. 'GL-1625 8.11 1,3 12. GL-1639 8.12 4,1 13. LV-1136 33.1 2,8 14. LV-1087 34.1 1,8 15. LV-1154 34.2 2,9 16. LV-1155 34.3 3 17. LV-1157 34.4 6,5 18. LV-1170 34.5 2,2 19. LV-1077 34.6 0,6 20. LV-1130 35.1 2,7 21. LV-1124 35.2 2,9 22. KD-302 36.1 0.38 23. VGP-153 36.2 1,2 24. KD-294 44 3,5 25. KD-263 47 i.a 26. KD-304 48.1 1,8 27. KD-307 48.2 2,8 28. 1CD-309 48.3 1,6 29. 1CD-329 48.4 1,9 30. KD-330 48.5 1,2 31. 1CD-315 48.6 0,78 32. KD-199 56.1 10 33. KD-233 56.2 13,2 34. LV-1341 63 10.0 35. LV-1402 71 8.0 36. LV-1417 72 15 37. LV-1528 84 4.5 38. LV-1532 85 5.7 39. LV-1570 88 2.2 i.a. ¨ inactive at the concentration below 200 uM; n.d. ¨ not determined
Claims (6)
1. A compound with general formula I
G¨J R2 N¨R1 II)(-) Formula l wherein:
It'/R2 are attached to a nitrogen atom and wherein Wile are H/unsubstituted benzyl, H/
benzyl substituted with methoxy or phenyl, H/phenyl, H/CH2c-hexyl, H/CH(Me)Ph, H/H, H/C1_6alkyl, C1-6alkyl/C1-6alkyl, or Et/CH2pyridiny1, or R1, R2 together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocyclyl, or R1, R2 together with the nitrogen atom to which they are attached form a 6-membered heterocyclic ring fused with a phenyl ring;
IV is pyridinyl, unsubstituted phenyl, phenyl substituted with t-butyl, -0Me, -OH, morpholinyl or NH2C(0)-, thiophenyl, or bromo;
R4 is methyl or C5H11(n-pentyl);
A-D-E-G-J constitutes saturated or unsaturated azole ring;
wherein:
A is C= or CH;
D is independently N= or C=;
E is independently CH, C= or N=;
G is independent1yCH2, CH= or N=;
J is independently CH=, 0 or N=;
and at least one of D-E-G-J is nitrogen;
and wherein:
Q is unsubstituted C1_3alkylene;
or an optical isomer, a pharmaceutically acceptable salt, a hydrate, or a solvate thereof.
G¨J R2 N¨R1 II)(-) Formula l wherein:
It'/R2 are attached to a nitrogen atom and wherein Wile are H/unsubstituted benzyl, H/
benzyl substituted with methoxy or phenyl, H/phenyl, H/CH2c-hexyl, H/CH(Me)Ph, H/H, H/C1_6alkyl, C1-6alkyl/C1-6alkyl, or Et/CH2pyridiny1, or R1, R2 together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocyclyl, or R1, R2 together with the nitrogen atom to which they are attached form a 6-membered heterocyclic ring fused with a phenyl ring;
IV is pyridinyl, unsubstituted phenyl, phenyl substituted with t-butyl, -0Me, -OH, morpholinyl or NH2C(0)-, thiophenyl, or bromo;
R4 is methyl or C5H11(n-pentyl);
A-D-E-G-J constitutes saturated or unsaturated azole ring;
wherein:
A is C= or CH;
D is independently N= or C=;
E is independently CH, C= or N=;
G is independent1yCH2, CH= or N=;
J is independently CH=, 0 or N=;
and at least one of D-E-G-J is nitrogen;
and wherein:
Q is unsubstituted C1_3alkylene;
or an optical isomer, a pharmaceutically acceptable salt, a hydrate, or a solvate thereof.
2. The compound with general formula I according to claim 1 for use in the treatment of malaria infection.
Date Regue/Date Received 2022-08-23
Date Regue/Date Received 2022-08-23
3. The compound with general formula I according to claim 1 for use in the treatment of a disease or disorder that is mediated by plasmepsins (malarial aspartic protease) or human aspartic proteases.
4. The compound with general formula I according to claim 1 for use in the treatment of a disease or disorder that is ameliorated by the inhibition of plasmepsins (malarial aspartic protease) or human aspartic proteases.
5. The compound with general formula I according to claim 1 for use in the treatment of a disease or disorder that is treated by a plasmepsins (malarial aspartic protease) or human aspartic proteases inhibitor.
6. A kit comprising a compound with general formula I as defined in claim 1 provided as a pharmaceutical composition and in a suitable container and/or with suitable packaging.
Date Regue/Date Received 2022-08-23
Date Regue/Date Received 2022-08-23
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/LV2015/000007 WO2017069601A1 (en) | 2015-10-19 | 2015-10-19 | Substituted aminoalkylazoles as malarial aspartic protease inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2988391A1 CA2988391A1 (en) | 2017-04-27 |
| CA2988391C true CA2988391C (en) | 2023-05-09 |
Family
ID=54352486
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2988391A Active CA2988391C (en) | 2015-10-19 | 2015-10-19 | Substituted aminoalkylazoles as malarial aspartic protease inhibitors |
Country Status (3)
| Country | Link |
|---|---|
| CA (1) | CA2988391C (en) |
| GB (1) | GB2557753B (en) |
| WO (1) | WO2017069601A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3936192A4 (en) | 2019-03-06 | 2022-11-16 | Daiichi Sankyo Company, Limited | Pyrrolopyrazole derivative |
| WO2020263191A1 (en) | 2019-06-27 | 2020-12-30 | Nanyang Technological University | Compounds having antimalarial activity |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5671073A (en) * | 1979-11-12 | 1981-06-13 | Takeda Chem Ind Ltd | Imidazole derivative |
| CA2428266A1 (en) * | 2000-11-10 | 2002-05-16 | Actelion Pharmaceuticals Ltd. | Substituted alkyldiamines as inhibitors of plasmepsin or related proteases |
| US20090170907A1 (en) * | 2005-06-06 | 2009-07-02 | Smithkline Beecham Corporation | Chemical Compounds |
-
2015
- 2015-10-19 WO PCT/LV2015/000007 patent/WO2017069601A1/en active Application Filing
- 2015-10-19 CA CA2988391A patent/CA2988391C/en active Active
- 2015-10-19 GB GB1800785.6A patent/GB2557753B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| GB201800785D0 (en) | 2018-03-07 |
| CA2988391A1 (en) | 2017-04-27 |
| GB2557753A (en) | 2018-06-27 |
| GB2557753B (en) | 2020-06-10 |
| WO2017069601A1 (en) | 2017-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cai et al. | A CuAAC/Ullmann C–C coupling tandem reaction: copper-catalyzed reactions of organic azides with N-(2-iodoaryl) propiolamides or 2-iodo-N-(prop-2-ynyl) benzenamines | |
| US7576098B2 (en) | Heterocyclic compounds as inhibitors of factor VIIa | |
| Ghabraie et al. | Synthesis of functionalized β-lactams and pyrrolidine-2, 5-diones through a metal-free sequential Ugi-4CR/cyclization reaction | |
| CA2828524C (en) | Histone deacetylase inhibitors | |
| JP5236293B2 (en) | Substituted biaryl compounds as XIA factor inhibitors | |
| AU2014239677B2 (en) | Histone deacetylase inhibitors | |
| CA2570472A1 (en) | Five-membered heterocycles useful as serine protease inhibitors | |
| TWI282337B (en) | Substituted chromone compounds,the compositions comprising the said compounds, and the use of said compounds for treating disorders associated with KSP kinesin activity | |
| Li et al. | One base for two shots: metal-free substituent-controlled synthesis of two kinds of oxadiazine derivatives from alkynylbenziodoxolones and amidoximes | |
| US8946430B2 (en) | Quinolinone carboxamide inhibitors of endothelial lipase | |
| CA2703718A1 (en) | Inhibitors of histone deacetylase | |
| AU2002364549A1 (en) | Vanilloid receptor ligands and their use in treatments | |
| WO2013106761A2 (en) | Antimicrobial agents | |
| CA2988391C (en) | Substituted aminoalkylazoles as malarial aspartic protease inhibitors | |
| Medvedeva et al. | Microwave assisted solvent-and catalyst-free three-component synthesis of NH-1, 2, 3-triazoloimines | |
| KR20090018946A (en) | Benzylamine derivatives as cetp inhibitors | |
| CA3134791A1 (en) | Inhibitors of notch signalling pathway and use thereof in treatment of cancers | |
| Andrade et al. | Design, synthesis and structure-activity relationship studies of a novel focused library of 2, 3, 4-substituted oxazolidines with antiproliferative activity against cancer cell lines | |
| Lu et al. | Synthesis and structure-activity relationships for tetrahydroisoquinoline-based inhibitors of Mycobacterium tuberculosis | |
| KR20090080523A (en) | Heterocyclic derivatives as cetp inhibitors | |
| JP6190067B2 (en) | Fluorophenylpyrazole compounds | |
| Habib et al. | Catalyst-free 1, 3-dipolar cycloaddition of 3-nitrochromen with sodium azide: a facile method for the synthesis of 4-aryl-1, 4-dihydrochromeno [4, 3-d][1, 2, 3] triazole derivatives | |
| KR20090078352A (en) | Organic compounds | |
| JP2011515359A (en) | Therapeutic triazole amide derivatives | |
| Zhu et al. | Iodine-Promoted Oxidative Cyclization of Methyl Azaarenes and α-Amino Ketones for One-Pot Synthesis of 2-Azaaryl-5-aryl Oxazoles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200715 |
|
| EEER | Examination request |
Effective date: 20200715 |
|
| EEER | Examination request |
Effective date: 20200715 |
|
| EEER | Examination request |
Effective date: 20200715 |
|
| EEER | Examination request |
Effective date: 20200715 |
|
| EEER | Examination request |
Effective date: 20200715 |
|
| EEER | Examination request |
Effective date: 20200715 |